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Abstract 
 
Tuberculosis remains a major global health challenge, particularly in 
low-to-middle income countries such as China. At the same time, the 
country is facing a rapidly increasing diabetes incidence over the last 10 
years. Diabetes aggravates the tuberculosis epidemic which poses a serious 
challenge in public health. In recent years, the high prevalence of vitamin D 
deficiency represents a global health problem, which is also associated with 
the risk of diabetes, and tuberculosis. Therefore, we carried out this study 
aimed to investigate the epidemiology of co-occurrence of tuberculosis and 
diabetes and to elucidate the role of vitamin D deficiency. 
 
In a rural area setting in Linyi, Shandong, China, 6382 active tuberculosis 
patients, together with 6674 non-tuberculosis controls were screened for 
diabetes. The prevalence of diabetes in tuberculosis was 6.3%, nearly 35% 
higher than controls. Tuberculosis was independently associated with about 
three times higher risk of having diabetes. Hyperglycemia was found to be 
associated with a nearly two-fold higher probability of patient delay of 
tuberculosis in a randomly selected subgroup from this study. Compared 
with the highest quartile, subjects in the lowest quartile of serum 25(OH)D 
had a more than four-fold and two-fold increased risk of having tuberculosis, 
and concurrent tuberculosis and diabetes. Subsequently, a city level 
hospital-based study was carried out. A high prevalence of vitamin D 
deficiency of nearly 80% was observed in tuberculosis patients, and serum 
25(OH)D was observed to be inversely associated with TNF-α, while 
positively associated with leptin, indicating a possible immune-modulatory 
mechanism of vitamin D. In the intervention trial of vitamin D3 (800IU/d), 
358 newly diagnosed tuberculosis patients were included and more severe 
signs and symptoms at presentation were observed in those with diabetes. 
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Vitamin D showed a favourable adjunctive effect on clinical manifestations in 
this subgroup, while no similar effects were found in patients with 
tuberculosis only.  
 
In conclusion, active tuberculosis patients had an increased risk of having 
diabetes, as well as prevalent hypovitaminosis D. Vitamin D showed an 
adjunctive effect in the therapy, i.e., improvement of tuberculosis clinical 
manifestations in patients with combined diabetes and tuberculosis. Our 
study provides possible etiological clues for the combined diseases, and the 
possible role of vitamin D deficiency. We recommend bidirectional screening 
for tuberculosis and diabetes, especially early detection of tuberculosis in 
diabetes patients; and health education to increase awareness of the double 
burden. In addition, vitamin D supplementation may benefit tuberculosis 
patients in general. Moreover, extra vitamin D may benefit the general 
population especially in a situation of a heavy tuberculosis burden combined 
with prevalent vitamin D deficiency. We suggest future studies to address 
long-term treatment outcomes of patients with the combined diseases and 
to define certain markers to set up a prognostic model. Also, longitudinal 
studies to verify the role of vitamin D deficiency in the double burden, and 
confirmative trials on the effect of vitamin D supplementation are needed. 
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Tuberculosis in China 
Tuberculosis, which is caused by Mycobacterium tuberculosis, continues to 
be an important global health challenge, with an estimated 9 million 
incident cases worldwide each year.  Although a downward trend of 
tuberculosis incidence has been observed from 2000 to 2015, China still 
accounts for nearly 17% of the world's tuberculosis burden, with 
approximately 0.9 million new cases in 2016 (1).   
Several factors are known to increase the risk of active tuberculosis, 
including age, malnutrition, underweight, unhealthy living habits like 
smoking and alcoholism, and comorbidities like human immunodeficiency 
virus (HIV) infection, and diabetes mellitus.  
 
 Diabetes Mellitus in China    
In recent years, the global incidence of type 2 diabetes mellitus has 
increased significantly, rising from 4.7% in 1980 to 8.5% in 2014 in the adult 
population (2). It is estimated that the number of people living with diabetes 
will rise from 382 million (in 2013) to 592 million by 2035 (3). About 85-95% 
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of the global prevalence of diabetes is attributed to type 2 diabetes mellitus, 
which results from the body’s failure to adequately respond to insulin.  
Genetics, age, family history of diabetes, unhealthy nutrition and physical 
inactivity are the main factors that are associated with the risk of type 2 
diabetes. Also, it is widely accepted that excess weight is closely related to 
increased risk of developing type 2 diabetes (4) (5). In comparison to women 
with normal BMI, overweight, obese (30 ≤ BMI < 39.99), and severely obese 
(BMI ≥ 40) women face increased risk of developing type 2 diabetes with 
7.6%, 20.1% and 38.8% greater risk, respectively (4). Moreover, BMI above 
normal weight levels has been observed to be associated with an increased 
risk of complications of diabetes mellitus (6). However, low BMI may also be 
related with adverse effects on health. Accumulating evidence in recent 
years has indicated the potential adverse influence of underweight on 
cardiometabolic milieu. A U-shaped relationship was observed between BMI 
and all-cause mortality (7), and low BMI was associated with adverse 
outcomes of coronary heart disease in an Asian patient population (8). A 
large-scale cohort study in Japan showed that underweight may be 
associated with the risk of type 2 diabetes among older adults aged 60–79 
years (9). 
 In China, due to industrialization, urbanization, extended life expectancy 
and lifestyle changes, the prevalence of diabetes has increased especially 
rapidly over the last 10 years (10). The International Diabetes Foundation 
Diabetes Atlas estimated that in 2017 the number of persons with diabetes 
in China was 114 million, equating to nearly a quarter of cases worldwide. 
 
The Double Burden of Diabetes Mellitus and Tuberculosis 
About one-third of the world's population is infected with M. tuberculosis. 
Most of them will develop latent infection, and only nearly 5~10% of them 
will progress to the active form of the disease, with approximately 9 million 
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individuals developing tuberculosis each year (1).  When the integrity of the 
immune system is compromised, as is the case for instance in HIV infection 
and diabetes, the risk increases significantly.  
 
Diabetes is a well-known 
risk factor for tuberculosis. 
Prior to the insulin era, 
diabetes was a great threat 
to health and the leading 
cause of death was 
tuberculosis.  Due to the 
rapidly increasing 
prevalence of 
diabetes worldwide 
in recent years, the correlation between tuberculosis and diabetes and its 
implication to public health is attracting renewed and intensive attention.           
Diabetes is estimated to triple the risk of active tuberculosis (11), whereas 
about 10~15% of cases is attributable to  diabetes (1; 12) (13; 14) (Figure 1-1). 
These findings suggest that diabetes is a moderate to strong risk factor for 
active tuberculosis.  
Although there has been some dispute with respect to cause and 
consequence, it is widely accepted that diabetes usually comes first in the 
occurrence of combined disease. Whether tuberculosis might in turn 
increase the risk of diabetes is still inconclusive. Some studies have pointed 
out that tuberculosis can cause temporary elevation of blood glucose by 
fever and toxin produced by M. tuberculosis. Furthermore, anti-tuberculosis 
drug treatment may be harmful to islet cells and hamper insulin secretion. 
However, this may also be the result of a stress response and even resolve 
with treatment.  
Figure 1-1   The percentage of tuberculosis cases                                                                  
attributable to diabetes in the world (2011) 
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Currently, 80% of global diabetes mellitus burden is in low-and middle-
income countries. Six of them (India, China, Brazil, Indonesia, Pakistan and 
The Russian Federation) also have a high tuberculosis burden (1).  
Due to its immuno-compromising effect, diabetes is known to have an all-
around effect on the natural course of tuberculosis, including a higher risk of 
the individual becoming infected with M. tuberculosis (latent infection), a 
higher lifetime risk of tuberculosis activation, and an unfavourable clinical 
course. Presentation of more symptoms, more relapses, treatment failures 
and deaths (15; 16) were observed in tuberculosis combined with diabetes 
mellitus, especially those with uncontrolled diabetes (17). Baseline bacterial 
load of tuberculosis with diabetes is higher than tuberculosis without, and 
the time to positive sputum conversion is prolonged (18). It was reported that 
the 6 months percentage of positive sputum culture in tuberculosis patients 
with diabetes was 22.2%, compared with 6.9% in patients without diabetes 
(19). According to a pooled analysis of four studies which adjusted for age 
and other potential confounders, diabetes was associated with nearly 5 
times higher risk of death during tuberculosis treatment (pooled OR 4.95, 
95%CI 2.69~9.10) (15) (20). In a nationwide population-based study in an Asian 
population, a nearly 20% higher risk of 10 year accumulated all-cause 
mortality was observed in newly-diagnosed tuberculosis patients with 
diabetes than those without diabetes (21). In addition, tuberculosis patients 
with diabetes showed atypical imaging changes and lesion distribution, 
especially in the lower lobe, while lesions in patients with tuberculosis only 
usually locate in the upper lobe. This has important clinical implications 
because tuberculosis occurring in the lower lobes is easily misdiagnosed as 
community-acquired pneumonia or tumors. Also, this has significant public 
health implications since early diagnosis and immediate initiation of 
treatment play a key role in tuberculosis control, especially in arresting 
tuberculosis transmission within a community.  
The blueprint of WHO’s End tuberculosis Strategy aims to reduce 
tuberculosis incidence by 80% and tuberculosis death by 90% by 2030 in the 
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world (22). However, as mentioned previously, the effects of diabetes 
mellitus on the natural course of tuberculosis, may make the challenge for 
prevention and control of tuberculosis even greater. In the setting of the 
globally rapidly rising epidemic of type 2 diabetes, especially in low-to-
middle income countries, the aggravation of the tuberculosis epidemic due 
to diabetes will pose a serious challenge to tuberculosis control for a 
relatively long period of time to come (23) (24). In accordance, the WHO has 
recently identified T2D as neglected risk factor for the re-emergence of 
tuberculosis.    
 
The Role of Vitamin D Deficiency in the Double Burden of 
Tuberculosis and Diabetes 
In recent years, the non-skeletal function of vitamin D has aroused intense 
interest. Vitamin D is involved in the regulation of various genes in the body 
(25), and may be an important modulating factor in endocrine and immune 
functions. Vitamin D deficiency has been reported to be related to impaired 
insulin secretion and function, as well as anti-Mycobacterium tuberculosis 
immune response, and is significantly associated with the increased risk of 
diabetes and tuberculosis (26; 27; 28). 
-The prevalence of Vitamin D deficiency in the Chinese population 
Vitamin D deficiency is a global health problem (29)  (30) (31). High prevalence 
of vitamin D deficiency and insufficiency has been documented in Europe, 
China, India, Middle East and South America (30) (32), even in some areas with 
very  sunny climates, such as Saudi Arabia and India (33) (34)(Figure 1-2).  
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Figure 1-2 Reported incidence of vitamin D deficiency around the globe in pregnant 
women and the general population(35) 
Some studies demonstrate that vitamin D deficiency is much higher in dark-
pigmented populations and Asian populations due to a reduced ability of 
their skin to produce vitamin D (36). Also, pregnant women, obese children 
and adults, and those who practice abstinence from direct sun exposure are 
at especially high risk (31) . 
Sunlight exposure remains the major source of vitamin D. Vitamin D is 
mainly synthesized from 7-dehydrocholesterol in the skin under the action 
of ultraviolet light. Very few foods naturally contain vitamin D. These include 
oily fish such as salmon, mackerel and herring, mushrooms and cod liver oil. 
The absorbed or synthesized vitamin D3 undergoes hydroxylation in the liver 
and kidney to form 25-hydroxyvitamin D3 [25(0H)D3] and 1,25-
dihydroxycholecalciferol [1,25(OH)2D3]. 1,25(OH)2D3 is the main active form 
that performs the physiological functions of vitamin D in the body (Figure 1-
3). 25(OH)D, the half-life of which is close to 3 weeks and the concentration 
of which in blood is stable, is the most valuable indicator for evaluating the 
individual nutritional status of vitamin D. The current widely accepted 
vitamin D nutritional status evaluation criteria are shown in Table 1-1 (37). 
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Figure1- 3 Main sources of vitamin D and its metabolism in the body 
 
Table 1-1 The criteria of Vitamin D nutritional status in the body(37) 
 
 
 
 
 
 
The prevalence of vitamin D deficiency in China is high (38) (39). In 5531 (5-101 
years old) urban Beijing residents reporting for health check-up, vitamin D 
deficiency and severe vitamin D deficiency percentages were 87.1 and 44.7, 
respectively (38). A cross-sectional study including 6014 healthy elderly adults 
(≥ 60 years) showed that 34.1% of men and 44.0% of women presented with 
vitamin D deficiency (39).  A study of 418 Chinese immigrant population with 
mean age of 56 years in the Netherlands found that the prevalence of 
vitamin D deficiency in men and women was 67.9% and 53.1%, respectively 
(40). Although there are some discrepancies in the reported vitamin D 
    Serum 25(OH)D  Nutritional status 
<10ng/ml(25nmol/L) Severely deficient 
<20ng/ml(50 nmol/L) Deficient 
<20～29ng/ml(52~72 nmol/L) insufficient 
≥30 ng/ml (75 nmol/L) Sufficient 
30～40 ng/ml(75-100nmol/ L ) Favorable 
>150 ng/ml (374 nmol/ L) Toxic 
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deficiency rates due to different season of blood collection, analysis method, 
etc, vitamin D deficiency certainly is a great public health problem in the 
Chinese population. 
The public health consequences of vitamin D deficiency are profound. In 
recent years, there has been an increasing number of studies focusing on 
exploring the relationship between vitamin D deficiency and metabolic 
abnormalities, such as hypertension, dyslipidemia, central obesity, glucose 
intolerance, type 2 Diabetes, as well as infectious diseases like tuberculosis.  
- Vitamin D Deficiency and Diabetes Mellitus 
Epidemiological evidence for an inverse association between serum vitamin 
D levels and the risk of type 2 diabetes is abundant. A cross sectional study 
in overweight and pre-diabetic populations in China (2813 males with mean 
age 52·7 years, 3784 females with mean age 52·3 years) reported 83·3 % 
vitamin D deficiency, and vitamin D status was inversely associated with 
HOMA-IR (homeostasis model assessment of insulin resistance) (41). Cohort 
studies provided stronger proof. A recent study in Asia found that compared 
to individuals with vitamin D concentrations ≥ 20 ng/mL, those with 
concentrations of 10-19.9 ng/mL and of <10 ng/mL have a 2.06 and 3.23 fold 
increased risk of developing type 2 diabetes, respectively (28).  
The effects of vitamin D supplementation on insulin resistance and glycemic 
control give more insight in the correlation between vitamin D and risk of 
diabetes. In non- diabetic adults with impaired fasting glucose at baseline, 
calcium and vitamin D supplementation for 3 years attenuated the increases 
in glycemia and insulin resistance (42). Improved insulin secretion was 
reported for vitamin D supplementation in women with type 2 diabetes (43). 
However, some other studies did not find effects of vitamin D 
supplementation on glucose metabolism (44 ; 45). Vitamin D supplementation 
of a bolus oral dose of 100,000 IU cholecalciferol followed by 4000 IU 
cholecalciferol/d for 16 weeks did not improve insulin sensitivity or 
secretion in overweight or obese adults with vitamin D deficiency (46).  
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In addition, low serum vitamin D level has been observed to be associated 
with impaired glycemic control in diabetes (47) . And a RCT study found a 
significant effect of vitamin D supplementation on HbA1c after 6 months 
supplementation in severe vitamin D deficient patients (48). 
Summarizing, there is convincing evidence that vitamin D deficiency is 
associated with higher risk of diabetes, as well as with impaired glycemic 
control in diabetes patients. 
 
- Vitamin D Deficiency and Tuberculosis 
Previous studies have suggested that low serum 25(OH)D may be associated 
with acquiring wheezing and lower respiratory tract infections and with the 
disease severity both in children (49) and in adults (50), indicating the possible 
link between vitamin D deficiency and increased susceptibility to infection. A 
meta-analysis in 2008 combining 7 epidemiological studies, showed a 
modest to strong association of vitamin D deficiency with tuberculosis risk, 
with a pooled effect size of 0.68 (95% CI, 0.43~0.93), i.e. serum vitamin D 
levels are 0.68 SD lower in people with tuberculosis compared to controls (51). 
In a global country-based ecological study, across 154 countries, annual 
solar UV-B exposure was associated with tuberculosis incidence (averaged 
over the period 2004-2013). Tuberculosis incidence in countries in the 
highest quartile of UV-B exposure was 78% lower than that in countries in 
the lowest quartile, and 6.3% global variation in tuberculosis incidence could 
be attributed to variations in annual UV-B exposure (52). Further, several 
prospective longitudinal studies in recent years discovered the association 
between vitamin D deficiency and possible higher risk of active tuberculosis 
(53; 54; 55). Higher serum vitamin D concentration was associated with low 
incidence of tuberculosis infection conversion (TBIC) (P trend=0·005), and an 
increase of 1ng/mL vitamin D concentration decreased the incidence of TBIC 
by 6% (relative risk 0.94, 95% CI 0.90-0.99, P=0.015) (53). Low 25-
hydroxyvitamin D (<32ng/mL) in South African infants was associated with 
Chapter 1 
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higher risk of tuberculosis (adjusted hazard ratio 1.76, 95% CI 1.01–3.05; p = 
0.046), as well as significant interaction with two SNPs (Single nucleotide 
polymorphisms) that are considered to be associated with innate immunity (54). 
In fact, vitamin D3 isolated from cod liver oil was used for tuberculosis 
treatment in the 1930s and widely introduced in the pre-antibiotic era. 
Starting in the 1950s, anti-infective chemotherapy was introduced, and 
vitamin D was no longer used for clinical treatment. At present, there is still 
controversy about the efficacy of adjunctive use of vitamin D on tuberculosis 
treatment. Some studies reported that adjunct therapy of vitamin D3 to 
standard therapy may have beneficial effects towards clinical recovery. This 
includes sputum culture conversion (56), weight gain and chest radiographic 
findings (57), resolution of inflammatory responses that are associated with 
increased risk of mortality (58). Furthermore adjunct therapy may modulate 
specific cytokine levels that mediate immune cell to cell signaling such as IL-
1β signaling. This is critical for signaling between macrophages and lung 
epithelial cells, leading to epithelial antimicrobial peptide production that 
helps to contain Mtb infection (59). However, other trials did not find a 
significant effect of vitamin D concomitant with standard first-line anti-
tuberculosis drugs on improving the rate of sputum Mtb clearance (60; 61; 62). 
A recent study reported that the improvement of sputum clearance by high 
dose vitamin D (four biweekly doses of 140,000 IU vitamin D3)  was modified 
by SNPs in genes encoding the vitamin D receptor (VDR) and  25-
hydroxyvitamin D 1α-hydroxylase (CYP27B1) (63).        
Recent meta-analyses reinforce the finding that 10-20 μg per day of vitamin 
D can reduce all-cause mortality and cancer mortality in middle-aged and 
older people. However, a role of vitamin D to improve non-skeletal health 
conditions including glucose metabolism and tuberculosis has not been 
confirmed with sound evidence in randomized trials till now (64). Therefore, 
clinical studies are urgently needed to verify the possible adjunctive role of 
vitamin D. Adjunctive use of vitamin D in active tuberculosis combined with 
diabetes merits further investigation.   
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In summary, diabetes triples the risk of tuberculosis. The rapidly increasing 
diabetes incidence and still high burden of tuberculosis in China poses a new 
challenge for public health. Therefore, the prevention and control of 
tuberculosis may still be a significant task in the coming decade. Vitamin D 
deficiency is associated with increased risk of diabetes mellitus as well as the 
severity of the disease. At the same time, vitamin D deficiency is correlated 
with increased risk of tuberculosis independently of diabetes. We 
hypothesize that the double burden of diabetes and tuberculosis and its 
implications to public health in this country are heavily influenced by the 
high prevalence of vitamin D deficiency (Figure 1-4).  
 
Figure 1-4 Working hypothesis of a double burden of diabetes and tuberculosis and 
the role of vitamin D deficiency 
The red arrow represents the effect of diabetes mellitus on tuberculosis risk; 
The yellow arrow represents an independent effect of vitamin D deficiency 
on tuberculosis risk; The light blue arrow represents an effect of vitamin D 
deficiency on diabetes mellitus risk and severity; the dark blue arrow 
represents an additional effect of vitamin D deficiency on tuberculosis risk 
mediated by diabetes.  
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Possible Mechanisms Underlying the Double Burden of Diabetes 
and Tuberculosis   
Although it is widely accepted that diabetes weakens the immune system 
through impairing both innate and adaptive immune functions, and that 
vitamin D is also involved, the biological basis underlying the correlation 
between diabetes and tuberculosis is poorly understood. 
 
-impaired immune responses to M. tuberculosis due to diabetes 
Dysregulation of the immune system was observed in diabetic patients, 
involving innate and adaptive immune responses, especially with respect to 
macrophage and T lymphocyte function that play a key role in the defence 
against M. tuberculosis (65) (66) (67; 68) (69). This was especially the case in those 
with chronic hyperglycemia (70). A significant decrease in the activity of 
natural killer cells was found in diabetic patients, making them more 
susceptible to infection with respiratory pathogens such as M. tuberculosis 
(71). Macrophages are key to the progression of tuberculosis due to their dual 
role, forming a primary host cell reservoir for M. tuberculosis, as well as 
being effective cells that control and eliminate M. tuberculosis (72). Recent 
evidence shows that human monocytes and macrophages were altered in 
the context of T2D (73; 74) , resulting in impaired anti- Mycobacterium 
tuberculosis immunity.  
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Figure 1-5 The possible immunity related mechanism of the increased risk of 
tuberculosis in diabetes 
It was reported that tuberculosis patients with diabetes had a different 
profile of circulating levels of cytokines compared with those without 
diabetes (75), which indicates that cytokine profile may be a biomarker of the 
immunity response to M.tuberculosis in diabetes patients. Cytokines play an 
important role as mediator in the interaction between immune cells, 
notably IFN-Ƴ and TNF-α, the functions of which have been well 
documented (76) (77). This interaction results in macrophage activation to 
control mycobacterial replication, and the production of granulomas which 
contain the bacterium. Type 1, type 17, and the IL-1 family of cytokines have 
been implicated in protection against M. tuberculosis whereas type 2 and 
anti-inflammatory cytokines such as IL-10 frequently are associated with 
either increased susceptibility to disease and/or enhanced pathology (78). 
Leptin, with a main role in regulating body weight, is also involved in both 
innate and adaptive immunity (79) (80) (81). Leptin receptors have been found 
in neutrophils, monocytes, and lymphocytes. Systemic levels of leptin were 
reported to be lowered in tuberculosis patients with diabetes compared to 
tuberculosis without diabetes, indicating a potential contribution to the 
pathogenesis of tuberculosis in diabetes (82; 83). A recent meta-analysis of 
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twelve case-control studies found serum leptin levels of healthy controls 
were markedly higher than those of tuberculosis patients (84), and an 
increase in plasma leptin levels after treatment of tuberculosis was reported (85).  
The possible immunity mechanism of the increased risk of tuberculosis in 
diabetes is shown in figure 1-5. 
 
- possible mechanism of Vitamin D deficiency underlying the combination 
of diabetes and tuberculosis 
The vitamin D receptor (VDR) can be demonstrated in many organs and this 
suggests that vitamin D metabolites may have many extra-skeletal effects. 
The VDR is present in the pancreatic β-cell, activated T Cells, B cells, 
macrophages, monocytes, etc.  
Vitamin D has important regulatory effects on insulin secretion and insulin 
signaling. vitamin D binds to its receptor to activate L-type calcium channels 
on beta cells, promoting insulin release and tyrosine phosphorylation of 
insulin receptor substrates, and initiating insulin signaling. Lack of vitamin D 
may cause the calcium channel to shut down, or the phosphorylation of the 
insulin receptor substrate to be blocked, thereby affecting insulin signaling.  
In recent years, the immunomodulatory effects of vitamin D both in the 
innate and adaptive immune system have been widely accepted. Significant 
concentrations of VDR have been found in immune cells which have 
important effects in bactericidal activities in the body. Vitamin D was 
discovered to stimulate innate immunity during M. tuberculosis infection 
resulting in control of M. tuberculosis proliferation inside macrophages (86). 
The active metabolite of vitamin D, 1, 25-dihydoxyvitamin D, has long been 
known to enhance the immune response to mycobacteria in vitro. When 
vitamin D binds to the macrophage membrane Toll-like receptor, it activates 
1-alpha hydroxylase and induces the expression of the anti-microbial 
peptide Cathelicidin. In turn, this inhibits and kills intracellular M. 
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tuberculosis (87). In tuberculosis patients with vitamin D deficiency, this 
polypeptide was reduced in granulomatous lesions (88). Similarly, Wang et al. 
found that vitamin D regulates the expression of polypeptide β-defensin on 
the mucosal surface (89), which is also an antimicrobial polypeptide with 
multiple effects in the immune system. Vitamin D was reported to be 
involved in the regulation of host cytotoxic T lymphocyte responses and the 
differentiation of naive T cells to regulatory T cells, rather than to T helper 
type 1(Th1) or Th17 cells (90), indicating its possible role in adaptive immunity 
during infections  (Figure 1-6).  
A recent report  proposed that vitamin D deficiency in diabetes patients may 
increase tuberculosis susceptibility, based on the observation that the 
intracellular mycobacterial growth in monocytes obtained from T2D patients 
with vitamin D deficiency was significantly higher than in healthy volunteers,  
while no difference existed between T2D patients without vitamin D 
deficiency and healthy volunteers  (91).  
 
    Figure 1-6      Mechanism of vitamin D deficiency on diabetes and tuberculosis 
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Research objectives    
The worldwide trend of increasing obesity, diabetes and still high prevalence 
of tuberculosis in low to middle-income areas constitute a double burden 
which will challenge public health systems in the coming decades. Multidrug 
resistant tuberculosis will complicate the situation even more. Also, the 
endemic vitamin D deficiency may play a role, due to its association with 
both immune function and insulin secretion and resistance.  If so, 
supplementation may open perspectives for prevention and even therapy.  
Therefore, we carried out this epidemiologic study with the purpose: 
1. To investigate the epidemiology of concurrent tuberculosis with diabetes.  
2. To investigate the risk factors of co-occurrence of tuberculosis and 
diabetes. 
3. To identify the role of vitamin D in the risk of diabetes and tuberculosis, 
and their co-occurrence.  
4. To explore whether adding vitamin D to standard therapy can improve 
the prognosis of tuberculosis with and without diabetes mellitus.  
 
Outline of the thesis 
First, a large epidemiological survey was carried out among newly diagnosed 
tuberculosis patients and non-tuberculosis controls from a rural community, 
to screen for diabetes (Figure 1-7). In addition, we explored possible risk 
factors for concurrence of the diseases, in order to provide a scientific basis 
for early diagnosis of tuberculosis in diabetes. To our knowledge, this is the 
first large scale survey of diabetes mellitus in tuberculosis patients in the 
community (chapter 2). 
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Figure 1-7 The study area of Linyi, Shandong 
Many tuberculosis patients have a significant vitamin D deficiency, and this 
may be closely related to the onset and progress of the disease. To 
investigate whether diabetes may influence the time lag from onset of 
typical symptoms until diagnosis of tuberculosis, we randomly selected 
patients from the epidemiological survey in chapter 2 (Chapter 3). Four 
hundred and sixty-one active tuberculosis patients (192 with diabetes and 
269 without diabetes) were randomly selected from a city level chest 
hospital (latitude 36°N) to evaluate the vitamin D status and the possible 
predictors of vitamin D deficiency.  And we investigated whether vitamin D 
may be a possible link between tuberculosis and diabetes in (chapter 4 and 
chapter 5). In a subsequent study, cellular immune function related cytokine 
levels in tuberculosis patients with and without diabetes were observed, 
with further analysis of their relationship with serum 25(OH)D (Chapter 6).  
A cluster randomized trial of vitamin D supplementation added to 
pharmacotherapy in tuberculosis patients with and without diabetes was 
carried out in a city-level chest hospital.  Possible effects of vitamin D 
supplementation on treatment outcomes were observed. The main purpose 
was to further explore the role of vitamin D in tuberculosis and diabetes 
(Chapter 7). 
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Abstract 
Background: Patients with type 2 diabetes (DM) have a higher risk of 
developing pulmonary tuberculosis (PTB); moreover, DM co-morbidity in 
PTB is associated with poor PTB treatment outcomes. Community based 
prevalence data on DM and prediabetes (pre-DM) among TB patients is 
lacking, particularly from the developing world. Therefore we conducted a 
prospective study to investigate the prevalence of DM and pre-DM and 
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evaluated the risk factors for the presence of DM among newly detected 
PTB patients in rural areas of China. 
Methods and Findings: In a prospective community based study carried out 
from 2010 to 2012, a representative sample of 6382 newly detected PTB 
patients from 7 TB clinics in Linyi were tested for DM. A population of 6674 
non-TB controls from the same community was similarly tested as well. The 
prevalence of DM in TB patients (6.3%) was higher than that in non-TB 
controls (4.7%, p<0.05). PTB patients had a higherodds of DM than non-TB 
controls (adjusted OR 3.17, 95% CI 1.14-8.84). The prevalence of DM 
increased with age and was significantly higher in TB patients in the age 
categories above 30 years (p<0.05). Among TB patients, those with normal 
weight (BMI 18.5-23.9) had the lowest prevalence of DM (5.8%). 
Increasingage, family history of DM, positive sputum smear, cavity on chest 
X-ray and higher yearly income (≥10000 RMB yuan) were positively 
associated and frequent outdoor activity was negatively associated with DM 
in PTB patients. 
Conclusions: The prevalence of DM in PTB patients was higher than in 
non-TB controls with a 3 fold higher adjusted odds ratio of having DM. Given 
the increasing DM prevalence and still high burden of TB in China, this 
association may represent a new public health challenge concerning the 
prevention and treatment of both diseases. 
 
Introduction 
The association between diabetes mellitus (DM) and tuberculosis (TB) has 
been recognised for centuries. DM was a well-known risk factor for TB(1) , 
but this association was nearly forgotten after the advent of widely available 
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treatment for both diseases. With the current global increase in DM largely 
driven by increasing prevalence in the developing world, the DM population 
is anticipated to reach 552 million by 2030(2) and the link is re-emerging. The 
co-morbidity of DM and TB represents a double burden with significant 
public health implications as recently recognised by several authors(3)(4) . In 
developing countries such as India, China, Bangladesh, Indonesia and Brazil, 
where TB is still highly endemic(5), the double burden and interaction of DM 
and TB will be more ominous. China accounts for nearly 17% of the world’s 
TB burden, with an estimated 1.5 million new cases and approximately 
270,000 deaths each year. In the meantime, the country has also witnessed 
an escalating epidemic of DM(2) as the consequence of industrialization, 
urbanization, increase in life expectancy, and changes in lifestyle in recent 
years. It was recently reported that the agestandardised prevalence of DM 
and impaired glucose tolerance (IGT) reached to 9.7% and 15.5% 
respectively in China(6). 
Jeon CY et al carried out a large meta analysis and discovered that DM 
patients were 3.1 times (95% CI 2.27 - 4.26) more likely to have TB than 
non-diabetic controls(7)and it has been estimated that the TB risk 
attributable to DM was between 15% and 25%(8)(9). Two large scale 
longitudinal cohort studies from Korea and UK have shown similar findings 
with risk ratios of 3.47 (95% CI 2.98 - 4.03) and 3.80 (95% CI 2.30 - 6.10)(10)(11). 
The mechanism behind the association between TB and DM is not fully 
understood but studies suggest that DM depresses the immune response 
through effects on macrophage and lymphocyte function, which in turn 
facilitates active TB disease. Conversely, it is also possible that TB can induce 
glucose intolerance and also deteriorate glycemic control in subjects with DM (12). 
However, only a few studies have reported on screening for DM in TB 
patients. A wide range of DM prevalence among TB patients (1.9% to 39%) 
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has been reported and most of the studies are based on secondary data 
analysis, self-reported DM, or have a small sample size(7)(10)(13). Gaining a 
deeper understanding of the differences between TB patients with and 
without DM is urgently needed to prevent the co-morbidity and to improve 
the prognosis of the patients with DM and TB. Therefore, we initiated this 
large scale prospective epidemiologic study using primary data to identify 
the current prevalence of DM and pre-DM in newly- diagnosed PTB patients 
together with non-TB controls from the same community. Also, the odds 
ratios for DM among TB patients were analysed in order to get the clues to 
the early detection of DM in TB patients, and to figure out DM patient with 
what characteristics should be given priority to the prevention of TB. 
 
Methods 
Ethics Approval 
This study was carried out in accordance with requirements documented in 
the Declaration of Helsinki. Ethics approval was obtained from the medical 
ethics committee of Qingdao Disease Prevention and Control Centre, 
Qingdao, People’s Republic of China. All participants were fully informed 
and gave their written informed consent. This trial is registered in the 
Chinese Clinical Trial Registry (No. ChiCTR – OCC - 10000994, URL: http:// 
www.chictr.org/cn/proj/show.aspx?proj = 411). 
Study Population 
The study population was selected from Linyi rural area, Shandong province 
in North China. Seven TB clinics were randomly selected for this study 
including Yishui, Yinan, Lanshan, Cangshan, Tancheng, Feixian and Pingyi. 
Each TB clinic had a defined catchment area comprising approximately 0.9 
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million inhabitants. The diagnosis of PTB was made within the existing TB 
prevention and control system in China, in which clinical manifestations, 
sputum smear microscopy and chest radiography were the central 
component. Suspected PTB person was investigated by sputum smear 
examination. The patient was diagnosed as smear-positive PTB if sputum 
specimens were smear positive; if sputum smears were negative and chest 
radiograph was compatible with active PTB, the patient was diagnosed as 
smear-negative PTB after discussion by clinical and radiographic doctors(9). 
All adult (≥18 years) newly-diagnosed PTB patients who registered for 
Directly Observed Treatment, Short Course (DOTS) in these TB clinics from 
September 2010 to December 2012 were included. HIV-positive patients 
were excluded because of the influence of antiretroviral therapy on insulin 
resistance as were subjects with type 1 diabetes. 
A sample size of 7000 was calculated, assuming a prevalence of DM as 6.7% 
amongst the TB subjects as reported in the literature(14), considering 
non-response rate of 20%(15). We adjusted it to 6200 because of better 
compliance of the participants observed in the pilot study than expected 
(modifying non-response rate to 10%). For estimating DM and pre-DM 
prevalence amongst the non-TB cohort, cluster random sampling was used 
to recruit subjects from the same communities as the TB cases. 
Diagnosis of DM and pre-DM was based on WHO criteria for the 
classification of glucose tolerance based on fasting plasma glucose (FPG)(16). 
After an overnight fast, venous blood of each participant was collected. 
Glucose oxidase method was used to estimate FPG level. Those with 
FPG≥6.1 mmol/L were referred to DM clinics for diagnostic confirmation 
with a second FPG test. Those with FPG level in the range of 6.1 mmol/L to 
6.9 mmol/L were screened as pre-DM; those with FPG level ≥7.0 mmol/L 
were screened as DM. Lipid indexes including total cholesterol, triglyceride 
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and HDLC were estimated by enzymatic procedure. Anthropometric 
measurements including height and weight by standard procedure were 
measured by trained investigators. Body mass index (BMI, kg/m²) was 
calculated by using the formula: BMI = Weight (kg)/Height² (m²). 
Underweight, normal weight, overweight, and obesity were defined by using 
the modified criteria for Chinese population (17). The BMI cut-off value for 
underweight (severe underweight, moderate underweight, mild 
underweight), normal weight, overweight, and obesity was﹤18.5 kg/m2 (﹤
16 kg/m², 16- 16.9 kg/m², 17-18.4 kg/m²), 18.5-23.9, 24.0-27.9 kg/m² and 
≥28.0 kg/m²,respectively. Two blood pressure measurements were taken 
using sphygmomanometer with the subject in sitting posture, and the 
average of the two readings was recorded. 
A structured questionnaire was administered to obtain information 
regarding socio-demographics, personal and family disease history, and 
lifestyle risk factors including smoking, alcohol consumption, educational 
level, outdoor activity, yearly income and marital status. The interviews 
were conducted by trained local TB workers in order to assure compliance 
and quality of the data collected. 
Data Management and Quality Control 
Double data entry was carried out, and then a computer based error 
detection system was used to check the consistency of data. In case of 
inconsistency, the original questionnaire was checked and the error 
corrected via a re-entry. During the investigation, different methods of 
quality control including inter-lab comparison of glucose measurement were 
carried out. 
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Statistical Analysis 
The study design followed STROBE Guidelines(18). SPSS version 19.0 was used 
for statistical analysis. Characteristics of TB and non-TB controls were 
compared and the study characteristic of TB patients by diabetes status 
including normoglycemia (Non-DM), prediabetes (Pre-DM), and diabetes 
(DM) were analyzed. Mean and standard deviation for continuous variables 
and proportions for categorical variables are reported. Independent sample 
t test and ANOVA were used to test continuous variables. Chi-square or 
Fisher’s exact test was used to compare categorical variables. Kruskal-Wallis 
H test was used to compare ranked variable. Two multinomial logistic 
regression analyses were performed. The variables for inclusion in the 
multivariate model were chosen based on plausibility and variables with p 
values of﹤0.1 in univariate analysis were entered into the multivariate 
analysis. One multivariate logistic analysis was to examine the association 
between PTB and DM and pre-DM and to calculate odd ratios and 95% 
confidence intervals. The dependent variable was either DM or pre-DM, the 
independent variables being suffering from active PTB and we examined the 
following covariates for the effect modification or confounding: age [(years) 
(categorized in 4 units: ﹤30, 30 - 39, 40 - 49, ≥50)], sex, BMI [(kg/m²)  
(categorized as﹤18.5, 18.5 - 23.9, ≥24.0)], yearly  income[(RMByuan) 
(categorized as﹤2000, 2000 - 9999, ≥10000)], family history of DM, 
smoking, alcohol consumption, outdoor activity, education level and marital 
status. The other logistic regression analysis was performed to qualify the 
odds of having DM and pre-DM in active PTB patients, the dependent 
variable being either DM or pre-DM and the independent variables being 
the same as the first model without active TB and with PTB profile including 
positive sputum smear, cavity and involved lung field on chest radiograph. 
The entry probability was p≤0.05 and the removal probability was p>0.10. 
All variables were checked for collinearity in both models. The model fit was 
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significant for both multinomial logistic regression analyses (x2 = 285.6 and 
372.8, respectively, p<0.001) and the fit was good (x2 = 1093.47 and 1067.52, 
respectively, p>0.05). A p value of <0.05 was considered statistically 
significant. 
 
Results 
The details on the total number of eligible PTB patients, those who gave 
written consent to undergo screening of DM and those included in the final 
analysis are illustrated in a flow chart (Figure 2-1). A total of 8410 patients of 
≥18 years of age were registered for TB treatment in the above 7 TB clinics 
in the study period. Finally, 6902PTB patients completed the study. After the 
exclusion of 520 persons for whom demographic information or fasting 
glucose levels were missing, 6382 patients (4627 men and 1715 women) 
were included in the final analysis. The recorded response rate was 92.5%. 
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Figure 2-1. Flowchart of the pulmonary tuberculosis patients in the study, Linyi, 
2010-2012. 
The details on the total number of eligible participants, those who have given written 
consent to undergo screening of DM and the patients included in the final analysis are 
illustrated in Figure 1. There were 8410 newly detected pulmonary tuberculosis patients 
in total study period. Finally, 6382 patients were included in the final analysis. 
General Characteristics 
The demographic and anthropometric information of the TB and non-TB 
cohort is detailed in Table 2-1. 
Data from 6382 TB patients and 6675 non-TB controls was available for 
analysis. The mean age of the PTB patients was 50.4±18.6 and of the non-TB 
controls 50.8±16.4 (p>0.05). There was a significant sex difference between 
TB and non-TB (p<0.001). Mean BMI of non-TB cohort was significantly 
higher than that of the TB cohort (p<0.001). Systolic blood pressure and 
diastolic blood pressure were higher in non-TB cohort compared to TB 
cohort (p<0.001). Plasma glucose level was higher in TB patients compared 
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to non-TB controls (p<0.001). Smoking was more common in TB patients 
than in non-TB controls (p<0.001), while alcohol consumption was higher in 
non-TB (p<0.001). 
Table 2-1.  Characteristics of TB patients and non-TB controls, Linyi, 2010–2012. 
TB(n=6382)        Non-TB(n=6675)   p value 
Male, n(%) 4631(72.90) 3712(55.61) <0.001 
Age 50.41±18.63 50.77±16.40 0.242 
BMI 20.91±2.76 22.52±2.99 <0.001 
Sbp 119.69±11.43 123.95±15.00 <0.001 
Dbp 76.70±7.70 79.31±9.80 <0.001 
Plasma glucose 5.39±1.88 5.15±1.20 <0.001 
Hemoglobin 131.89±17.25 131.07±43.48 0.610 
Total cholesterol 4.39±1.09 4.69±1.20 <0.001 
HDLC 1.46±0.60 1.63±0.82 <0.001 
Triglyceride 1.20±1.11 1.31±0.94 0.884 
DM Family history, n (%) 695(11.4) 765(12.6) <0.001 
Smoking, n (%) 900(14.1) 379(5.7) <0.001 
Alcohol consumption, n (%) 414(6.5) 753 (11.6) <0.001 
Yearly income, n(%) 
<2000 883(13.9) 935(14.0) 0.002 
2000~9999 3937(61.9) 4507(67.5)  
10000 1541(24.2) 1232(18.5)  
Marital status, n(%) 
Married 4694(79.4) 5419(87.8) <0.001 
Single/widowed/divorced 1221(20.6) 754(12.2)  
Educational status, n(%) 
illiteracy 1625(27.4) 1553(25.2) <0.001 
primary or middle school 3558(59.9) 3300(53.5)  
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high school or higher 758(12.8) 1312(21.3)  
Outdoor activity, n (%) 
>2 hours/d 3779(63.6) 4041(67.5) <0.001 
2 hours/d 1863(31.4) 1644(27.5)  
None 300(5.0) 302(5.0)  
 
Relationship Between PTB and DM 
Details of the DM and pre-DM prevalence in TB patients and non-TB controls 
are shown in Figure 2. Based on FPG, out of 6382 TB patients, 403 (6.3%) 
had DM; while out of 6675 non-TB controls, 313 (4.7%) had DM. The 
prevalence of DM in TB patients was significantly higher than in non-TB 
controls (p<0.05). In males, the prevalence of DM was 52% higher in TB than 
in non-TB (p<0.05). Taking into account possible confounding factors such as 
age, sex, BMI, family history of DM, education level, smoking, alcohol 
consumption, outdoor activity and marital status, we found that PTB 
patients had 3.17 times higher odds of having DM compared with non-TB 
control (Table 2-2). 
Table2-2 Odds Ratio for diabetes and pre-diabetes by PTB in Linyi, China, 2010–2012. 
 Diabetes 
 Crude OR P Adjusted OR* P 
overall 1.38(1.19-1.61) <0.001 3.17(1.14-8.84) 0.027 
male 1.59(1.35-1.94) <0.001 3.27(1.06-10.06) 0.039 
 Pre-diabetes 
Crude OR       P       Adjusted OR*          P 
overall 1.15(1.01-1.32) 0.041 1.14(0.50-2.57) 0.76 
male 1.25(1.05-1.48) 0.013 1.09(0.46-2.56) 0.84 
*Adjusted for age, BMI, sex, family history of DM, yearly income, education level, 
smoking, alcohol consumption, outdoor activity, marital status. 
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The prevalence of DM increased with increasing age and was significantly 
higher in the TB groups than in the non-TB groups except for the age 
subgroup <30. The same tendency existed for pre-DM but the difference 
was only significant in the age subgroup of 30 - 39 (Figure 2-2). 
Among BMI subgroups in TB patients, those with normal BMI (18.5 - 23.9) 
had the lowest prevalence of DM (5.8%), while the prevalence of DM in 
overweight and obese cases (BMI≥24) was the highest (7.7%). The greatest 
difference (2.6 fold) in DM prevalence between TB and non-TB was 
observed in the underweight group (p<0.05) (Figure 2-2). 
DM was newly detected in 177 (43.9%) PTB patients and in 136 (43.5%) 
non-TB controls, respectively. In general, patients with previously diagnosed 
DM had higher fasting plasma glucose levels than did those with 
newly-diagnosed DM. 10.3% of previously known DM cases had their blood 
glucose level tested regularly. The prevalence of pre-DM in TB patients and 
non-TB controls was 7.4% and 6.6%, respectively, all previously 
undiagnosed. 
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Figure 2-2. The prevalence of diabetes and prediabetes in TB and non-TB. 
The overall prevalence of diabetes and prediabetes in TB and non- TB was shown in 
Figure 2. Also, the sex, age (<30, 30<39, 40 - 49, ≥50) and BMI (<18.5, 18.5 - 23.9, ≥24.0) 
stratified prevalences were shown. The prevalence of diabetes in PTB patients was 6.3%, 
which was significantly higher than in non-TB controls (4.7%). The prevalence of 
diabetes increased with increasing age and was significantly higher in the TB than in the 
non-TB groups except for the age group <30. Among BMI subgroups in TB patients, 
normal weight patients with a body mass index of 18.5 - 23.9 had the lowest prevalence 
of DM (5.8%), while the prevalence in overweight and obese cases (BMI≥24) was the 
highest. TB: pulmonary tuberculosis patients, non-TB: non tuberculosis controls. 
Chapter 2 
 
 - 48 - 
 
Characteristics of TB Patients with DM or Pre-DM 
Table 2-3 shows the comparison of the study characteristics of PTB patients 
with Non-DM, Pre-DM, and DM. 
Among PTB cases (6382), 403 patients had DM and 470 had pre-DM. 
PTBpatients with DM and pre-DM were older than the subjects with 
normoglycemia (57.81,  57.11 vs 49.29, p<0.001). PTB patients with DM 
had a higher systolic and diastolic blood pressure in comparison with 
patients with normoglycemia and pre-DM (p = 0.024, 0.017, respectively). 
Triglyceride and total cholesterol were higher compared with patients with 
normoglycemia (p = 0.024, <0.001, respectively). 
Profile of PTB also showed significant difference. A higher proportion of PTB 
patients with DM were smear positive (61.6%) compared to those with 
normoglycaemia (46.8%). A small proportion of patients were categorised as 
PTB relapse, and patients with DM had the highest relapse rate (p<0.001). 
Table 2-3 Study characteristics of TB patients by diabetes status in Linyi, China, 
2009-2012 
Characteristics Non-DM          Pre-DM DM P value 
N 5509 470 403  
Male, n(%)      3992(72,5) 341(72.6)                 298(73.9) 0.813 
Age(years)    
BMI(kg/m2)                   
Underweight 
Normal 
Overweight and obesity 
Blood Pressure(mmHg) 
Systolic  
Diastolic 
49.29±18.97          
20.90±2.72               
866(17.2) 
3504(69.5) 
674 (13.4) 
 
119.53±11.26               
77.51±7.70                
57.11±14.72* 
20.86±2.97           
95(21.8)* 
265(60.8)* 
76(17.4)* 
 
119.91±11.77            
77.85±6.78               
57.81±14.23* 
21.09±3.06          
77(20.8)* 
231(62.3)* 
63(17.0)* 
 
121.62±13.07* 
78.61±8.61*
<0.001 
0.234 
<0.001 
 
 
 
0.024 
0.017 
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Fasting glucose(mmol/l) 4.94±0.60         6.44±0.26* 10.30±4.81*& <0.001 
Haemoglobin(g/L)        
131.88±16.90            132.30±18.99      131.54±20.08          0.762 
Triglyceride(mmol/l)         1.19±1.09              1.23±1.47            1.35±0.74* 0.024 
Total cholesterol(mmol/l) 
4.34±1.01       4.61±1.24* 4.75±1.62* <0.001 
HDLC(mmol/l)    1.44±0.59           1.65±0.74* 1.47±0.52& <0.001 
Type of PTB*, n(%)     
Smear positive cases 2513(46.8) 237(55.3) 198(61.6) <0.001 
Smear negative cases 
2857 (53.2) 192(44.7) 123(38.4)  
Relapse, n(%) 247 (4.6) 24(5.6) 28(8.8) <0.001 
 * P<0.05 compaired with non-DM group, & P<0.05 compaired with pre-DM group 
 
Odds Ratios for DM and Pre-DM among PTB Patients by Multivariate Risk 
Assessment 
In the multivariate logistic regression models, increasing age, family history 
of DM, positive sputum smear, cavity on chest X- ray and higher yearly 
income (≥10000RMB yuan) were significantly associated with an increased 
odds of DM in TB patients. Underweight had a borderline significant 
association with DM compared with normal weight (OR = 1.30, p = 0.082). 
Frequent outdoor activity was negatively associated with DM odds. Age 
category of ≥50 years had the highest odds ratio of 13.20 (p<0.001), 
followed by age category of 40 - years and family history of DM with OR 9.46, 
5.85 respectively. Associations were not observed for sex, education, 
smoking, alcohol consumption, marital status and involved lung field on 
chest X-ray (Table 2-4). 
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As to having pre-DM, age, family history of DM, overweight, obesity and 
underweight were positively associated, and frequent outdoor activity was 
also negatively associated with pre-DM odds. 
 
 Table 2-4 Multivariable-adjusted odds ratios for diabetes and pre-diabetes  
in pulmonary tuberculosis patients 
Variables Diabetes 
OR(95% CI)   
P value Prediabetes 
OR(95% CI)   
P value 
Age(years) 
<30(reference)      
30~ 
40~            
≥50 
 
-- 
5.35 (2.47-11.57) 
9.46 (4.61-19.43) 
13.20 (6.71-25.96) 
 
-- 
<0.001 
<0.001 
<0.001 
 
-- 
3.61 (1.96-6.64) 
4.29 (2.40-7.66) 
5.74 (3.37-9.76) 
 
-- 
<0.001 
<0.001 
<0.001 
DM Family history 
BMI 
18.5-23.9(reference)       
5.85 (4.44-7.69) 
 
-- 
<0.001 
 
-- 
1.58 (1.14-2.20) 
 
-- 
0.006 
 
-- 
<18.5 1.30 (0.97-1.76) 0.082 1.38 (1.05-1.80) 0.019 
≥24.0 1.08 (0.77-1.53) 0.644 1.44 (1.07-1.93) 0.015 
Positive sputum smear 
Cavity in chest X-ray 
Frequent outdoor activity 
Yearly income(RMB) 
<2000(reference)       
2000-9999 
≥10000 
1.61(1.08-2.40) 
1.66(1.07-2.59) 
0.63 (0.49-0.80) 
 
-- 
1.34 (0.94-1.92) 
1.65 (1.09-2.50) 
0.021 
0.025 
<0.001 
 
-- 
0.106 
0.017 
1.36(0.96-1.94) 
0.76(0.46-1.26) 
0.72 (0.58-0.89) 
 
-- 
0.87 (0.65-1.16) 
0.95 (0.67-1.34) 
0.085 
0.285 
0.003 
 
-- 
0.337 
0.768 
Non significant variables: sex, marriage, smoking, alcohol drinking, educational level, 
involved lung field 
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Discussion 
The present study shows that the prevalence of DM based on FPG values 
was higher in the PTB (6.3%) patients than in the non-TB (4.7%) controls, 
and PTB patients had 3.17 times the odds of having DM as non-TB subjects, 
when adjusted for possible confounding factors. 
Our study was designed to discover the prevalence of DM and pre-DM in TB 
patients and estimate the odds ratios. The strength of this study is its 
community based setting. To avoid selection bias, we chose community 
based TB clinics instead of TB hospitals, which means the prevalence and 
odds ratios can be regarded as representative for the general population. 
Also, the large sample size allowed us to provide relatively precise estimates 
of current prevalence of DM in TB. To accurately define DM, we used 
primary data collected from newly-diagnosed PTB patients and also in a 
non-TB control group. In other related studies, either the DM prevalence in 
non-TB was not reported or the prevalence being calculated from secondary 
data with inherent biases(19; 20). Only a few reports concerning the 
prevalence of DM in active TB patients in China are available until now. 
Zhang Q et al carried out a retrospective analysis in Shanghai pulmonary 
hospital from 2008–2009 and discovered 9.2% TB patients were complicated 
by DM (21). Also from Shanghai, in 1997, Lin S et al reported 4.86% 
prevalence of DM in TB cases, DM tending to be more prevalent among TB 
patients in urban area and in older patients(22). Liang Li et al reported a 
prevalence of 12.4% in a study based in different parts of China, primarily 
based on hospital data using FPG(23). Until now, there were no community 
based data on the prevalence of DM among sufficiently large samples of TB 
patients as well as comparative data from non-TB controls from the same 
community collected in the same time period. 
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It has been reported that PTB may induce temporary hyperglycemia, which 
resolves with treatment(14). Thus, over- diagnosis might take place if tested 
for glucose prior to initiation of TB treatment. Most of our study subjects 
were screened for DM 2–3 weeks after the initiation of TB treatment. 
We found that the associated factors for having DM were basically the same 
for PTB patients as for the general population. Increasing age, family history 
of DM and high income were positive associated factors for DM in PTB 
patients. For BMI the pattern looks somewhat different. The World Health 
Organization’s (WHO) “standard” definition for underweight, overweight, 
and obesity by BMI are ≤18.5 kg/m2, 25.0 to 29.9 kg/m2, and ≥30.0 kg/m2, 
respectively(24). But in China as in other parts of Asia, a modified criteria is 
more appropriate to forecast the risk of DM, dyslipidemia and the related 
diseases(17) and we used this criteria for the cut-off value. The severe 
underweight and moderate underweight categories only account for 3.4% 
and 3.7% of the TB patients respectively in our study, so we combined them 
with mild underweight accounting for totally 17.7% underweight patients in 
our study. Similarly, obesity only accounts for 0.7% in the PTB cases and we 
combined it with the overweight subgroup, together accounting for 13.9% 
overweight and obese PTB cases. Although the average BMI in PTB patients 
with DM, pre-DM and normoglycemia did not show obvious difference, in 
logistic regression analysis, underweight (BMI<18.5 kg/m2) showed a 
significant association with pre-DM and borderline significance for DM. This 
finding was more or less similar to the study carried out in Tanzania (25) that 
reported severe underweight (BMI<16 kg/m2) among male TB patients was 
associated with DM (OR 2.52, p=0.004). Underweight is a risk factor for 
many chronic diseases such as respiratory diseases, osteoporosis, as well as 
DM(26) . Like in the general population, TB patients with overweight and 
obesity were at 1.44 fold odds of having pre-DM compared to normal 
weight patients. But the association was not significant for DM. However, 
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the proportion of overweight and obesity in patients with DM (17.0%) was 
higher than in patients without DM (13.4%). The association for BMI in the 
setting of co-morbid DM and TB is complex. While increasing the risk of DM 
and pre-DM, overweight and obesity is protective against TB disease(27). 
Weight loss due to poorly controlled DM and metabolic de-compensation 
takes away this protection. Presence of TB increases risk of hyperglycaemia 
through stress but by causing weight loss reduces the risk. These 
interactions may play out differently in different individuals(28) . 
The association of positive sputum smear with DM in TB patients was similar 
to what has been reported earlier(20)(29). In our study, patients with DM had 
the highest rate of positive sputum smear, which indicates high risk of 
infectivity and spread of TB by these patients. Presence of cavities on chest 
X-rays was significantly associated with comorbid DM in our study. 
Over half of our DM cases (56.1%) were already diagnosed previously. This 
was lower than nearly all DM patients being aware in the report by Restrepo 
BI et al(19) and about 75% being aware of DM in the study by Liang Li et al(23). 
This difference maybe because our study population was primarily from 
rural areas where DM awareness and screening are limited. In this context 
the importance of strengthening monitoring and control of DM becomes 
relevant. In the present study, only 10.3% of previously known DM cases 
had their blood glucose level tested regularly. The need for improving DM 
care services as well as health education about the link between TB and DM 
cannot be overemphasized, particularly in areas with double burden of the 
diseases. Our findings show that the opportunities for preventing TB among 
DM patients should receive greater attention by the health system. DM 
patients should be aware of their increased risk of active TB. They should be 
educated to report to TB clinics in time when suspicious TB symptoms occur 
in order to benefit from having early diagnosis and treatment. Furthermore, 
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underweight persons with DM should be paid high attention given the 
observed positive association in our study. 
Also, updating the educational curriculum of health professionals to increase 
their awareness of the re-emerging association between TB and DM is 
urgently required. We discovered that the link of TB and DM was not 
prioritized in the seven TB clinics that participated in our project, three of 
which even did not measure the blood glucose level of the TB patients 
before we started this project. Within the framework of the current project, 
we implemented health education on the links between TB and DM for TB 
patients, health care providers and the lay public, the results of which will 
be reported later. 
However, our study also has some limitations. First, since isolated 
hyperglycemia 2 hours after glucose loading is common among Asian 
patients with DM(30), we may have underestimated the prevalence of DM 
because an oral glucose tolerance test (OGTT) was not done for practical 
reasons. However, the same level of underestimation will apply for the 
non-TB group and thus does not change the relative odds. 
In Shanghai Diabetes Study, 48.6% of patients with newly-diagnosed DM 
had isolated hyperglycemia 2 hours after glucose loading (31) . So, the actual 
prevalence rates of DM and pre-DM in our study may have been much 
higher. This may also explain the difference between our findings and other 
studies carried out where dual burden of TB and DM also exists. The 
prevalence rates of DM and pre-DM were 25.3% and 24.5% respectively 
among TB patients in South India(20). 
Another lacuna in our study is that M. tuberculosis (MTB) infection was not 
confirmed by sputum culture in a substantial number of participants in the 
clinical settings in our study. However, according to the recent national TB 
epidemiological survey in China, positive MTB culture is documented in only 
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26.4% of the active PTB patients (32) , which means that nearly three quarter 
of the active PTB may be missed if we would take the MTB culture result as 
the gold standard. As with most TB centres, clinical manifestations, sputum 
smear microscopy and chest radiographs were the central component for 
PTB diagnosis in our study. 
Our study provides further evidence of the links between DM and TB and 
the evidence that this interaction is playing out even in the rural settings in 
China where the presumed burden of DM appears low. Our findings indicate 
the potential benefits of partially integrating TB and DM prevention and 
control systems, and males may benefit the most given the higher 
prevalence of TB among them. Given the growing huge burden of DM in 
China and the high rate of undetected DM, systematic screening of all TB 
patients for DM through the infrastructure for TB control could serve to 
improve the early detection of DM, particularly in developing countries. 
Liang Li et al indicate that such screening has the potential of identifying 
almost 30,000 new cases of DM each year in China (23). Follow-up studies are 
needed to identify the causal mechanism of the link between TB and DM in 
the future. 
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Abstract
Background: Excessive time between the ﬁrst presentation of symptoms of
pulmonary tuberculosis (PTB) and diagnosis contributes to ongoing
transmission and increased risk of infection in the community, as well as to
increased disease severity and higher mortality. People with type 2 diabetes
mellitus (T2DM) have a higher risk of developing PTB. However, the effect of
T2DM on delayed diagnosis of PTB is not fully understood. This study
investigated the effects of hyperglycemia (diabetes and pre-diabetes) and
other factors on PTB patient delay in a rural area of China.
Methods: In the present community-based investigation, PTB patients aged
≥16 years newly diagnosed at county tuberculosis dispensaries were
recruited consecutively between September 2011 and December 2013.
Fasting blood glucose was determined in all subjects, and a structured
questionnaire was used to collect basic information.
Hyperglycemia is associated with
increased risk of patient delay in
pulmonary tuberculosis in rural
areas
Qiuzhen WANG, Aiguo MA, Xiuxia HAN, Shanliang ZHAO,
Jing CAI, Frans J. KOK, Evert G. SCHOUTEN
Journal of Diabetes. 2017, 9; 648-655
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Results: Of the 2280 patients, 605 (26.5 %) had hyperglycemia. The median
(inter-quartile range) time to seeking health care was 44 (59) days. Health
care seeking was delayed in 1754 subjects, and hyperglycemia was
independently associated with an increased probability (odds ratio 2.10; 95% conﬁdence
interval 1.49–2.97) of patient delay in subjects aged ≥30 years. Other factors
associated with patient delay were cough, night sweats, and lack of
knowledge regarding typical tuberculosis symptoms. The onset of
hemoptysis was negatively correlated with patient delay.
Conclusions: Patient delay appears to be a serious problem in this rural area
with a high prevalence of tuberculosis. Hyperglycemia is independently
associated with an increased probability of patient delay, which, in turn,
may result in more serious clinical manifestations.
Key words: community, determining factor, diabetes mellitus, infectious
disease, odds ratio
Introduction
Tuberculosis (TB) continues to be a global health problem. In 2014, the
worldwide incidence of TB was 9.6 million and it killed approximately 1.5
million people(1). Early diagnosis and immediate initiation of treatment play
a key role in TB control, especially in arresting TB transmission within a
community. Most transmissions occur between the onset of cough and
initiation of treatment. At the individual level, a delay in diagnosis is
associated with poor disease prognosis(2).
Type 2 diabetes mellitus (T2DM) triples the risk of developing TB(3), and
comorbidity of DM and TB represents a double burden with significant
public health implications. In 2011, a collaborative framework for the joint
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care and control of TB and DM was proposed by the World Health
Organization (WHO) and the International Union Against Tuberculosis and
Lung Disease. China has one of the highest prevalences of TB, with an
incidence of nearly 7.07 per 10000 people, accounting for 10% of all cases
worldwide(1). Although progress has been made in TB control, the results of
the fifth national TB survey in China in 2010 showed that the prevalence of
TB declined only minimally by 7 per 100000 people in 10 years(4). At the
same time, China has witnessed an escalating epidemic of DM(5), with the
prevalence of DM and pre-DM reaching 9.7 % and 15.5 %, respectively, in
2010-11(6). Consequently, the possibility of an interaction between DM and
TB has increased in recent years. In a rural area in China, the prevalence of
DM in TB patients was 6.3 %, with TB patients having a higher odds ratio (OR;
3.17) of having DM than non-TB controls(7). It has been reported that DM is
associated with more serious clinical presentations and adverse treatment
outcomes for pulmonary TB (PTB)(8). Delays in diagnosing PTB in patients
with DM may present an even greater challenge for the prevention and
control of PTB, with a consequently worse condition of patients.
Factors related to health system delays, including health facilities, diagnostic
procedures, and disease management, vary according to countries or
regions(9). Based on our data, the median health system delay for PTB was 3
days, which may be due primarily to the considerable improvement in TB
clinics in China in recent years. Therefore, in the present study, we focus on
the patient delay in PTB.
Until now, there has been little information available regarding the effect of
DM on diagnostic delays of TB. In a cross-sectional study conducted in two
TB dispensaries in Beijing(10), DM was associated with a longer delay in
diagnosis, which was, on average, 19 days (OR 3.10; 95 % confidence
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interval 1.66 - 5.76). Malbasa and Pesut reported that DM was associated
with a higher patient delay (>30 days) in the setting of intermediate-to-low
TB incidence(11). However, whether DM will increase the risk of a delay in
seeking health care for TB in the setting of a high incidence of TB has not
been reported. In China, county-level TB clinics play an important role in TB
diagnosis and treatment in the community. Therefore, the present
large-scale epidemiological study was undertaken using primary data to
identify the association between hyperglycemia (including DM and pre-DM)
with health seeking delays in PTB patients at the community level in a high
TB incidence setting in a rural area in China.
Methods
Study population
The present cross-sectional study consecutively recruited patients aged ≥16
years who had been diagnosed with active PTB at the county TB center
between September 2011 and December 2013. Patients who met these
inclusion criteria and agreed to participate in the study were interviewed
using a pretested questionnaire. Brieﬂy, newly diagnosed PTB patients who
registered for Directly Observed Treatment, Short Course (DOTS) treatment
for TB from seven TB clinics (Yishui, Yinan, Lanshan, Cangshan, Tancheng,
Feixian, and Pingyi TB clinics) in Linyi, China, were included in the study.
Patients positive for HIV and subjects who had experienced trauma in the
past 3 months or had cancer or severe cardiac, hepatic, or kidney disease
were excluded from the study.
The present study was approved by the Ethics Committee of Qingdao
Disease Prevention and Control Centre and was conducted according to the
guidelines laid down in the Declaration of Helsinki. Written informed
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consent was obtained from all subjects prior to their inclusion in the study.
The study is registered with the Chinese Clinical Trial Registry (No.
ChiCTROCC-10000994).
Diagnosis of DM and pre-DM
Patients reporting a prior history of DM by confirmed diagnosis or
antidiabetic drug treatment were classified as being known diabetics. The
screening of DM and pre-DM was based on WHO criteria for the
classification of glucose tolerance based on fasting plasma glucose
(FPG)(12).After an overnight fast, venous blood was collected from each
participant and the glucose oxidase method was used to estimate FPG levels
shortly after blood had been drawn. Subjects with FPG≥6.1 mmol/L were
referred to DM clinics for diagnostic confirmation with a second FPG test.
Those with FPG levels in the range 6.1 - 6.9 mmol/L were diagnosed as
pre-DM and those with FPG levels ≥7.0 mmol/L were diagnosed as DM.
Definition of patient delay
The health seeking interval was taken as the time from the appearance of
major pulmonary symptoms of the disease until an individual's first visit to a
county TB dispensary. In the present study, a health seeking interval > 28
days was defined as patient delay.
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Data collection
A pretested standardized questionnaire was used for data collection. A
face-to-face interview was conducted by investigators who had received
prior training. Information regarding demographic characteristics (age,
gender, occupation [peasant, manual laborer, white-collar worker, retired or
unemployed], marital status [married, widowed/divorced, or single], yearly
household income, and education level) was collected. In addition,
information was collected regarding the clinical features of PTB, such as
typical symptoms (cough, hemoptysis, fever, night sweats, sputum
production, chest pain, fatigue, loss of appetite), and chest X-ray results (the
presence of cavities), knowledge of TB-related symptoms (cough or sputum
production, hemoptysis, fever or night sweats, chest pain), and the attitude
towards TB (e.g. Do you know that TB is curable? Do you feel extremely
upset about the disease? Will you maintain strict secrecy of suffering the
disease?).
Statistical analysis
Data were analyzed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
Data are shown as the number of cases, as the mean±SD, or as median
values with the interquartile range (IQR) in parentheses. Categorical
variables were compared using the Chi-squared test, whereas continuous
variables were compared using t-tests or the Wilcoxon test. Multivariate
logistic regression (MLR) was used to evaluate risk factors for patient delay.
All factors associated with the outcome in univariate models(P<0.05) were
checked in the multivariate model, including the distance from home to the
TB dispensaries, even though no statistical significance existed in the
univariate model. Backward stepwise logistic regression, with entry and
removal criteria of P<0.05 and P>0.10 respectively, was used to establish the
Hyperglycemia and patient delay in TB
- 65 -
final multivariate predictive model. The model was significant (χ²=153.983,
P<0.001). The goodness of fit of the multivariate model was assessed using
the Hosmer-Lemeshow test, and the fitness was good (χ² =4.089, P=0.769).
Odds ratios and nominal 95 % confidence intervals (CIs) are presented.
Two-sided P<0.05 was considered significant for all analyses.
Results
From September 2011 to December 2013, 2403 PTB patients were eligible
for inclusion in the study. Of these patients, 112 patients refused to
participate and 11 patients were excluded because their TB diagnosis was
not confirmed. This left 2280 patients for analysis.
Table 1 lists the basic characteristics of the participants stratified by patient
delay (Group 1, >28 days; Group 2, ≤28 days). Patients in Group 1 were
significantly older than those in Group 2. Of the 1754 TB patients in Group 1,
515 (29.4 %) had hyperglycemia, which was significantly higher than the
proportion of TB patients in Group 2 who had hyperglycemia (17.1 %;
P<0.001; Table 1). With regard to the onset of typical TB symptoms, the
proportion of patients reporting cough, fever, and night sweats was higher
in Group 1 than in Group 2 (P < 0.001 for all), whereas fewer patients in
Group 1 than Group 2 reported hemoptysis (13.7 % vs 20.9%, respectively; P
< 0.001). Low education levels and a lack of knowledge about TB symptoms
were more common in Group 1. There were no significant differences in
chest pain, fatigue, loss of appetite, gender, body mass index (BMI), yearly
income, distance from home to TB clinics, smoking, and alcohol
consumption between the two groups (Table 1;P> 0.05). Although there was
a tendency for sputum production and the presence of cavities, as revealed
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by chest computed tomography, to be higher in Group 1 than Group 2, the
differences did not reach statistical significance (Table 3-1).
Crude and adjusted ORs for patient delay are presented in Table 3-2. In the
MLR models, hyperglycemia was significantly associated with an increased
probability of patient delay (OR 2.053; 95 % CI 1.506 - 2.798). Of the
TB-related symptoms, cough had the strongest association with patient
delay (OR 6.111; 95 % CI 3.670- 10.175), followed by night sweats (OR1.933;
95% CI 1.432 - 2.608). Hemoptysis was negatively associated with patient
delay (OR 0.634; 95% CI 0.460- 0.875). Other risk factors for patient delay
included age ≥50 years and a lack of knowledge of typical TB symptoms.
Because age distribution in the two groups was significantly different and
age is also closely related to the incidence of diabetes, we analyzed the
correlation of hyperglycemia with patient delay stratified by age. The results
of the MLR model after adjustment for cough, sputum production,
hemoptysis, fever, night sweats, the presence of cavities, marriage status,
education level, knowledge of typical TB symptoms, BMI, smoking, attitude
towards TB, loss of appetite, and distance from home to TB clinics revealed
that hyperglycemia was significantly related to patient delay in the age
subgroups ≥ 65, 50 - 64, and 30 - 49 years. Combining these three subgroups,
we found that hyperglycemia was independently associated with a nearly
twofold higher probability of patient delay in participants aged ≥ 30 years
(OR 2.105; 95 % CI 1.491 - 2.973; Table 3-3).
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Table 3-1. Characteristics of the study subjects according to patient delay
(Group 1, >28 days; Group 2, ≤ 28 days)
Grou Group1 Group 2 P value
No. (%)
Age(years), median(IQR)
1754 (76.9)
53.00(31.00)
526 (23.1)
45.00(35.00) <0.001
Age(years)
≥ 65 450(25.7%) 98(18.6%) <0.001
50~64 547(31.2%) 125(23.8%)
30~49 398(22.7%) 140(26.6%)
< 30 359(20.5%) 163(31.0%)
Men 1303(74.6%) 378(72.1%) 0.262
BMI(kg/m2), mean ± SD 20.69±3.07 20.76±3.31 0.159
BMI(kg/m2)
< 18.5 296(16.9%) 98(18.6%)
18.5~23.9 1297(73.9%) 368(70.0%)
≥ 24.0 161(9.2%) 60(11.4%)
Symptoms
Cough 1659(97.4%) 445(87.3%) <0.001
Hemoptysis 231(13.7%) 99(20.9%) <0.001
Fever 822(48.6%) 184(38.8%) 0.001
Night sweats 619(36.5%) 113(23.9%) <0.001
Sputum production 1176(67.7%) 320(63.1%) 0.054
Chest pain 370(21.9%) 119(25.4%) 0.113
Presence of cavities 226(13.9%) 50(10.5%) 0.054
Fatigue 611(35.6%) 157(32.1%) 0.147
Loss of appetite 377(22.2%) 91(19.2%) 0.169
Yearly income(CNY)
< 10000 869(59.8%) 278(63.6%) 0.153
≥ 10000 584(40.2%) 159(36.4%)
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Hyperglycemia1 515(29.4%) 90(17.1%) <0.001
Diabetes 135(7.7%) 22(4.2%)
Impaired fasting glucose 380(21.7%) 68(12.9%)
Distance to TB clinic(km),
median (IQR)
17.90(16.90) 18.75(19.55)
Distance to TB clinic(km)
> 27.1 433(24.7%) 156(29.7%) 0.115
18.7~27.1 421(24.0%) 112(21.3%)
9.8~18.6 442(25.2%) 121(23.0%)
< 9.8 458(26.1%) 137(26.0%)
Marital status
Married 1370(79.3%) 375(73.1) 0.002
Widowed or divorced 80(4.6%) 21(4.1%)
Single 278(16.1%) 117(22.8%)
Low education level2 975(56.3%) 241(46.6%) <0.001
Former or current smoker 460(26.2%) 147(27.9%) 0.432
Alcohol consumption3
Knowledge of TB-related
symptoms4
173(9.9%) 61(11.6%) 0.250
None 132(7.8 %) 21(4.4 %) 0.031
1+ 540(31.8%) 168(35.0%)
2+ 442(26.0%) 129(26.9%)
3+ 369(21.7%) 90(18.8%)
4+ 214(12.6%) 72(15.0%)
Attitude towards TB5
None 103(5.9%) 37(7.1%) 0.452
1+ 90(5.2%) 20(3.9%)
2+ 298(17.2%) 94(18.1%)
3+ 1245(71.7%) 367(70.8%)
Unless indicated otherwise, data are given as n (%).
1Includes both diabetes and impaired fasting glucose. 2Low education level was
defined as education to primary school level or lower. 3Alcohol consumption
Hyperglycemia and patient delay in TB
- 69 -
means drinking alcohol at least twice a week for no shorter than one year.
4Knowledge of tuberculosis (TB)-related symptoms was evaluated using a
questionnaire regarding typical TB-related symptoms and rated as follows:
none, no knowledge of TB-related symptoms; 1+, knowing one of the typical
TB-related symptoms; 2+, knowing two typical TB-related symptoms; 3+,
knowing three typical TB-related symptoms; 4+,knowing all typical TB-related
symptoms. 5Attitudes towards TB were evaluated using a questionnaire and
rated as follows: none, no right answer to this question on the questionnaire;
1+, YES; 2+, NO; 3+, NO.
BMI, body mass index; IQR, interquartile range.
Table 3-2. Risk factors related to patient delay as determined
by logistic regression analysis
Crude Adjusted
OR(95 % CI) P-value OR(95 % CI) P-value
Age(years)
≥ 65 2.08(1.67~2.7) <0.001 2.01(1.22~3.30) 0.006
50~64 1.99(1.52~2.59) <0.001 1.78(1.12~2.80) 0.01
30~49 1.29(0.99~1.69) 0.06 1.48(0.96~2.27) 0.07
<30 (ref.) - - - -
Male gender 1.13(0.91~1.41) 0.26 / /
Body mass
index(kg/m2)
< 18.5 0.88(0.66~1.11) 0.23 / /
≥ 24.0 0.76(0.55~1.05) 0.09 0.63(0.42~0.94) 0.02
18.5~23.9 (ref.)
Symptoms
- - - -
Cough 5.38(3.63~7.96) <0.001 6.11(3.67~10.17) <0.001
Hemoptysis 0.59(0.46~0.77) <0.001 0.63(0.46~0.87) 0.006
Fever 1.48(1.20~1.83) <0.001 / /
Night sweats 1.83(1.45~2.31) <0.001 1.93(1.43~2.60) <0.001
Sputum production 1.22(0.99~1.50) 0.05 / /
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Presence of cavities 1.37(0.99~1.90) 0.05 1.41(0.96~2.06) 0 0.08
Chest pain 0.82(0.65~1.04) 0.11 / /
Fatigue 1.17(0.94~1.45) 0.15 / /
Loss of appetite 1.19(0.92~1.54) 0.17 / /
Yearly income(CNY)
< 10000 0.85(0.68~1.06) 0.15 / /
≥ 10000(ref.) - -
Hyperglycemia 2.01(1.56~2.57) <0.001 2.05(1.50~2.79) <0.001
Marital status
Married (ref.) - - / /
Widowed or divorced 1.04(0.63~1.71) 0.86 / /
Single 0.65(0.51~0.83) 0.001 / /
Low educationlevel1 1.47(1.21~1.76) <0.001 / /
Alcohol consumption2 0.83(0.61~1.13) 0.25 / /
Smokers 0.92(0.73~1.14) 0.43 / /
Knowledge of
TB-related symptoms3
/ /
none 2.09(1.23~3.57) 0.006
1+ 1.08(0.78~1.48) 0.63
2+ 1.15(0.82~1.60) 0.40
3+ 1.37(0.96~1.96) 0.07
4+(ref.) - -
Attitude towards TB4
none 0.82(0.55~1.21) 0.3 2.29(1.21~4.36) 0.011
1+ 1.32(0.80~2.18) 0.26 / /
2+ 0.93(0.72~1.21) 0.60 / /
3+(ref.) - - - -
Distance to TB clinic
(km)
/ /
>27.1 0.83(0.63~1.08) 0.16
18.7~27.1 1.12(0.84~1.49) 0.41
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9.8~18.6 1.09(0.82~1.44) 0.53
<9.8(ref.) - -
1Low education level was defined as education to primary school level or lower.
2Alcohol consumption means drinking alcohol at least twice a week for no shorter than
one year. 3Knowledge of tuberculosis (TB)-related symptoms was evaluated using a
questionnaire regarding typical TB-related symptoms and rated as follows: none, no
knowledge of TB-related symptoms; 1+, knowing one of the typical TB-related
symptoms; 2+, knowing two typical TB-related symptoms; 3+, knowing three typical
TB-related symptoms; 4+, knowing all typical TB-related symptoms. 4Attitudes towards
TB were evaluated using a questionnaire and rated as follows: none, no right answer to
this question on the questionnaire; 1+, YES; 2+, NO; 3+, NO.
OR, odds ratio; CI, confidence interval.
Table 3-3. Logistic regression analysis for hyperglycemia stratified by age and the
probability of patient delay
Crude Adjusted1
OR(95 % CI) P-value OR(95 % CI) P-value
All 2.009(1.566~2.577) <0.001 2.053(1.506~2.798) <0.001
Age(years)
≥65 1.964(1.157~3.334) 0.012 1.921(1.003~3.678) 0.049
50~64 2.211(1.360~3.596) 0.001 2.125(1.189~3.797) 0.011
30~49 1.613(1.016~2.560) 0.042 2.303(1.234~4.297) 0.009
<30 1.751(0.979~3.002) 0.059 1.539(0.717~3.304) 0.269
Age(years)
≥30 1.931(1.457~2.558) <0.001 2.105(1.491~2.973) <0.001
<30 1.715(0.979~3.002) 0.059 1.539(0.717~3.304) 0.269
1Adjusted for cough, sputum production, hemoptysis, fever, night sweats, the presence
of cavities, loss of appetite, body mass index, marriage status, education level,
knowledge of tuberculosis (TB)-related symptoms, smoking status, attitudes towards
TB, and the distance to TB clinics. OR, odds ratio; CI, confidence interval.
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Discussion
In the present community-based observational study, hyperglycemia was
independently associated with an in- creased probability of patient delay in
subjects aged ≥30 years. Signiﬁcant associations were also found for the
onset of cough, night sweats, old age, and a lack of knowledge of TB-related
symptoms, whereas hemoptysis was inversely correlated with patient delay.
An important challenge for TB control is inadequate and late case detection
(13).People who experience signs and symptoms of TB should report
promptly for formal diagnosis in TB clinics. Unfortunately, in many low-to-
middle income countries that have a high TB burden (14; 15; 16), a diagnosis
delay is still common. The underlying reasons reﬂect factors related to
patients and the healthcare system. Because, as noted in the Introduction,
there was no signiﬁcant health system delay, we focused on patient delay in
the present study.
The median (IQR) health-seeking interval was 44 (59) days, with 76.9% of
patients having a health-seeking delay. In regions with a high prevalence of
TB, early diagnosis is considered one that occurs 2-3 weeks after the onset
of clinical symptoms and late diagnosis is considered one that occurs 4
weeks after onset (17).The patient delay in the present study was longer than
that reported in some previous studies. For example, it has been reported
that 47% of Chinese patients with TB symptoms seek health care in a timely
manner (4), but one-third knowledge of typical TB symptoms, BMI, smoking,
attitude towards TB, loss of appetite, and distance from of suspected TB
cases in China's rural areas do not seek care after 3 weeks of persistent
cough (18). The longer delay in the present study may be due to different
deﬁnitions of patient delay and the study populations selected for analysis.
In the present study, patient delay was deﬁned as the time between the
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onset of PTB symptoms and the ﬁrst visit to a county-level TB dispensary,
and participants were recruited from newly diagnosed PTB patients in a
rural area with a high incidence of TB. The education level of nearly half the
participants in the present study was primary school or lower. We suppose
that the low education level and the associated low ability to recognize TB
symptoms may have contributed to the higher patient delay. Although
programs such as DOTS have proven to be successful for TB control in China
(19), concerns regarding the effectiveness of such programs for the most
vulnerable members of society, particularly the rural poor, have been raised (20),
and similar ﬁndings were made in the present study.
Individual factors, involving rural residence, old age, female gender, and low
education level, have been re- ported to lead to patient delay (15; 21; 22).
However, in recent years, the coexistence of DM and TB has posed a new
challenge, and a deeper understanding of the effects of DM on TB patient
delay is urgently needed.
In the present study, hyperglycemia, including DM and pre-DM, was
associated with a nearly twofold higher probability of patient delay. This
indicates that DM may facilitate the transmission of TB within the
community. In addition, because diagnosis delay is closely related to a more
severe clinical presentation and poorer prognosis, this association further
aggravates the disease burden at the level of the individual. In terms of
underlying mechanisms, the risk of being afﬂicted with infectious disease
increases signiﬁcantly in DM patients who are immunocompromised, which
includes impaired neutrophil bactericidal function, cellular immunity, and
complement activation caused by hyperglycemia. It has been reported that
the incidence of infection in DM is in the range 35.0 % - 90.0 % (23), with
lower respiratory tract infections being one of the most common
Chapter 3
- 74 -
complications. We suppose that frequent symptoms of cough, fever, and
chills that are seen in lower respiratory tract infections overlap typical TB
manifestations, which may explain, in part, why patients with hyperglycemia
are prone to have a longer health-seeking delay. Stratiﬁed analysis revealed
that this association was present in patients older than 30 years of age. One
possible explanation is that the chances of suffering from hyperglycemia are
quite low in people younger than 30 years of age.
Similar to other studies (15; 21), in the present study we observed that old age,
low education level, the onset symptoms of cough and night sweats, and a
lack of knowledge of TB-related symptoms were associated with patient
delay. However, we did not ﬁnd an association between rural residence and
patient delay, as reported by others (22), and this may be due to the
signiﬁcantly improved transportation in the area investigated in the present
study.
To avoid selection bias, we chose to recruit subjects from community-based
TB clinics instead of TB hospitals, which means the existence of patient delay
and the risk factors can be regarded as representative of the general
population. This is the main strength of the present study. In addition, the
large sample size allowed us to provide relatively precise estimates of the
effects of hyperglycemia on patient delay. To deﬁne the association more
accurately, we used primary data collected from newly diagnosed PTB
patients.
A major limitation of the present study is that the definition of the onset of
TB symptoms relied on self-report, which may have led to recall bias.
However, the diagnostic procedures in this area were uniform and standard
diagnostic methods were used. The socio-demographic variables, including
income, education, and type of health facility consulted by TB patients, were
similar across participants. Another weakness of the present study may be
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that we did not perform 2-h oral glucose-tolerance tests (OGTTs). Most of
the participants lived in rural areas and often had a long way to travel to get
to the county TB clinics, which made impractical to perform OGTTs. This may
have led to an underestimate of the prevalence of diabetes. However, we
included patients with pre-DM in the present study, which may compensate,
in part, for the possibly lower number of TB patients.
The present study provides the ﬁrst evidence that hyperglycemia, including
DM and pre-DM, is independently associated with an increased risk of
patient delay in people aged ≥30 years in a rural area with a high incidence
of TB. The ﬁndings indicate that screening for TB in DM patients, especially
those aged≥30 years, may contribute signiﬁcantly to reduce the
transmission of TB through early diagnosis. The mechanism underlying the
effects of hyperglycemia on TB patient delay needs further investigation.
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Abstract
Background & aims: Tuberculosis (TB) patients have a significant vitamin D
deficiency (VDD) endemic, which may be closely related to the onset and
progress of the disease. The comorbidity of diabetes (DM) and TB has posed
an increasing challenge in recent years. However, the influence of DM on TB
and the possible mechanism are still uncertain. We carried out this study to
identify the nutritional status of vitamin D (VD) in TB patients in a northern
city in China (latitude 36°N) and investigate the possible predictors of severe
vitamin D deficiency (SVDD).
Methods: A cross-sectional study including 461 active TB patients (192 with
and 269 without DM) was randomly selected from Qingdao Chest Hospital
from June 2015 to August 2016. We measured serum 25-hydroxyvitamin D
[25(OH)D], and investigated the association between socio-demographic,
dietary intake, DM, body mass index (BMI), severity of initial TB signs and
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symptoms (TB score) and VD status. Multivariate logistic regression analysis
was used to define the possible predictors of SVDD.
Results: The median serum 25(OH)D concentration was 8.50 ng/mL. Of the
461 TB patients included, 383(83.1%) had VDD [25(OH)D < 20 ng/mL], and
217 (47.1%) had SVDD [25(OH)D<8 ng/mL]. The variables associated with
serum 25(OH)D concentrations were DM, outdoor activity level, TB score
and BMI (p < 0.05). Patients with severe TB score had nearly 5 fold higher
risk of having SVDD compared with those in mild subgroup [OR (95% CI)
4.919 (2.644 - 9.150), p < 0.001]. Low outdoor activity level also increased
the odds of SVDD, while DM and high fish consumption showed protect
effects.
Conclusions: Severe hypovitaminosis D is prevalent in active TB patients,
and the main predictors of SVDD were severe TB score, low outdoor activity,
inadequate fish consumption. Lowered serum 25(OH)D may be associated
with increased risk of TB in DM.
Introduction
Vitamin D deﬁciency (VDD) is a worldwide public health problem that is the
cause of rickets, but is also associated with a range of common chronic
diseases including diabetes, infection, cardiovascular disease, autoimmune
diseases and cancer. Mainly due to new ﬁndings of the functions of this
sunshine vitamin, a surge of research investigating the relationship between
vitamin D (VD) and tuberculosis (TB) started in the 21st century (1; 2; 3; 4; 5; 6; 7; 8).
Exposure of TB patients to sunlight, which induces cutaneous VD synthesis,
became common practice already in the early 20th century (9). However, in
the middle of the 20th century, anti-tuberculosis drugs like rifampin,
isoniazide, pyrazinamide were introduced and VD lost its role in therapy. It
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has been reported that in activated macrophages and T lymphocytes, the
main effectors of anti-TB immunity in the body, there exist receptors of the
active form of vitamin D [1,25(OH)2D3] (10), which was discovered to be
important in the congenital antimicrobial response pathway in macrophages
(11). Serum 25-hydroxyvitamin D[25(OH)D] is the most reliable index of
vitamin D (VD) status in the body (12). VDD [serum 25(OH)D < 20 ng/mL] and
severe vitamin D deﬁciency (SVDD) (13) [serum 25(OH)D < 8 ng/mL] were
reported in TB patients (2; 3; 4; 13; 14), even in equatorial countries like Tanzania
(2). A systematic review showed that up to 88.9% patients with TB had VDD
and the main predictors were lack of ultraviolet exposure, inadequate
dietary intake, comorbidities and old age (5).
In recent years, the double burden of increasing prevalence of diabetes
mellitus (DM) in addition to endemic city of TB in the developing world, has
posed an increasing challenge to public health care. According to the global
tuberculosis report 2016 (WHO), the TB epidemic was greater than
previously estimated, with a total of 10.4 million new cases in 2015, and 1.4
million deaths attributable to TB. Although a downward trend of TB
incidence has been observed from 2000 to 2015, China still accounts for
nearly 8.8% of the world's TB burden, with an estimated 918 thousand new
cases in 2015 (15). In the meantime, the country has also witnessed an
escalating incidence of DM. The age standardized prevalences of DM and
impaired glucose tolerance (IGT) have reached 9.7% and 15.5% respectively
(16), and a 4-year cumulative incidence of DM of 11.8% was reported in
Qingdao (17), our research center. Epidemiologic studies showed that DM
patients had a higher risk of active TB (18; 19). Similarly, we reported that
compared with non-TB controls, TB patients had a higher odds of DM
(adjusted OR 3.17) in a large scale epidemiologic study (20). A possible
underlying mechanism is that patients with DM have impaired immune
responses due to depressed macrophage and lymphocyte function, which in
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turn may facilitate active TB (21). Although there still exist discrepancies (22),
low circulating 25(OH)D has been widely reported to be correlated with
impaired insulin secretion and insulin action among diabetic patients (23; 24; 25; 26).
However, few studies have looked into the association of DM with vitamin D
status or VDD prevalence in active TB.
Therefore, we carried out this study to evaluate vitamin D nutritional status
in active TB patients, investigating the role of DM, and exploring the main
predictors of circulating 25(OH)D and SVDD.
Methods
Design and participants
In this cross-sectional study, 461 active TB patients aged 16 - 86 years and
registered for Directly Observed Treatment, Short Course (DOTS) were
randomly selected from Qingdao Chest Hospital from June 2015 to August
2016, including 192 TB with DM (TB+DM) and 269 TB without DM (TB-DM).
The hospital is located in Qingdao, Shandong province of China which has a
catchment area of about 9 million people, and the average number of
hospitalized patients with TB was about two thousand cases per year. TB
was diagnosed based on chest radiography, sputum smear microscopy and
clinical manifestations according to the standard tuberculosis diagnosis
criteria. DM was deﬁned on the basis of self-reported previous diagnosis of
DM, the use of either insulin or oral hypoglycaemic drugs, or FPG (fasting
plasma glucose) ≥7.0 mmol/L in admission biochemical test. Patients with
AIDS, cancer, severe cardiac, hepatic or renal diseases, trauma in the last
three months, or those taking vitamin supplements in the previous 6
months were excluded.
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The Ethics Committee of Qingdao Disease Prevention and Control Centre
approved the present study, and all the participants provided written
informed consent. This investigation research was registered in the Chinese
Clinical Trial Registry (No. ChiCTR-IPR - 15006395).
Sample size calculation
We estimated the number of TB patients recruited in this investigation by
using a power calculation based on a study from Korea, a country at similar
latitude, reporting 51.5% VDD in TB patients (3). The number of tuberculosis
patients needed was 420. An estimated drop-out rate of 10% was taken into
account.
Questionnaire and anthropometrical measurements
Structured questionnaires were used by trained interviewers to collect
information on demographic variables (including age, gender, educational
level, marital status, address, occupation and ethnicity), medical history,
dietary intake and lifestyle. For dietary intake, 3 day 24-h dietary recall and
semi-quantitative Food Frequency Questionnaire (SQ-FFQ), a valid tool to
assess habitual dietary intake were used. The SQ-FFQ used in the present
study consisted of food items known to contribute to dietary VD intake and
was modiﬁed according to local dietary pattern. Fish, milk, meat (pork, beef,
mutton, chicken and duck) and eggs were included. Fish and meat intakes
were assessed overall. Lifestyle included smoking, alcohol consumption and
outdoor activity level. Individuals who had smoked ≥100 cigarettes in
previous years or continued smoking were considered as smokers. Those
who consumed alcohol ≥1 cup/30 days (half a pint of beer, 125 g wine or 40
g spirits) regularly in the past or continued drinking alcohol were considered
as alcohol consumers. Outdoor activity level was assessed based on
self-reported outdoor exercise time including running, jogging, walking,
swimming, bicycling, dancing in public square, etc for the purpose to
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estimate sunlight exposure time, and the results were categorized into <2
h/day and ≥2 h/day.
Height and weight were measured according to a standardized procedure
with the patient in light clothes, without shoes and with an empty stomach
between 6.30-8.30 am. We used the formula BMI= weight (kg)/[height (m)2
to calculate body mass index (BMI). The cut-off value of BMI for Chinese
population (<18.5, 18.5-23.9, ≥24) was used for the classiﬁcation of
underweight, normal weight, overweight and obesity, respectively.
Severity categories of initial TB clinical manifestation
Based on signs and symptoms of TB including cough, haemoptysis, dyspnoea,
chest pain, night sweating, anaemia, tachycardia, lung-auscultation ﬁnding,
fever(axillary temperature>37℃), and BMI before treatment, we assessed
initial TB clinical manifestation using TB score (27; 28). The patients were
divided into three severity categories: mild, moderate and severe with a TB
score of 0-2, 3-4 and >4 points, respectively (Table 4-1). The signs and
symptoms were extracted from the patient records.
Table 4-1. Parameters used for TB score
Parameters Points assigned
Self-reported
Cough 1
Haemoptysis 1
Dyspnoea 1
Chest pain 1
Night sweating 1
Anaemia 1
Tachycardia 1
Lung-auscultation finding 1
Fevera 1
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Note: BMI, body mass index. The parameters used for calculating TB score, including
cough, haemoptysis, dyspnoea, chest pain, night sweating, anaemia, tachycardia, lung
auscultation finding, fever, BMI <18, BMI <16 were shown. a Fever, axillary temperature
>37.0℃.
Laboratory analysis
Blood samples were drawn from each subject after fasting for at least 12 h
and an overnight rest. Glucose and lipid indexes were determined
immediately after blood was drawn. The remaining serum samples were
stored at 80℃ until measurement for 25(OH)D.
Serum 25(OH)D concentration was measured as described (29) in Beifang
Institute of Biotechnology (Beijing, China). Brieﬂy, 125I radioimmunoassay
(RIA) kit from DiaSorin Inc (Stillwater, Minnesota, USA) was used. The
25(OH)D assay was a two-step procedure. First, 25(OH)D and other
hydroxylated metabolites from serum were rapidly extracted. Then, the
treated sample was assayed based on an antibody with speciﬁcity to
25(OH)D using an equilibrium RIA procedure. As claimed by the company
DiaSorin, the kit antibody would demonstrate some cross-reactivity with all
forms of dihydroxyvitaminD2 and D3 steroids; however, in humans, these
compounds were naturally present only in picomolar concentrations. For
quality control, two reference controls provided with the kit were utilized
(one at low-normal level and one at high-normal level) to guarantee assay
performance. The sensitivity of the assay was 1.5 ng/mL. The interassay
variability was 10.5% and the intra- assay variability was 8.2%.
BMI <18 1
BMI <16 1
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Glucose oxidase method was used for the determination of FPG using a
Hitachi automatic analyzer. Lipid indexes including total cholesterol (TC),
triglyceride (TG), high density lipoprotein cholesterol (HDLC) were
determined by autoanalyser under standard procedure.
The following cut-off values were used for assessing vitamin D status: serum
25(OH)D concentrations < 8 ng/mL (<20 nmol/L) were classiﬁed as severe
vitamin D deﬁciency (SVDD); 25(OH) D <20 ng/mL (<50 nmol/L) as VD
deﬁciency (VDD); 25(OH)D of 20 - 30 ng/mL (50 - 75 nmol/L) as VD
insufﬁciency; and those who had serum 25(OH)D 30 ng/mL (≥75 nmol/L)
were VD adequate (13; 30).
Statistical analysis
Continuous data were expressed as mean ± standard deviation or median
and interquartile range (IQR) and compared using independent T test or
non-parametric Mann-Whitney U test. For categorical variables, proportions
were reported and Pearson's χ2 test was used for the comparisons.
Univariable analysis of factors associated with serum 25(OH)D
concentrations was carried out using Pearson's or Spearman's correlation
analysis and univariate linear regression analysis. Further, multiple linear
regression was used. Univariate and multivariate logistic regression analyses
were used to calculate odds ratios of SVDD for age (year), sex (male, female),
DM (yes, no), BMI (kg/m2), TB score (mild, moderate and severe), outdoor
activity (<2 h/day, 2 h/day), consumption of foods providing VD (ﬁsh, milk,
meat, egg) (as categorized variables), smoking (yes, no), alcohol
consumption (yes, no), season of blood sampling (Spring: March-May;
Summer: June-August; Autumn: September- November; Winter:
December-February). Factors found to be signiﬁcant in the univariate model
were analyzed as independent variables or covariates in the multiple models.
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The variables in multivariate analyses were included in the ﬁnal models if p <
0.05 and excluded when p > 0.10. BMI, age and season were known to affect
vitamin D status in the body, therefore, these covariates were adjusted in
both multivariate models, and co-linearity diagnosis among the variables
was performed prior to the analysis. All the analyses were performed using
SPSS version 21.0 software (IBM SPSS Statistics 21); statistical signiﬁcance
was deﬁned as p < 0.05.
Results
Serum 25(OH)D concentrations in active TB patients
A left skewed distribution of serum 25(OH)D was observed in the total
population (n=461). The maximum concentration was 75.85 ng/mL, with a
median of 8.50 ng/mL and an interquartile range of 12.49 ng/mL. 83.1% of
the participants had VDD (n= 381/461), and 47.1% had SVDD (n=217). TB
patients with DM had a signiﬁcantly higher concentration of serum 25(OH)D
compared with those without DM (Median, IQR 10.58, 13.71 vs 7.26, 12.17
ng/mL, p=0.002). TB with DM patients had a signiﬁcantly lower proportion
of SVDD (38.5% vs 53.2%, p < 0.05).
General characteristics of the participants by vitamin D status
Basic characteristics of SVDD (n =217) and non-SVDD (n =244) subjects are
presented in Table 4-2. There were no signiﬁcant differences in age, SBP,
DBP, BMI, FPG, TG, LDLC between the two groups (p > 0.05). Also, the
proportions of males, milk consumption, smoking, alcohol drinking, and
season of blood sampling categories showed no signiﬁcant differences (p >
0.05). SVDD patients had a signiﬁcantly lower prevalence of DM than
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non-SVDD (34.1% vs 48.4%, p < 0.01), but a higher percentage of severe and
moderate TB score (p < 0.001). The proportion of patients in the highest
quartile of ﬁsh consumption in non-SVDD was greater than SVDD (p < 0.05).
Also, a higher proportion of outdoor activity ≥2 h/day was observed in non-SVDD
(44.7%vs25.8, p< 0.001).
Table 4-2. Characteristics of the participants by vitamin D status ( ±s )
SVDD Non-SVDD P-value
N 217 244
Age(years) 46.23±17.06 47.60±16.91 0.388
Male, n(%) 166(76.5) 175(71.7) 0.243
SBP(mmHg) 124.57±17.11 121.50±15.94 0.104
DBP(mmHg) 77.32±11.42 75.14±9.79 0.074
BMI( kg/m2) 21.64±3.08 21.43±3.43 0.508
DM 74(34.1) 118(48.4) 0.002
FPG(mmol/L)a 5.32,2.65 5.81,2.75 0.834
TC(mmol/L) 4.17±1.22 4.46±1.28 0.018
TG(mmol/L)a 0.95,0.73 1.03,0.66 0.074
HDLC(mmol/L)a 1.21,0.41 1.27,0.56 0.002
LDLC(mmol/L)a 2.35,0.89 2.54,1.09 0.102
TBscoreb, n(%)
Mild 50(23.0) 108(44.3) <0.001
Moderate 98(45.2) 90(36.9)
Severe 69(31.8) 46(18.9)
Fish consumption(g/d)
<10 60(27.6) 52(21.3) 0.003
10~ 76(35.0) 62(25.4)
20~ 40(18.4) 51(20.9)
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≥42.86 41(18.9) 79(32.4)
Milk consumption(g/d)
<50 37(17.0) 49(20.2) 0.292
50~ 64(29.5) 49(20.2)
100~ 74(33.9) 105(43.1)
≥200 42(19.6) 41(16.5)
Egg consumption(g/d)
100 30(14.0) 39(16.1) 0.018
50 163(75.2) 148(60.5)
<50 24(10.9) 57(23.4)
Meat
consumption(g/d)
<77.85 49(22.5) 67(27.3) 0.697
77.85~ 56(25.6) 59(24.2)
164.29~ 60(27.9) 55(22.7)
≥313.81 52(24.0) 63(25.8)
Smoking
Yes 111(51.1) 122(50.0) 0.855
No 106(48.9) 122(50.0)
Alcohol drinking
Yes 71(32.6) 91(37.4) 0.412
No 146(67.4) 153(62.6)
Season
Spring 57(26.3) 52(21.3) 0.535
Summer 55(25.3) 59(24.2)
Autumn 50(23.0) 66(27.0)
Winter 55(25.3) 67(27.5)
Outdoor activity
<2hs/day 161(74.2) 135(55.3) <0.001
2hs/day 56(25.8) 109(44.7)
SVDD, severe vitamin D deficiency; non-SVDD, severe vitamin D deficiency; SBP, systolic
blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting
plasma glucose; TC, total cholesterol; TG, triglyceride; HDLC, high density lipoprotein
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cholesterol; LDLC, low density lipoprotein cholesterol. The basic characteristics of the
subjects by vitamin D status (SVDD, non-SVDD) were shown. Number of cases, age,
gender, SBP, DBP, BMI, DM, FPG, lipid indexes, TBscore, fish, milk, egg and meat
consumption, smoking, alcohol drinking, season ofthe blood collection and outdoor
activity in each group were presented.
a Skewed distribution was observed and median, interquartile range were used for the
description. b TB-score, mild 0~2 points, moderate 3~4 points, severe >4 points.
The predictors of serum 25(OH)D concentrations
Correlation analysis showed that BMI was negatively associated with Log10
25(OH)D (r =-0.119, p= 0.013). TB score was negatively related with serum
25(OH)D (r =-0.270, p < 0.001), while positive associations were observed
between DM, outdoor activity level and 25(OH)D. Univariate linear
regression analysis showed similar results, indicating outdoor activity level
and TB score may explain 10.1% and 8.5% of the variation in 25(OH)D
concentrations, respectively. Multivariate linear regression analysis showed
that outdoor activity level, DM, TB score, BMI were predictors for serum
25(OH)D adjusted for age and season of blood sampling. The variables
included in the ﬁnal model together explained 22.2% of the variation in
serum 25(OH)D (R2=0.222, p < 0.05). See in Table 4-3.
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Table 4-3. The results of linear regression analysis of serum 25(OH)D (ng/mL)
Univariable Multivariable
Β(95% CI) P-value Β (95% CI) P-value
Agea 0.045(-0.021~0.110) 0.180 0.017(-0.048~0.082) 0.614
Sex 0.332(-2.203~2.868) 0.797
DM 3.189(-5.427~-0.951) 0.005 5.250(2.948~-7.551) <0.001
BMIa (kg/m2) -0.562(-0.914~-0.211) 0.002 -0.750(-1.069~-0.431) <0.001
TBscoreb -4.617(3.224~6.011) <0.001 -4.989(-6.447~-3.532) <0.001
Seasonh -0.067(-1.076~0.942) 0.896 -0.729 (-.663~0.205) 0.126
Outdoor activityd 8.036(5.835~10.237) <0.001 5.711 (3.480~7.943) <0.001
Fish consumptionc 0.426(-1.418~0.566) 0.399
Milk
consumptione
-0.376(-1.443~0.691) 0.488
Meat
consumptionf
-0.382(-1.264~0.499) 0.394
Egg consumptiong -1.083(-2.830~0.664) 0.223
Alcohol drinking -0.300(-1.313~0.714) 0.561
Smoking -0.565(-2.502~1.371) 0.566
DM, diabetes mellitus; BMI, body mass index.
aAge, BMI were analyzed as continuous variables; b Categorized as mild: 0 - 2 points,
moderate: 3 - 4 points, severe:>4 points; cCategorized as <10, 10~g/d, 20~, ≥42.86 g/d;
dCategorized as <2, ≥2 h/d. e Categorized as <50, 50~, 100~-,≥200 g/d; f Categorized as
<77.85, 77.85~, 164.29~, ≥313.81 g/d. g The weight of an egg was estimated to be 50 g,
and the egg consumptions were categorized as 100, 50 and <50 g/d; hCategorized as 1:
March-May, 2: December-February, 3: June-August, 4: September-November.
Odds ratios for severe vitamin D deﬁciency among active TB patients
As shown in Table 4-4, the possible factors associated with SVDD found in
univariate logistic regression analysis were DM, TB score, ﬁsh consumption
and outdoor activity. Multivariate logistic regression showed a 70%
decreased odds of having SVDD for DM [OR (95% CI) = 0.287 (0.175-0.470), p
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< 0.001]. Severe and moderate TB score, low ﬁsh consumption and low
outdoor activity were associated with increased risk of having SVDD (p <
0.05). Patients with severe TB score had nearly 5 fold higher risk of having
SVDD compared with those in mild subgroup [OR (95% CI) 4.919 (2.644 -
9.150), p < 0.001]. BMI showed a borderline positive association with the
odds of SVDD [OR (95% CI) = 1.062 (0.994 - 1.136, p = 0.074].
Table 4-4. Logistic regression of predictors of severe vitamin D deficiency in TB
Univariate OR
(95%CI)
P-value Multivariate OR
(95%CI)
P-value
DM 0.553(0.379~0.805) 0.002 0.287(0.175~0.470) <0.001
TBscorea
Mild
Moderate 2.352(1.514~3.655) <0.001 2.327(1.408~3.847) 0.001
Severe 3.240(1.962~5.350) <0.001 4.919(2.644~9.150) <0.001
Fishconsumption(g/d)
<10 2.449(1.439~4.169) 0.001 3.158(1.675~5.955) <0.001
10~ 2.452(1.482~4.054) <0.001 3.995(2.195~7.272) <0.001
20~ 1.569(0.897~2.742) 0.114 1.988(1.057~3.737) 0.033
42.86
Outdooractivity(hs/d)
<2 2.321(1.564~3.446) <0.001 2.016(1.263~3.220) 0.003
2
BMI(kg/m2) 1.020(0.963~1.080) 0.507 1.062(0.994~1.136) 0.074
Age(years) 0.995(0.985~1.006) 0.388 0.996(0.982~1.009) 0.533
Season
Spring 1.176(0.695~1.989) 0.546 0.858(0.473~1.555) 0.613
Autumn 0.881(0.528~1.469) 0.626 0.756(0.423~1.352) 0.346
Winter 0.813(0.483~1.366) 0.434 0.684(0.375~1.248) 0.216
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Summer
Male 1.283(0.844~1.953) 0.244
Smoking 1.046(0.645~1.697) 0.855
Alcohol drinking 0.809(0.487~1.343) 0.412
Meatconsumption(g/d)
<77.85 0.882(0.440~1.767) 0.723
77.85~ 1.133(0.567~2.267) 0.724
164.29~ 1.321(0.661~2.641) 0.430
313.81
Eggconsumption(g/d)
<50 0.536(0.218~1.321) 0.176
50 1.437(0.710~2.907) 0.313
100
Milkconsumption(g/d)
<50 0.707(0.295~1.694) 0.436
50~ 1.227(0.538~2.798) 0.626
100~ 0.662(0.311~1.408) 0.284
200
BMI, body mass index. a TB-score, mild 0 - 2 points, moderate 3 - 4 points, severe >4
points.
The result of logistic regression including univariable and multivariable models for the
predictorsof severe vitamin D deficiency (SVDD) in TB patients was shown. Severe and
moderate TB score, low fish consumption, low outdoor activity may increase the odds
ratio of SVDD, while DM had a protective effect.
Discussion
We observed a high prevalence of VDD (83.1%) in active tuberculosis
patients with a median circulating 25(OH)D concentration of 8.50 ng/mL,
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which was about 50% of 25(OH)D in the general Chinese population (16.37
ng/mL)detected inourearlier study (29).
A study in an equatorial population found that mean serum 25(OH)D in TB
patients was 34.64 ng/mL and the deﬁciency rate was 41.2% (2). Another
investigation in Korean population reported that TB patients had a lower
median 25(OH)D concentration than the control (9.86 ng/mL vs 16.03 ng/mL)
(3). This result was close to our ﬁndings. From an ecological epidemiology
viewpoint, we get the impression that latitude is an important factor of VD
status in TB. It has been discovered that vitamin D elicits pleiotropic
antimicrobial responses in vitro (31). Coussens et al. reported that adjunctive
high-dose vitamin D in TB treatment could accelerate sputum smear
conversion, and reduce the inﬂammatory responses associated with higher
risk of mortality (32). Therefore, the common occurrence of hypovitaminosis
D in active TB patients should be given full attention. Although the reasons
of the high prevalence of VDD in TB patients are still uncertain, we speculate
that the following aspects may be relevant. First, the synthesis of VD under
skin upon exposure to sunlight, the main source of VD, may be impaired due
to restricted outdoor activity of the patients. Second, severe weight loss,
decreased appetite and food intake may result in nutrients depletion (33) in
general and VDD in particular. Third, TB patients have obviously reduced
adipose tissue, which may result in diminished VD reserves (34). Furthermore,
the requirement of VD increases in TB. Vitamin D plays a key role in anti-TB
immunity, binding to toll-like receptors on macrophages and leading to
increased production of 1,25(OH)2D from 25(OH)D (35), which may also
contribute to lowered 25(OH)D concentrations.
Furthermore, compared with VD concentrations in DM patients(19.50
ng/mL) as reported in our earlier study (29), TB patients with DM had
signiﬁcantly lower serum 25(OH)D level which was approximately half that
of DM. This may partially explain the positive correlation of DM with VD
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status in TB patients in our study. Also, this may give us important clue of
the possible consequences of hypovitaminosis D in the presence of active TB
in DM. Since DM usually develops before TB in the patients with combined
diseases (36), our ﬁndings indicate that signiﬁcant decreasing of vitamin D
status may be associated with increasing possibility of active TB in DM
patients.
TB score, outdoor activity, ﬁsh consumption were also found to be
associated with the prevalence of SVDD. The severity of initial TB signs and
symptoms showed a negative association with serum 25(OH)D and patients
with severe TB score had a nearly 5 fold higher odds of SVDD compared with
those with mild TB score. This provides further evidence for the perspective
that VD deﬁciency may be associated with TB incidence (1; 2; 3). Also, TB is a
typical chronic wasting disease, and the synthesis and bioavailability of
vitamin D in the body may be impaired. Further research is needed to
establish a causal relationship between vitamin D status and the incidence
of active TB.
Patients who have outdoor activity <2 h/d had 2 fold higher odds of SVDD
compared with ≥2 h/d. Similarly, a cross-sectional study in 782 Danish
children found that outdoor walking during school hours was positively
associated with 25(OH)D (37), and outdoor exercise was associated with 47%
lowered possibility to have hypovitaminosis D in the obese (38). Outdoor
activity means sunlight exposure, resulting in vitamin D synthesis in the skin.
Therefore, various kinds of outdoor activity suitable for TB patients should
be encouraged. Fish consumption, the major source of VD from natural food,
has been reported to increase concentrations of 25(OH)D (39; 40; 41; 42). In our
study, 120 (26.3%) patients in the highest quartile of ﬁsh consumption
(≥42.86 g/d) had signiﬁcantly lower odds of SVDD. Although there are some
exceptions (43), it is often reported that vitamin D content in different species
of ﬁsh differs signiﬁcantly, and fatty ﬁsh may be a better VD source than
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lean ﬁsh (41; 44). In our study, total ﬁsh consumption was evaluated, which
hinders further analysis of the correlation between ﬁsh species and the odds
of SVDD. Nevertheless, since Qingdao is a seaside city where marine ﬁsh
such as Spanish mackerel, yellow croaker, butterﬁsh, weever, hairtail are the
main species people consume, our results may provide evidence for a
negative relationship between marine ﬁsh consumption and SVDD in TB.
We found BMI had a weak negative correlation with VD status with β
coefﬁcient of -0.75 and it had a borderline positive association with
increased odds of SVDD. It has been reported by many researches in recent
years that an inverse correlation exists between circulating 25(OH)D and
BMI in the healthy population, in overweight/obese subjects and in diabetic
patients (45; 46; 47; 48; 49; 50; 51). It was speculated that low vitamin D status in
obesity is due to a greater pool of distribution (52). However, there is still
insufﬁcient evidence in TB patients, and the available data differ. Similar to
our study, Friis et al. reported that TB patients with lower BMI had higher
serum 25(OH)D (53). However, an investigation in 105 TB patients found that
VDD is more obvious in those with low BMI (4), and BMI is a positive
predictor of serum 25(OH)D (2). The main reason of the discrepancy may be
relatively small sample size and different inclusion criteria. Therefore, the
correlation between BMI and VD status in TB needs further study in larger
populations.
A major limitation of this cross-sectional study is that it does not allow
causal inference. Nevertheless, the evidence with respect to the possible
predictors of serum 25(OH)D concentration and the prevalence of SVDD in
active TB patients and the role of DM is worthy of further investigation.
Since the epidemic of vitamin D deﬁciency in active TB is of great
signiﬁcance, we suggest that various strategies concerning the improvement
of VD status such as more outdoor activity, higher consumption of ﬁsh, egg,
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etc and fortiﬁed items, or use of VD supplements, should be given full
consideration in this population.
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Abstract 
Background and Objectives: Although vitamin D is implicated in the 
generation of anti-microbial peptide cathelicidin, which plays a key role 
against pulmonary tuberculosis (PTB), and may have an inverse association 
with the risk of type 2 diabetes (DM), its role in the co-existence of these 
two diseases (PTB-DM) is still uncertain. This study explored the association 
of vitamin D status with prevalent PTB, PTB-DM and DM.  
Methods and Study Design: We randomly selected 130 PTB patients, 90 
PTB-DM, 91 DM and 134 controls. Serum 25(OH)D was determined. A 
structured questionnaire and anthropometric measurements were 
administered.  
Results: Serum 25(OH)D in PTB and PTB-DM were 12.2±2.2 ng/mL and 12.9±2.5 
ng/mL, respectively, which were lower than those in DM and control groups. 
Qiuzhen Wang, Aiguo Ma, Xiuxia Han, Huizhen Zhang, Shanliang 
Zhao, Hui Liang, Jing Cai, Frans J Kok, Evert G Schouten 
Asia Pac J Clin Nutr. 2017;26(2):241-246 
 
Is low serum 25-hydroxyvitamin 
D a possible link between 
pulmonary tuberculosis and type 
2 diabetes? 
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Odds ratios of PTB and PTB-DM comparing extreme quartiles of 25(OH)D 
(lower than 8.6 ng/mL versus ≥26.6 ng/mL) were 3.26 and 2.27, respectively. 
These associations remained after adjustment for possible risk factors [OR 
(95% CI)=4.73 (2.04-10.9) and 2.50 (1.04-6.02), respectively]. A synergistic 
interaction was observed between low 25(OH)D and underweight in respect 
to prevalent PTB-DM [OR=24.6 vs 2.50 for lowest quartile of 25(OH) D and 
4.59 for underweight].  
Conclusions: Odds ratios of low serum 25(OH)D for PTB and PTB-DM were 
greater than 1.0, and were even much greater when combined with 
underweight. However, since the association of serum 25(OH)D with PTB 
was stronger than with PTB-DM, we could not draw the conclusion that 
vitamin D is a link between PTB and DM. 
 
Introduction 
The co-morbidity of pulmonary tuberculosis (PTB) and type 2 diabetes (DM) 
represents a double burden with significant public health implications(1). 
With increasing global prevalence of DM that is anticipated to reach 552 
million by 2030(2), and the continued high rates of tuberculosis in developing 
countries, the number of individuals with both diseases will increase 
markedly in the coming decades. Until now, the mechanisms that might 
underlie this association are still uncertain. 
Vitamin D, which is mainly derived from endogenous synthesis after 
exposure of the skin to solar ultraviolet radiation, has been proven to have 
more functions in the body than the classical effects on calcium metabolism. 
Receptors for its active form, 1,25-dihydroxyvitaminD3, are widely expressed 
in human cells, including pancreatic β-cells as well as numerous cell types of 
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the immune system such as monocytes and macrophages, dendritic cells, T 
cells, B cells, and natural killer cells(3; 4). 
Epidemiologic studies have shown a higher incidence of TB disease in 
populations with diminished 25-hydroxyvitamin D [25(OH)D](5). It is 
hypothesised that vitamin D is closely associated with the onset and 
treatment of active tuberculosis. Sufficient vitamin D can decrease the risk 
of infection with MTB and the progression of active tuberculosis from latent 
TB, and may decrease the duration and improve the treatment outcome (6; 7; 
8; 9). Vitamin D was also discovered to mediate the important innate 
antimicrobial immune response against MTB in vitro (10). 
At the same time, the associations between vitamin D and DM have been 
reported recently. Cross-sectional studies showed that 25 (OH)D 
concentration was lower in individuals with DM and impaired glucose 
tolerance than in those with normal glucose tolerance (11). A prospective 
study (12) in 1080 subjects of 5 year follow-up suggested that participants 
with 25(OH)D deficiency had an increased risk of DM, and the 
supplementation may be protective (13; 14). Associations of 25(OH)D with 
insulin resistance and β cell function were reported by some authors (15), 
whereas others did not find an association (16). 
It was supposed by Handel et al that Vitamin D may be the missing link 
between TB and DM (17). However, there were hardly any related 
epidemiological reports. The current case control study was carried out to 
investigate whether lower serum 25(OH)D might be associated with higher 
prevalence of PTB, PTB-DM and DM, which might provide evidence for a role 
of vitamin D in the co-morbidity of these two diseases. 
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Methods 
Study Population 
The subjects were randomly selected from a previous large scale community 
based study of the prevalence of DM in active PTB patients and non-TB 
subjects in rural area in China (18). The investigation study was registered in 
the Chinese Clinical Trial Registry (No. ChiCTR-OCC- 10000994, URL: 
http://www.chictr.org/cn/proj/show.aspx?proj=411).Briefly,newly-diagnose
d PTB patients, 18 to 85 years of age, who registered for Directly Observed 
Treatment, Short Course (DOTS) were recruited consecutively from 7 TB 
clinics (Yishui TB clinic, Yinan TB clinic, Lanshan TB clinic, Cangshan TB clinic, 
Tancheng TB clinic, Feixian TB clinic and Pingyi TB clinic) in Linyi area (Linyi, 
China) from September 2010 to December 2012. PTB was diagnosed by 
chest radiography followed by sputum smear examination or sputum 
culture for those with a suspicious TB symptoms and shadow on chest X-ray. 
Diagnosis of diabetes was based on WHO criteria for the classification of 
glucose tolerance based on fasting plasma glucose (FPG). HIV-positive 
patients as well as subjects with type 1 diabetes, trauma in the last three 
months, cancer, sever cardiac, hepatic and kidney diseases were excluded. 
Cluster random sampling was used to recruit non-TB subjects from the same 
communities as TB cases, using the same exclusion criteria. Stratification 
was performed based on economic level (low/middle/high). Fasting blood 
samples were obtained from the participants for screening of DM. According 
to the DM screening results, the subjects were divided into four groups 
including PTB patients with DM (PTB-DM) and without DM (PTB), non-TB 
subjects with DM (DM) and without DM (NON). Finally, the study comprised 
130 PTB, 90 PTB-DM, 91 DM and 134 NON. 
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Structured questionnaires were used by trained interviewers to collect 
information on demographic variables, medical history, medications, dietary 
and lifestyle habits. 24-hour dietary recall and food frequency questionnaire 
were used concerning the dietary habit together with the information of 
vitamin and mineral supplements. The Ethics Committee of Qingdao Disease 
Prevention and Control Centre approved the present study (No. 200904), 
and informed consent was obtained from each subject. 
Laboratory analyses 
Serum 25(OH)D was measured by using a radioimmunoassay (RIA) kit from 
DiaSorin Inc (DiaSorin, USA) in Beifang Institute of Biotechnology 
(Beijing,China). The sensitivity of the assay was 1.5 ng/mL. The inter assay 
variability was 10.5% and the intra assay variability was 8.2%. Lipid indexes 
including total cholesterol (TC), triglyceride (TG) and high density lipoprotein 
cholesterol (HDLC) were estimated by enzymatic procedure. 
Anthropometric measurements 
Height and weight were measured by trained investigators using standard 
procedure. Body mass index (BMI, kg/m2) was calculated by using the 
formula: BMI = weight (kg)/ height2 (m²), and the cut-off value for Chinese 
population was used, as described previously (18). 
Statistical analyses 
Serum 25(OH)D exhibited a lognormal distribution, and data were therefore 
transformed (log10) before logistic regression analysis and Pearson’s 
correlation analysis. Subjects were divided into quartiles based on their 
serum 25(OH)D. Multiple logistic regression analysis was used to evaluate 
the association(s) between serum 25(OH)D and PTB, PTB-DM or DM, with 
appropriate adjustment for covariates, including age [(years) (categorized in 
3 units: <30, 30-49, ≥50], sex, BMI [(kg/m2) (categorized as <18.5, 18.5-23.9, 
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≥24.0)], family history of DM and former smoking (smoking index, package 
per year multi- plied with smoking year was used and categorized in 4 units: 
0, <15, 15-29, ≥30). The model fit was significant (χ2=203.15, p<0.001) and 
the fit was good (Pearson χ2=448, p=0.12). All probability values were 
derived from 2-tailed analyses, and those below 0.05 were considered to be 
of statistical significance. Analyses were performed with SPSS version 21.0 
software (IBM SPSS Statistics 21). 
 
Results 
Characteristics of the study population 
The general characteristics of the study population are displayed in Table 
5-1. Patients with PTB-DM were older than PTB and NON (p<0.05). Male 
proportion was highest in PTB. And BMI in PTB and PTB-DM was lower than 
in the other two groups (p<0.05). There existed a difference in the lipid 
profile among these groups. Former smoking, evaluated by smoking index 
(SI) of package per day multiplied with smoking years, was more common 
among PTB cases and heavy smoking (SI ≥30) was more common in PTB-DM 
and PTB groups. Patients with PTB-DM and DM were more likely to have a 
family history of diabetes. Serum 25(OH)D concentrations were significantly 
lower in PTB and PTB-DM groups than in DM and controls (p<0.05). 
Most of the subjects were peasants, with an educational level lower than 
college. Occupation, education level and alcohol drinking history were 
distributed equally in the four groups, as also were the seasons in which the 
blood samples were collected. 
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Table 5-1. Basic characteristics of the subjects (𝐱±SD) 
 PTB PTB-DM DM NON p 
N 130 90 91 134  
Age 45.6±18.7* 56.9±14.5*,** 55.8±13.8** 51.7±15.8 <0.05 
Male, n(%) 102(77.3) 54(61.4) 55(61.1) 60(44.4) <0.05 
BMI 20.3±2.83* 20.9±3.32* 22.9±2.61 22.1±2.79 <0.05 
SBP(mmHg) 120±12.7 119±14.0 124±13.3** 121±11.5 <0.05 
DBP(mmHg) 75.7±8.14 78.0±6.60** 79.8±10.0** 79.5±6.85** <0.05 
Hypertension,n(%) 14(10.8) 10(11.1) 22(24.2) 20(14.9) <0.05 
FPG(mmol/L) 4.66±1.19 7.22±1.25 7.15±1.21 4.59±1.17 <0.05 
TC(mmol/L) 4.11±1.17 5.03±1.32** 4.68±1.01 ** 4.78±1.27** <0.05 
TG(mmol/L) 0.95±0.49 1.23±0.67*,** 1.25±0.54*,** 0.85±0.58 <0.05 
HDLC(mmol/L) 1.52±0.66* 1.67±0.59* 1.69±0.49* 1.99±0.73 <0.05 
VitaminD(ng/mL)† 12.2±2.15* 12.9±2.51* 17.86±1.98** 16.69±2.02** <0.05 
SI      
0 75(59.1) 59(67.8) 70(80.5) 94(73.4) <0.05 
< 15 16(12.6) 2(2.3) 4(4.6) 18(14.1)  
15～ 17(13.4) 6(6.9) 5(5.7) 12(9.4)  
≥ 30 19(15.0) 20(23.0) 8(9.2) 4(3.1)  
DM Family history 10(7.8) 19(21.2) 22(24.2) 6(4.5) <0.05 
Note: PTB: pulmonary tuberculosis patient without diabetes; PTB-DM: pulmonary 
tuberculosis patient with diabetes; DM: non-TB subjects with diabetes; NON: non-TB 
subjects without diabetes; BMI: body mass index; FPG: fasting plasma glucose; TC: total 
cholesterol; TG: triglyceride; HDLC: high density Lipoprotein Cholesterol; SI: smoking 
index. 
†Log10 transformed, then back-transformed for presentation. *p<0.05 compared to 
NON group;**p<0.05 compared to PTB group. 
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Determinants of PTB-DM 
After adjustment for potential confounders including sex, age, DM family 
history, BMI and smoking index, log serum 25(OH)D showed a protective 
association with PTB-DM (adjusted OR 0.37, 95% CI 0.15-0.92). 
Also,association was observed with PTB (adjusted OR 0.22, 95% CI 
0.09-0.52). A clear association of serum log25(OH)D with DM was not 
observed (p>0.05) (see in Table 5-2). 
Table 5-2. Multivariate logistic regression analysis of odds ratios on PTB, PTB-DM, and DM 
 PTB PTB-DM DM 
 OR(95%CI) OR(95%CI) OR(95%CI) 
Men 2.76(1.46~5.19)* 1.60(0.80~3.22) 2.34(1.21~4.51) * 
<30 1.00 1.00 1.00 
30~ 0.43(0.19~0.98)* 4.68(1.12~19.5)* 2.75(0.72~10.5) 
≥ 50 0.36(0.16~0.78)* 7.64(1.90~30.8)* 7.69(2.09~28.3)* 
DM family history 0.90(0.28~2.86) 6.62(2.21~19.8)* 7.91(2.73~22.9)* 
BMI    
18.5~23.9 1.00 1.00 1.00 
<18.5 1.88(0.87~4.09)* 4.73(2.06~10.9)* 0.41(0.11~1.55) 
≥24 0.37(0.16~0.83)* 1.29(0.60~2.75) 2.09(1.06~4.12)* 
SI    
0 1.00 1.00 1.00 
<15 0.68(0.29~1.58) 0.12(0.02~0.57)* 0.28(0.08~0.90)* 
15~ 1.31(0.52~3.30) 0.35(0.11~1.16)* 0.30(0.09~0.99)* 
≥ 30 3.91(1.15~13.3)* 4.20(1.20~14.7)* 1.26(0.33~4.84) 
LogVD† 0.22(0.09~0.52)* 0.37(0.15~0.92)* 1.30(0.50~3.37) 
PTB: pulmonary tuberculosis patient without diabetes; PTB-DM: pulmonary 
tuberculosis patient with diabetes; DM: non-TB subjects with diabetes; BMI: body mass 
index; SI: smoking index. 
†
Log10 transformed. 
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Relationship between vitamin D concentrations and PTB-DM 
The relationship between serum 25(OH)D and the presence of PTB, PTB-DM 
and DM is presented in Table 5-3. Subjects in the lowest quartile of 25(OH)D 
were about 3 times more likely to have PTB than those in the highest 
quartile (OR 3.26, 95%CI 1.56-6.82). This relationship was maintained after 
adjustment for other possible con- founders, including age, sex, body mass 
index, family history of DM and former smoking (adjusted OR 4.73, 95% CI 
2.04-10.9). An decreased association was observed between 25(OH)D and 
PTB-DM. Subjects in the lowest quartile of 25(OH)D (<25th) were 2 times 
more likely to have PTB-DM than those in the highest quartile (OR 2.27, 95% 
CI 1.05-4.92) and the adjusted OR was2.50 (95% CI 1.04-6.02). There was no 
significant association between 25(OH)D and the prevalence of DM. 
Table 5-3. Odds ratios for PTB, PTB-DM, DM by quartiles of serum 25(OH)D (ng/mL) 
Vitamin D ≥26.62 15.40～26.61 8.58～15.39 ≤8.57 
N 111 112 111 111 
PTB     
N (%) 23(17.7) 32(24.6) 30(23.1) 45(34.6) 
Crude OR 1.00 1.32(0.65~2.67) 1.11(0.55~2.26) 3.26(1.56~6.82)* 
Adjusted OR† 1.00 1.64(0.74~3.59) 1.35(0.61~2.97) 4.73(2.04~10.9)* 
PTB-DM      
N (%) 22(24.4) 18 (20.0) 20(22.2) 30(33.3) 
Crude OR 1.00 0.77(0.36~1.68) 0.78(0.36~1.65) 2.27(1.05~4.92)* 
Adjusted OR† 1.00 0.97(0.42~2.27) 0.79(0.34~1.83) 2.50(1.04~6.02)* 
DM     
N (%) 31(34.1) 25(27.5) 20(22.0) 15(16.5) 
Crude OR 1.00 0.76(0.38~1.54) 0.55(0.27~1.13) 0.81(0.36~1.83) 
Adjusted OR† 1.00 0.79(0.36~1.72) 0.58(0.26~1.29) 0.86(0.34~2.16) 
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PTB: pulmonary tuberculosis patient without diabetes; PTB-DM: pulmonary 
tuberculosis patient with diabetes; DM- non: TB subjects with diabetes.  
†Adjusted for age (categorical), sex, BMI (categorical), family history of DM, SI 
(categorical).*p<0.05 compared to the highest quartile (≥26.62 ng/mL). 
 
Synergistic association of 25(OH)D and BMI on the potential risk of 
PTB-DM 
A synergistic association was observed when the lowest quartile of 25(OH)D 
and the underweight category (BMI<18.5) were considered together. After 
adjustment for the possible confounders, the odds ratio of having PTB in 
subjects with both characteristics was 14.1 (1.56-128). This association was 
enhanced with a nearly 2-fold increased odds ratio of 24.6 (95% CI 2.55-242) 
with prevalent PTB-DM compared with persons with highest quartile of 
25(OH)D and normal weight, while the odds ratio was 2.50 (95% CI 1.04-6.02) 
for lowest quartile of 25(OH)D and 4.59 (95%CI 1.98-10.6) for underweight 
separately. 
 
Discussion 
Lower serum 25(OH)D was significantly associated with higher prevalence of 
PTB and PTB-DM after adjustment for confounders. A synergistic interaction 
was observed between underweight (BMI <18.5) and low 25(OH)D. 
It has been indicated by several case-control studies and large scale 
longitudinal cohort studies that DM will increase the risk of active TB (19). 
However, the link behind the association is not fully understood. Several 
studies have suggested that DM depresses the immune response through 
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effects on macrophage and lymphocyte function, which in turn facilitates 
active TB disease. Conversely, it is also possible that TB induces glucose 
intolerance and deteriorates glycemic control in subjects with DM (19; 20). 
It has been indicated that vitamin D is associated with antimicrobial immune 
activity of human macrophages (21). In vitro, the actions of monocytes and 
macrophages on Mycobacterium tuberculosis (MTB) are heavily dependent 
on vitamin D concentrations (13), and the antimicrobial peptide cathelicidin 
was induced by the increased expression of the vitamin D receptor and the 
vitamin D 1-hydroxylase genes in human macrophages, which may play a 
key role in killing of intracellular MTB (10). Also, a growing body of evidence 
from observational studies suggests an association between low 25(OH)D 
and increasing DM risk (22) with impaired pancreatic β cell function being the 
possible mechanism (23). 
The present study, therefore, compared the odds ratio of prevalent PTB, 
PTB-DM and DM in individuals with lower concentrations of serum 25(OH)D 
to that in individuals with higher concentrations, to check for evidence that 
vitamin D might be a link that explain part of the association between these 
two diseases. 
We found a negative association between 25(OH)D and prevalent PTB, 
which was in accordance with other reports (5; 6; 24). However, the odds ratio 
was clearly lower for the association between 25(OH) D and prevalent 
PTB-DM. Till now, the association of vitamin D and the prevalence of 
PTB-DM has not been reported. The lowered odds ratio compared with PTB 
alone indicates that vita- min D may not be a link between PTB and DM. 
Given the association of BMI with 25(OH)D in PTB-DM, it might be that 
combined lower 25(OH)D and underweight reflects a heightened potential 
risk that is associated with or drives the progress of PTB-DM. Moreover, it 
might therefore be possible to use the combined information of these 
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factors to better estimate an individual’s possible risk of having PTB-DM, 
and combined low 25(OH)D and underweight may be a possible link 
between PTB and DM. As we have discussed in our former study (20), the 
association for BMI in the setting of comorbid DM and TB is complex. While 
increasing the risk of DM, increased BMI is a protective factor against 
developing TB (25). Weight loss due to poorly controlled DM and metabolic 
de-compensation takes away this protection, and would result in significant 
weight loss in patient with combined TB and DM (24). Similarly, a study 
carried out in Tanzania(26) reported severe underweight (BMI <16 kg/m2) 
among male TB patients was associated with DM. However, the number of 
subjects with both characteristics was relatively small (n=23), which may 
explain partly the wide confidence interval: 2.55-242. Therefore, the precise 
evaluation of the possible synergistic effect of low vitamin D level and 
underweight and its possible link of PTB and DM should be investigated in 
studies of larger sample size preferably prospective. 
Other than what had been expected, low 25(OH)D were not significantly 
associated with the prevalence of DM. Similarly, a 5-year follow-up study 
found that low 25(OH)D status was not significantly associated with incident 
diabetes but it was indicated that low vitamin D status could be related to 
deterioration of glucose homeostasis (27). However, Pittas et al reported that 
the relative risk of type 2 diabetes was 0.87 (95% CI 0.75-1.00; p for 
trend=0.04) comparing the highest with the lowest category of vitamin D 
intake from supplements (14). Hitherto, strong epidemiological evidence of a 
link between vitamin D deficiency and increased risk of type 2 diabetes has 
been limited, since most studies were cross sectional (28). Therefore, more 
longitudinal studies are needed to get a full insight into the association. 
In conclusion, we observed an inverse correlation between circulating 
concentrations of vitamin D and the prevalence of PTB-DM, while we did not 
find any evidence that low vitamin D was a link between PTB and DM. It was 
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also indicated that low 25(OH)D and under- weight might cooperate in the 
co-occurrence of PTB and DM. The precise mechanisms underlying the 
relationship need further investigation. 
 
Limitations 
A major limitation of our study is that it may not allow causal inference. 
Vitamin D status might be a consequence of the disease status instead of a 
cause. Furthermore, despite adjustment for confounders, residual 
confounding cannot be completely ruled out. Most of the DM patients in 
this community based study were non-insulin dependent diabetes mellitus 
(NIDDM), the severity of DM with PTB and the role of vitamin D could not be 
analyzed. Nevertheless, the evidence with respect to the association of 
vitamin D with PTB and PTB-DM based on our study are worthy of further 
investigation. 
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Abstract 
Vitamin D deficiency (VDD) is common in active tuberculosis (TB) patients 
and may be implicated in the etiology of the disease and in its clinical course. 
The aim of this study was to investigate the association between leptin, 
inflammatory markers and vitamin D status in TB patients, stratified for 
presence or absence of diabetes mellitus (DM). As part of a 
supplementation trial, at baseline we carried out a cross-sectional study. 
Two hundred ninety-nine active TB patients aged 18-65 years were recruited 
from Qingdao TB clinics from October 2015 to August 2016. Also, ninety-one 
normal controls undergoing routine medical examination were included 
from a general hospital in Qingdao. The information including 
socio-demographics, dietary intake and living habits was obtained from all 
the subjects by face-to-face interview using structured questionnaire. Serum 
concentrations of leptin and the inflammatory markers TNF-α, CRP and IL-6 
were compared between TB patients with and without VDD and severe VDD 
(SVDD). Pearson’s correlation was used to analyze the association between 
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the concentrations of TNF-α, leptin and 25-hudroxyvitamin D [25(OH)D]. A 
significantly higher prevalence of VDD and SVDD was observed in TB patients 
compared with normal controls (93.0% vs 70.3%, 65.9% vs 3.3% respectively). 
Concentration of leptin was significantly lower, while TNF- higher in TB 
patients with SVDD compared to those without (P<0.05). After adjustment 
for confounders such as BMI, age and gender, leptin concentration was 
positively associated with 25(OH)D (r= 0.210, P=0.002) with similar 
correlation in TB patients with DM (r=0.240, P=0.020). A negative 
association between serum TNF-α and 25(OH)D was observed (r=-0.197, 
P=0.003), which was significant only in the subgroup without DM (r=-0.304, 
P=0.001). In contrast, no correlation between both leptin and TNF-α with 
serum 25(OH)D was found in normal controls. Our findings indicate that a 
higher vitamin D status in TB patients may be related to higher immune 
activity and less serious tissue damage, and that this relation is different 
according to presence or absence of DM co-morbidity. 
Key words: serum 25(OH) D; tuberculosis; leptin; TNF-; diabetes 
 
           Promote; Leptin-R,leptin receptor; TNF, tumor necrosis factor; CRP, C-reactive 
protein;  TB,tuberculosis; JAK,Janus kinase; STAT, signal transducer and activator of 
transcription; MMP, matrix metalloproteinase; , phosphorylate. 
Correlation of VD status with Leptin and TNF-α 
 
 
- 121 - 
 
The present study in active TB patients found that serum TNF-α was independently 
inversely correlated with 25(OH)D, while leptin levels showed a positive correlation with 
VD. TNF-α has been reported to be closely related to excessive tissue damage in TB, 
while optimal leptin levels were related to normal T-cell function in the body. Therefore, 
we supposed that the modification of certain cytokines such as TNF-α and leptin by 
vitamin D may be one of the underlying mechanisms of the immune-modulatory effects 
of vitamin D in TB patients.   
 
Introduction 
Tuberculosis (TB) continues to be a major public health problem. According 
to the global TB report (WHO), the epidemic was larger than previously 
estimated. There were a total of 10.4 million new TB cases worldwide in 
2016, with China still ranking high among the epidemic countries (1). China is 
also facing a rapidly increasing incidence of diabetes mellitus (DM) in the 
past ten years (2). DM has been reported to triple the risk of active TB(3)and 
to result in poor response to anti-TB treatment (4). However, the underlying 
mechanisms are still uncertain. 
In recent years, the non-skeletal function of vitamin D (VD) has aroused 
intense interest. VD was discovered to stimulate innate immunity during 
Mycobacterium tuberculosis (Mtb) infection resulting in control of Mtb 
proliferation inside macrophages (5; 6). It is also involved in the regulation of 
host cytotoxic T lymphocyte responses (7) and the differentiation of naive T 
cells to regulatory T cells, indicating a possible role in adaptive immunity 
during infections.  
VD deficiency (VDD) is a global health problem (8). High prevalence of VDD 
has been documented in Europe, Southeast Asia (9), Middle East and South 
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America (8), even in some areas with very sunny climates, such as Saudi 
Arabia and India (10; 11). High prevalence of VDD was reported in TB patients. 
A meta-analysis combining seven epidemiological studies showed a modest 
to strong association of VDD with tuberculosis risk, reporting serum vitamin 
D levels are 0.68 SD lower in people with tuberculosis compared to controls 
(12). Although still lacking solid evidence, VD supplementation was reported 
to accelerate sputum smear conversion and the resolution of inflammatory 
responses during tuberculosis treatment (13). 
Cytokines play an important role as mediator in the interaction between 
immune cells (14). The production of pro-inflammatory cytokines such as 
TNF-α indicates an important immunity response against Mtb in the host (15). 
However, exacerbated inflammatory responses may lead to poor bacterial 
control and development of TB in the host (16). It was reported that a high 
level of TNF-α during the treatment may lead to deleterious effects in the 
tissues, while anti-TNF-α antibody during the treatment resulted in 
augmented bacterial clearance and attenuated lung pathology, which 
indicates TNF-α level may be a marker of exaggerated inflammation during 
TB course (17). VDD was reported to be correlated with increased production 
of pro-inflammatory cytokines (18), which indicates the possible mechanism 
of the role of VD in TB. Although a potential role for VD in modulation of 
the inflammatory response in TB patients has been suggested (13), most of 
the available evidence is provided by in vitro studies (19; 20), and direct proof 
of the correlation of inflammatory levels with VD status in active TB patients 
is still lacking. 
Leptin, a “satiety” hormone predominantly secreted by adipose cells to help 
to regulate energy balance, is also involved in both innate immune and 
adaptive immunity (21; 22; 23). Falling leptin concentrations appeared to be 
responsible for reduced T-cell function during starvation (24). A recent 
meta-analysis of twelve case-control studies found serum leptin levels of 
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healthy controls were markedly higher than those of PTB patients (25), and 
after treatment of TB plasma leptin levels were observed to increase (26). 
However, the correlation between leptin and VD in TB patients has not been 
reported until now. 
It is now well established that chronic inflammation, indicated by modestly 
increased levels of cytokines, contributes to the development and 
progression of DM. Impaired immune function in diabetic patients, 
especially with respect to macrophage and T lymphocyte functions, play a 
key role in the defence against M. tuberculosis(27; 28; 29), contributing 
significantly to higher risk of TB in DM patients. It was reported that 
tuberculosis patients with diabetes had a different profile of circulating 
levels of cytokines compared with those without diabetes(30).  
We hypothesize that there may exist certain correlations between 
inflammatory cytokines, leptin and VD status, which may underlie the 
mechanism of the immune-modulatory effects of VD in TB, and this 
correlation may differ depending on the presence or absence of comorbid 
diabetes. Therefore, we carried out this cross-sectional study in active TB 
patients with and without DM. At the same time, a normal control group 
was included to compare the possible correlation between inflammatory 
cytokines, leptin and VD status. 
 
Methods 
Design and subjects 
In this cross-sectional study, 299 active TB patients (178 TB without DM and 
121 TB with DM) were recruited from Qingdao TB clinics from October 2015 
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to August 2016. Also, 91 normal controls undergoing routine medical 
examination were included from a general hospital in Qingdao. The 
diagnosis of TB was made according to standard clinical criteria in which 
clinical manifestations, sputum smear microscopy and chest radiography 
were the central components. Diagnosed TB patients registered for Directly 
Observed Treatment, Short Course (DOTS) before the start of TB treatment, 
aged 18-65 years were recruited. The diagnosis of DM was based on 
self-report by patients who had already taken anti-diabetic medicines, or on 
the results of fasting plasma glucose (FPG) at the routine admission 
biochemistry test according to WHO criteria (1990) for the classification of 
glucose tolerance. Volunteers were excluded if they were pregnant or 
HIV-positive, had cancer, severe cardiac, hepatic and kidney diseases or 
trauma in the last three months, took VD supplements in the former 6 
months, had a current or previous medical condition or took medication 
affecting immune function or affecting VD status in the body.  
This study was carried out in accordance with requirements documented in 
the Declaration of Helsinki. Ethical approval for this study was received from 
the Ethics Committee of Qingdao Disease Prevention and Control Centre 
(Qingdao, China), and informed consent was obtained from each subject. 
The study was registered in the Chinese Clinical Trial Registry (No. 
ChiCTR-IPR-15006395). 
Questionnaires and anthropometrical measurements 
Structured questionnaires were administered by face-to-face interview to all 
subjects to collect information of socio-demographics, previous health 
conditions or diseases and family disease history, as well as lifestyle habits 
including smoking, alcohol drinking and outdoor activity level. 
Height and weight were measured without shoes and heavy clothing by 
trained investigators and body mass index (BMI) was calculated as body 
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weight divided by height squared (kg/m2). The cut-off value for Chinese 
population (31) was used for the classification of underweight (<18.5), normal 
weight (18.5-23.9), overweight and obesity (24). 
Biochemical detection and laboratory analyses 
Blood samples were drawn from each subject between 6:30 am and 9:00 am 
after fasting for at least 12 h and an overnight rest. Venous blood was 
collected into vacutainer tubes and allowed to clot at room temperature for 
30 minutes. The coagulated blood was centrifuged to collect the serum. 
Glucose levels were measured by glucose oxidase method and lipid indexes 
including serum total cholesterol (TC), triglyceride (TG), high density 
lipoprotein cholesterol (HDLC) and low-density lipoprotein cholesterol (LDLC) 
were determined by enzymatic procedure. All the analysis were performed 
by an automatic biochemical analyzer. The rest serum was aliquoted into 
sterile microcentrifuge tubes, and stored at -80°C until measurement of 
25(OH) D, leptin and inflammatory indexes of TNF-, IL-6 and CRP. 
Serum 25(OH)D concentrations were measured as described before (32). 
Briefly, 125I radioimmunoassay (RIA) kit from DiaSorin Inc (Stillwater, USA) 
was used. The sensitivity of the assay was 1.5 ng/mL. The inter-assay 
variability was 10.5% and the intra-assay variability was 8.2%. 
Leptin levels were determined by the method of radioimmunoassay (RIA, 
XH6080). The sensitivity of the assay was <0.4ng/mL. The inter-assay 
variability was <10% and the intraassay variability was <15%, and the 
average recovery was 93%-99%.TNF-α and IL-6 levels were also measured by 
125I radioimmunoassay kit. For TNF-α, the sensitivity of the assay was 6 
fmol/mL; the inter-assay variability was <10% and the intra-assay variability 
was <15%.For IL-6, the sensitivity of the assay was 50pg/mL; the inter-assay 
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variability was <7% and the intra-assay variability was <15%.Serum levels of 
CRP were measured by immuno-turbidimetric assay. 
Definition of VDD and SVDD 
The current widely accepted vitamin D nutritional status evaluation criteria 
by the Institute of Medicine was used to define vitamin D deficiency (VDD) 
and severe vitamin D deficiency (SVDD) (33). Serum 25(OH)D <20ng/ml (50 
nmol/L) was defined as VDD, and Serum 25(OH)D <10ng/ml(25nmol/L) was 
defined as SVDD. 
Statistical analyses 
Characteristics of TB patients and normal controls were presented, also the 
results of comparison between TB patients with and without SVDD. Mean 
and standard deviation for continuous variables with normal distribution 
and proportions for categorical variables were reported. Median and 
inter-quartile range were used for the description if the continuous data 
that were not normally distributed based on the results of 
Kolmogorov–Smirnov test. If the data were normally distributed after log10 
or ln transfer, anti-log10 or anti-ln values were presented.  
Independent-samples T test was used to determine the differences between 
the groups; for data not normally distributed or of unequal variance, rank 
sum test was performed. Spearman’s correlation analysis was used to 
determine the relationships between serum leptin, TNF-α and 25(OH)D, and 
these data were log10- or ln-transformed into normal distribution data for 
correlation analysis. Also, partial correlation analysis was used to adjust for 
the influence of BMI, age and gender. All statistics were performed using 
SPSS version 21.0 software (IBM SPSS Statistics 21). A p-value of <0.05 was 
considered statistically significant. 
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Results 
General characteristics of the participants 
General characteristics of patients and controls are shown in Table 6-1. No 
significant difference between age and gender was observed between the 
two groups. TB patients had lower total protein (g/L) (66.28±7.01 
vs74.16±3.84), albumin (g/L) (39.12±5.80 vs 45.97±2.44), hemoglobin (g/L) 
(126.64±18.99 vs144.73±15.94), lymphocyte count (0.51±0.61vs 2.05±0.60) 
and lymphocyte percentage (%) (24.36±11.31 vs 35.57±7.65) compared with 
controls, indicating decreased nutritional status in TB patients. Serum 
25(OH)D (ng/mL) in TB patients was significantly lower than normal controls 
(6.50±0.22 vs 17.21±0.14), which was nearly 40% of the latter. The 
prevalence of VDD was higher (93.0% vs 70.3%), and of SVDD much higher 
(65.9% vs 3.3%) than in controls.  
 
Table 6-1. General characteristics of the participants (Mean SD) 
 TB patients Control P-value 
N 299 91     
Age 45.14±16.45 47.45±9.24 0.203 
Male, n(%) 219(73.2) 63(69.2) 0.504 
SBP 123.60±17.08 127.23±17.49 0.083 
DBP 76.11±10.75 79.06±12.27 0.026 
BMI 22.03±3.41 22.78±2.98 0.068 
FPG(mmol/L)^ 5.42,3.58 4.86,0.55 0.000 
TC(mmol/L) 4.19±1.12 4.76±0.56 0.000 
TG(mmol/L)* 1.03±0.18 0.88±0.15 0.019 
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^Skewed distribution in the data, median and inter-quartile range were used for 
presentation and Mann-Whitney U test was used to test the difference. *log 
transferred and 10x for presentation, † log10 transferred, and 10x for 
presentation. 
TB, tuberculosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, Body 
Mass Index; FPG, Fasting Plasma Glucose; TC, Total Cholesterol; TG, triglyceride; HDLC, 
High-density Lipoprotein Cholesterol; LDLC, Low-density Lipoprotein Cholesterol; TP, 
total protein; WBC, white blood cell; NEUT, neutrophils; MONO, Monocyte; LYM, 
Lymphocyte; 25(OH)D, 25-hydroxyvitamin D; VD, vitamin D; VDD, vitamin D deficiency; 
HDL-C(mmol/L)* 1.19±0.14 1.44±0.13 0.013 
LDL-C(mmol/L)^ 2.42,1.03 2.71,0.73 0.207 
TP(g/L) 66.28±7.01 74.16±3.84 0.000 
ALB(g/L) 39.12±5.80 45.97±2.44 0.000 
ALT(U/L)* 15.59±2.35 16.94±1.58 0.382 
AST(U/L)^ 15.00,11.00 20.00,7.00 0.000 
GGT(U/L)* 32.80±2.07 1.99±1.61 0.000 
BUN(mmol/L) 4.73±2.69 5.08±1.23 0.242 
CRE(mmol/L) 57.31±35.79 62.60±13.05 0.168 
Hb(g/L) 126.64±18.99 144.73±15.94 0.000 
WBC count* 6.52±1.44 5.66±1.26 0.001 
NEUT count* 4.32±1.65 3.10±1.36 0.000 
NEUT% 67.92±12.65 55.42±8.46 0.000 
LYM count 0.51±0.61 2.05±0.60 0.000 
LYM% 24.36±11.31 35.57±7.65 0.000 
MONO count* 2.95±1.79 3.40±1.36 0.026 
MONO%* 4.50±1.93 5.60±1.28 0.000 
25(OH)D(ng/mL)† 6.50±0.22 17.21±0.14 0.000 
<20ng/mL, n(%) 278(93.0) 64(70.3) 0.000 
<10ng/mL, n(%) 197(65.9) 3(3.3) 0.000 
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SVDD, severe vitamin D deficiency; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, 
tumor necrosis factor-alpha. 
 
Difference according to presence or absence of SVDD and DM 
As shown in Table 6-2, 299 TB patients were classified into two groups based 
on the cut-off value of SVDD (serum 25(OH)D<10 ng/mL). Log normal 
distribution of the data was found for serum 25(OH)D, Leptin, TNF-, IL-6 
and CRP. Leptin (ng/mL) concentration in SVDD group was significantly 
lower than in non-SVDD group (2.70±0.22 vs 3.70±0.19, P=0.0001), while 
TNF- (fmol/mL) concentration was higher in SVDD group (12.47±1.89 vs 
9.68±2.11, P=0.004). No obvious differences were observed in IL-6 and CRP 
levels.  
When stratified by the presence of DM, 121 TB patients with DM (TB-DM) 
and 178 without DM (TB-nonDM) were identified. Compared with 
TB-nonDM, TB-DM had higher levels of serum 25(OH)D (ng/mL) (8.07±0.26 
vs 5.61±0.23, p<0.001). Significant difference of TNF- (fmol/mL) and CRP 
(mg/L) existed between them (10.07±2.02vs12.53±1.94, p=0.009 and 
52.84±3.69 vs 16.52±4.80, p=0.000). No significant difference in leptin and 
IL-6 was observed between the two groups. 
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Table 6-2. Characteristics of TB patients by presence of SVDD（Mean SD) 
 SVDD Non- SVDD P-value 
N 197 102  
Age 44.79±16.75 45.83±15.92 0.605 
Male, n(%) 144 (73.1) 75 (73.5) 0.936 
SBP 124.16±16.87 122.47±17.53 0.424 
DBP 76.05±10.80 76.24±10.69 0.882 
BMI 22.03±3.29 22.03±3.60 0.997 
<18.5, n(%) 21(14.5) 14(14.6)  
18.5~23.9, n(%) 85(58.6) 59(61.5) 0.873 
    ≥24, n(%) 39(26.9) 23(24.0)       
FPG(mmol/L)^ 5.32,3.36 5.84,4.10 0.139 
TC(mmol/L) 4.17±1.12 4.21±1.13 0.812 
TG(mmol/L)† 0.97±0.17 1.14±0.18 0.028 
HDL-C(mmol/L)† 1.17±0.14 1.24±0.14 0.184 
LDL-C(mmol/L)^ 3.29,0.94 2.49,1.09 0.510 
Hemoglobin(g/L) 125.66±19.13 128.56±18.67 0.219 
TP(g/L) 66.37±6.46 66.10±7.98 0.756 
Albumin(g/L) 38.89±5.49 39.55±6.36 0.357 
LYM count 1.50±0.58 1.51±0.65 0.950 
LYM% 24.89±11.20 23.28±11.52 0.269 
WBC count* 6.28±1.45 6.99±1.40 0.016 
NEUT count 4.69±2.80 5.37±2.84 0.063 
NEUT% 66.93±13.19 69.92±11.28 0.065 
MONO count† 0.30±0.18 0.27±0.17 0.153 
MONO%* 4.68±1.94 4.15±1.89 0.166 
25(OH)D†(ng/mL)† 4.08±0.17 15.92±0.14 0.000 
Leptin(ng/ml)$ 2.70±0.22 3.70±0.19 0.001 
TNF-(fmol/mL)* 12.47±1.89 9.68±2.11 0.004 
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IL-6(pg/ml)* 85.50±2.68 90.78±2.06 0.593 
CRP(mg/L)* 27.10±4.72 27.54±5.06 0.945 
Outdoor activity    
 2hrs/d,n(%) 60(40.3) 31(32.3) 0.207 
< 2hrs/d,n(%) 89(59.7) 65(67.7)  
Smoking history, n(%) 48(24.4) 38(37.3) 0.020 
Alcohol history, n(%) 75(38.1) 49(48.0) 0.097 
† log10 transferred,*log transferred, $ln10 transferred.^Skewed distribution in the 
data, median and inter- quartile range were used for presentation and Mann-Whitney 
U test was used to test the difference 
TB, tuberculosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, Body 
Mass Index; FPG, Fasting Plasma Glucose; TC, Total Cholesterol; TG, triglyceride; HDLC, 
High-density Lipoprotein Cholesterol; LDLC, Low-density Lipoprotein Cholesterol; TP, 
total protein; WBC, white blood cell; NEUT, neutrophils; MONO, Monocyte; LYM, 
Lymphocyte; 25(OH)D, 25-hydroxyvitamin D; SVDD, severe vitamin D deficiency; CRP, 
C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha. 
 
Relationship between serum leptin and 25(OH)D levels in active TB 
patients 
Leptin concentrations were significantly positively correlated with serum 
25(OH)D in TB patients (r=0.246, P<0.001), which persisted after adjustment 
for BMI, age and gender (r=0.210, P=0.002). Stratified analysis showed that 
serum leptin concentrations were both positively correlated with 25(OH)D in 
TB patients with and without DM (r=0.240, r=0.182, respectively). R2 -value 
in TB-DM was 0.104, which indicated 10.4% variation of serum leptin 
concentration could be explained by serum 25(OH)D. No significant 
correlation was observed between serum leptin and 25(OH)D in normal 
controls. (Figure6-1) 
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Figure 6-1. Correlation between serum leptin and 25(OH)D concentrations* 
1, all TB; 2, TB-nonDM; 3, TB-DM; 4: normal control.*25(OH)D was log10* transformed, and leptin was ln10* 
transformed. 
Relationship between serum TNF-α and 25(OH)D levels in active TB 
patients 
A negative correlation between TNF-α and serum 25(OH) in active TB 
patients was observed (r=-0.226, P <0.001), which persisted after 
adjustment for BMI, age and gender (r=-0.197, P=0.003). Further stratified 
analysis by presence of DM showed different profiles. The correlation was 
stronger in TB patients without DM (r=-0.304, P = 0.001), and R2 value was 
0.104 which indicating that serum 25(OH)D status explained 10.4% of the 
variation in TNF-α concentrations. However, no such association was 
observed in TB-DM patients. The analysis of the correlation of TNF-α and 
25(OH)D in normal controls gave no significant result. (Figure6-2) 
R2=0.06 R2=0.04 
R2=0.10 
2 
3 
1 
4 
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Figure 6-2. Correlation between serum TNF-α with 25(OH)D concentrations* 
1, all TB; 2, TB-non DM; 3, TB-DM; 4: normal control; *25(OH)D was log10* transformed, and TNF-α was log 
transformed. 
Discussion 
The present study demonstrates poor vitamin D (VD) status and a positive 
association between leptin and VD status in active TB patients, while the 
pro-inflammatory marker TNF-α was inversely correlated with VD. 
Furthermore, these correlations showed a different profile depending on 
presence or absence of comorbid DM, especially for TNF-α. 
In this observational study, the participants were recruited from a city level 
hospital in Qingdao, located in Shandong province in Eastern China. This 
hospital has a catchment area of about 9 million people, and the average 
R2=0.05 R2=0.10 
1 2 
3 4 
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number of hospitalized patients with tuberculosis was about two thousand 
cases per year. A total of 299 active tuberculosis patients were randomly 
recruited, together with 91 normal controls randomly selected from persons 
undergoing physical check-up in a general hospital in the same city. No 
significant difference of age and gender existed between the patients and 
controls, which supports comparability. 
The most widely accepted criteria(33) were used to characterize the 
participants as VDD and SVDD in our study, i.e. cut off’s for serum 25(OH)D 
of 20ng/mL and 10ng/mL, respectively. Serum leptin and TNF-α levels were 
highly correlated with BMI(34), also age, gender may explain variance in their 
levels in the body(35; 36). These potential confounders were considered in the 
present study. Partial correlation analysis was used to adjust the possible 
confounding effect of these variables. 
We observed a high prevalence of VDD (93.0%) and SVDD (65.9%) in active 
tuberculosis patients, which was significantly lower than in normal controls 
(70.3% and 3.3%, respectively).Together with our previously reported study 
in a partly overlapping population(37), we might draw the conclusion that the 
VD status in active TB patients is very poor, especially in hospitalized 
patients. 
Serum leptin levels were found to be positively correlated with 25(OH)D 
concentrations in TB patients in the present study, which was in accordance 
with the result of a cross-sectional study in a cohort of 259 Saudi normal 
adults (38). Leptin was reported to activate T lymphocytes via activating 
JAK-STAT signal pathway (39), together with the modification of Th1/Th2 
balance, indicating its positive correlation with immune activity in the body. 
Low leptin levels may be a possible mediator of the association between 
severe weight loss and the suppressed cellular immunity(39; 40) in TB patients. 
Different to our result, an inverse association was claimed between leptin 
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and 25(OH)D concentrations in a recent meta-analysis of 14 cross-sectional 
studies (41). However, most of the subjects included in this study were 
severely obese subjects, healthy persons or hemodialyzed patients, while no 
TB patients were included. The analysis stratified by DM showed similar 
results, while the correlation was somehow stronger in TB-DM patients. The 
possible reason may be that vitamin D is correlated with increased risk both 
of TB and DM (42; 43), which may have resulted in a closer link between VD 
and leptin in patients with the combined disease. To our knowledge, this is 
the first time to report a positive relationship between leptin concentrations 
and VD status in active TB patients, and our result indicates that a possible 
favorable role of VD may be mediated by up-regulating leptin level.  
Serum TNF-α concentrations was inversely related to 25(OH)D in TB-nonDM 
patients, and about 10% of the variation in TNF-α concentrations was 
explained by VD. TNF-α, a pro-inflammatory cytokine secreted by 
macrophages, monocytes, T-cells and adipocytes, plays an important role in 
anti-TB immunity with a complex manifestation. Changes of TNF-α may be 
closely related to the progress of TB. A recent study claimed that TNF-α was 
correlated with TB severity, suggesting that it may be a marker of severity(44), 
and even a slight drop in circulating TNF-α may have clinical significance, 
indicating protection against excessive tissue damage at the site of infection 
(45).Until now, a few in vitro studies about the correlations between TNF-α 
and VD in TB are available.1,25-dihydroxyvitamin D (1,25(OH)D) stimulation 
led to elevated levels of TNF-α in human monocyte-derived macrophages 
from TB patients(46). However, 1,25(OH)D was also reported to significantly 
suppress most Mtb antigen induced pro-inflammatory cytokines including 
TNF-α. Notably, our stratified analysis showed that this inverse correlation 
did not exist in TB-DM patients. As we found in this study, co-existing DM 
presented with a different TNF-α level in TB patients. Similarly, increased 
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inflammatory status was reported in TB-DM patients compared with TB(47). 
This may partially explain the different correlation between VD and TNF-α in 
TB-DM patients from those with only TB. Our result indicates that the 
down-regulation of TNF-α by vitamin D may contribute to its effects in TB 
patients. 
The main strength of this study is that it provided renewed evidence on the 
correlation of inflammatory indexes and leptin with VD in TB patients in an 
in vivo situation. This may add valuable clues of the possible mechanism of 
the effect of VD in active TB patients. Also, the modification of comorbid DM 
was analyzed and a different profile of the associations was observed, 
especially with respect to TNF-α. In the setting of double burden of TB and 
DM in developing countries in recent years, our study provides important 
data for the understanding of the characteristics of the diseases. Of course, 
the study has its limitations. We cannot make a convincing causal 
interpretation due to the cross-sectional design. In addition, despite 
adjustment for possible confounders in the data analysis, residual 
confounding cannot be completely ruled out. Nevertheless, the evidence 
with respect to the correlation of serum VD status with leptin and 
inflammatory biomarkers in active TB patients, and the heterogeneity 
observed in patients with and without DM is worthy of further investigation. 
In conclusion, this study provides evidence that TNF-α in active TB patients 
is independently inversely correlated with circulating 25(OH)D concentration, 
while serum leptin levels show a positive correlation. This indicates that 
adequate VD status may lead to improved immune activity and less severe 
disease in TB. The underlying molecular mechanisms need further research. 
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Abstract
Diabetes results in the presentation of more symptoms, more relapses,
treatment failures and deaths during anti-tuberculosis therapy in patients
with combined diseases. Therefore, new treatment strategies are urgently
needed. Vitamin D has been shown to have beneficial effects towards
clinical recovery such as sputum culture conversion. Therefore, we carried
out this intervention study with the main purpose to explore the possible
effects of vitamin D on treatment outcomes. A cluster randomized trial of
vitamin D supplementation added to pharmacotherapy in tuberculosis
patients with and without diabetes was carried out in a city-level chest
hospital. Three hundred and fifty eight newly diagnosed pulmonary
tuberculosis patients aged 18 y were included in this study, with 174 cases
in VD3 supplementation group (800IU/d) and 184 in control group. The
supplementation of vitamin D3 in patients with combined diseases showed
Figure2 TBscore and the severity class at various
times in all patients
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significant effects on the improvement of TB manifestation at 4th, 6th, 8th
week, adjusted for confounders as age, gender. However, no similar effects
of vitamin D were found in patients without diabetes. Our results provide an
important clue of the role of vitamin D in the adjunctive treatment in
patients with combined tuberculosis and diabetes, which may indicate a
new perspective for treatment. However, the limitations of the trial need to
be considered when making causal inference and more confirmative trials of
the effect of vitamin D supplementation are needed.
Key words: vitamin D3; tuberculosis; diabetes; TBscore; supplementation
Introduction
Tuberculosis is a major global public health problem, with an estimated 9
million incident cases worldwide each year, mainly in low and middle
income countries such as India, Indonesia, and China, which rank the top 3
of world tuberculosis burden in 2016 as WHO reported (1). Over the last
decades, diabetes mellitus has risen worldwide from 4.7% in 1980 to 8.5% in
2014 (2).Currently, 80% of global diabetes mellitus burden is in low and
middle countries. Six of them (India, China, Brazil, Indonesia, Pakistan and
The Russian Federation) also have a high tuberculosis burden(1). In China, the
prevalence of diabetes has increased especially rapidly over the last 10 years
(3). The International Diabetes Foundation Diabetes Atlas estimated that in
2017 the number of persons with diabetes in China was 114 million,
representing nearly a quarter of cases worldwide. Diabetes triples the risk of
active tuberculosis (4), and also results in the presentation of more symptoms,
more relapses, treatment failures and deaths(5; 6), especially among those
with poorly controlled diabetes (7). According to a pooled analysis of four
studies, diabetes was associated with nearly 5 times higher risk of death
during tuberculosis treatment, adjusted for age and other potential
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confounders(5; 8). Therefore, new treatment strategies given the double
burden of tuberculosis and diabetes are urgently needed.
Vitamin D may have an important role in host immune defense against
Mycobacterium tuberculosis (Mtb) (9). Vitamin D deficiency is common in
active tuberculosis, and a meta-analysis in 2008 combining seven
observational studies have found evidence of a moderate to strong
association between vitamin D deficiency and active tuberculosis(10). Several
prospective longitudinal studies further claimed an association between
vitamin D deficiency and higher risk of active tuberculosis (11; 12). Accordingly,
we found a high prevalence of vitamin D deficiency in tuberculosis patients,
regardless of the presence of diabetes (13). Also, Vitamin D deficiency has
been associated with the severity and relapse rate of tuberculosis disease.
Moreover, vitamin D deficiency has been reported to be related to impaired
insulin secretion and sensitivity, and is associated with risk of diabetes(14; 15;
16). Epidemiological evidence for an inverse association between serum
vitamin D levels and the risk of type 2 diabetes is abundant (17). A cross
sectional study in overweight and pre-diabetic populations in China reported
83.3 % vitamin D deficiency, and vitamin D status was inversely associated
with insulin resistance (17). A recent cohort study in Asia found that
compared to individuals with vitamin D concentrations ≥ 20 ng/mL, those
with concentrations of 10-19.9 ng/mL and of <10 ng/mL have a 2.06 and
3.23 fold increased risk of developing type 2 diabetes, respectively(16).
Indeed, vitamin D was used for treatment of tuberculosis in the
pre-antibiotic era. It has been reported that addition of vitamin D3 to
standard therapy had beneficial effects towards clinical recovery including
sputum culture conversion (18), weight gain, chest radiographic findings (19)
and resolution of inflammatory responses that are associated with increased
Chapter 7
- 144 -
risk of mortality (20). Recently, it was reported that the effect of vitamin D on
tuberculosis therapy was modified by SNPs in genes encoding the vitamin D
receptor (VDR) and 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) (21). A
possible mechanism of vitamin D–mediated effect on tuberculosis
treatment efficacy is that 25-dihydroxyvitamin D induces anti-mycobacterial
activity in macrophages in vitro, up-regulating protective innate host
responses, and triggering antimicrobial peptides such as cathelicidin (9).
However, there is still controversy about the efficacy of adjunctive use of
vitamin D on tuberculosis at present. Adding vitamin D to a background of
standard first-line anti-tuberculosis drugs did not find a significant effect of
on the rate of sputumMtb clearance (22; 23; 24).
We report findings from a hospital-based trial testing the effect of vitamin D
supplementation in tuberculosis patients with and without diabetes in China.
We aimed to test whether vitamin D supplementation could improve clinical
response to treatment in newly diagnosed pulmonary tuberculosis and
accelerate sputum clearance of Mtb. Further, we checked whether the
outcome in tuberculosis patients with concurrent diabetes might show a
different profile.
Methods
Study setting
The trial was implemented in a city level specialized tuberculosis hospital
located in Qingdao, Shandong province of China. This hospital has a
catchment area of about 9 million people, and the average number of
hospitalized patients with tuberculosis was about two thousand cases per
year.
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Study design and assignment of the participants
We conducted an intervention study, with an external control group from
the same hospital. Diagnosed tuberculosis patients were assigned, in order
of coming in, to one of the four clinical departments in the hospital in turn
according to their visiting sequence. In all departments the same standard
treatment procedure was used. One department was chosen randomly as
the vitamin D intervention arm, and all consenting patients in this section
received conventional anti-tuberculosis treatment plus oral vitamin D3
supplementation (800IU/d) for 8 consecutive weeks. One of the other
departments was chosen as a control department, where patients received
standard therapy. Physical examination including weight, height,
face-to-face questionnaire was the same in both departments.
Study subjects
Pulmonary tuberculosis patients with and without diabetes were recruited
between Jan 2000 and Dec 2012 from Qingdao tuberculosis hospital
(Qingdao, China). Medical records of consecutive patients with diagnosed
pulmonary tuberculosis disease were screened for eligibility. Potential study
subjects were identified after diagnosis with the use of standard methods
including of compatible signs and symptoms, and a chest radiograph.
Inclusion criteria were as follows: 1) age  18 y; 2) newly diagnosed
pulmonary tuberculosis disease; 3) <7d of anti-tuberculosis drug therapy
before entry. Exclusion criteria were as follows: 1) current extrapulmonary
tuberculosis; 2) retreatment patients; pregnant or lactating woman; 3) HIV
positive; 4) a history of nephrolithiasis, hyperparathyroidism, organ
transplant, hepatic cirrhosis, or cancer in the past 5 y; 5) a baseline plasma
calcium concentration >2.6 mmol/L, creatinine concentration >250 mmol/L,
or aspartate aminotransferase concentrations that was >3 times the upper
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limit of the normal range; 6) corticosteroid use in the past 30 d; 7) current
use of immunosuppressive drugs.
The Ethics Committee of Qingdao Disease Prevention and Control Centre
approved the present study, and consent was obtained from all subjects.
This investigation research was registered in the Chinese Clinical Trial
Registry (No. ChiCTR-IPR-15006395).
TBscore for evaluation of the severity of tuberculosis related clinical signs
and symptoms
TBscore is a tool aiming to assess changes in the clinical status in patients
with tuberculosis. It is based on points assigned to signs and symptoms,
including cough, hemoptysis, dyspnea, chest pain, night sweating, anemia,
tachycardia, lung auscultation finding, fever, BMI<18 and BMI<16, as we
previously stated (13).
The severity of tuberculosis clinical signs and symptoms was categorized
based on the distribution of TBscore in the present study: class 1(mild,
TBscore 0~2); class 2 (middle, TBscore 3~4); class 3 (severe, TBscore 5~9).
Improvement was defined as a change to a lower degree, i.e. class 3 to class
2 or 1, class 2 to class 1. Those without change or change to a higher
category were characterized as no improvement.
Sputum smear and culture and drug-susceptibility testing
Duplicate sputum specimens were collected from the subjects for an
acid-fast bacteria (AFB) smear at baseline, weeks 2, 4, 6 and 8. A smear
microscopy was performed at the lab in the hospital by using Ziehl-Neelsen
staining. All sputum samples at admission had AFB cultures performed with
the use of Löwenstein-Jensen solid media and standard methodologies.
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Drug-susceptibility testing was performed with the use of the absolute
concentration method on solid media with a standard procedure.
Multi-drug-resistant tuberculosis (MDR-TB) was defined as resistance to at
least isoniazid and rifampicin.
Anti-tuberculosis drug therapy
Standard anti-tuberculosis drug therapy (isoniazid, rifampicin, pyrazinamide,
and ethambutol) was started in all subjects based on the diagnosis of
tuberculosis. Subjects with confirmed MDR-TB were changed to appropriate
second-line drug therapy according to standard clinical care protocol. All
subjects received directly observed therapy of anti-tuberculosis drugs and
the intervention group received additional vitamin D3 supplements.
Baseline blood chemistry and serial calcium and 25(OH)D concentrations
Blood samples were drawn from each subject after fasting for at least 12 h
and an overnight rest. Glucose and lipid indexes were determined
immediately after blood was drawn. Glucose oxidase method was used for
the determination of FPG using a Hitachi automatic analyzer. Lipid indexes
including total cholesterol (TC), triglyceride (TG), high density lipoprotein
cholesterol (HDLC) were determined by autoanalyzer under standard
procedure. The remaining plasma/serum were stored at -80  C until
measurement for 25(OH)D. Other biochemical indexes such as aspartate
amino transferase, creatinine, calcium, and routine blood test such as white
blood cell count, lymphocyte count, etc were carried out by standard
method. Plasma calcium concentrations were serially monitored in all
subjects at weeks 2, 4, and 8. Patients with co-current diabetes were
monitored frequently for blood glucose level in fingertip blood fasting and
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two hours after meal. Serum 25-hydroxyvitamin D concentrations were
measured with the use of 125I radioimmunoassay (RIA).
Safety monitoring
Criteria for subject discontinuation were established before the intervention.
Subjects were withdrawn from the study drug if a plasma calcium
concentration was >2.6 mmol/L with signs and symptoms of hypercalcemia
during the following 8 wks or if a plasma calcium concentration was >2.9
mmol/L at any time regardless of the presence of symptoms. The subjects
were also queried for clinical symptoms that could potentially be related to
hypercalcemia with a specific case report form (CRF) once a week
continuously for a period of ten weeks. The reported symptoms included
stomachache, diarrhea, headache, dizzy, nausea, vomit, joint pain and
mental condition.
Statistical Analysis
All the analyses were performed using SPSS version 23.0 software (IBM SPSS
Statistics 23). We expressed variables by their means and standard
deviations. The Pearson chi-square (χ2) was used to assess statistical
differences in proportions between groups, and the Student t test to assess
differences in means between two groups when a normal distribution was
present. Log-normal distribution was present in serum 25(OH)D, and the
data were log transferred for the t test and 10x transfer for presentation.
Covariance analysis (ANCOVA) was used for the comparison of TBscore
between the two groups with adjustment of the baseline TBscore. TBscore
was further transferred into three categories namely mild, middle, severe,
and improvement rates were calculated as stated in the method section.
Multivariate logistic regression (MLR) was used to evaluate vitamin D
supplementation on the presentation of improvement. Possible
confounders i.e., age and gender was adjusted. Backward stepwise logistic
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regression, with entry and removal criteria of P<0.05 and P>0.10
respectively, was used to establish the final multivariate predictive model.
Odds ratios and nominal 95% confidence intervals (CIs) are presented.
Two-sided P<0.05 was considered significant for all analyses.
Results
A total of 537 patients were assessed for eligibility at the beginning.
Excluded were 180 due to: refused to take part in the trial (n=42), HIV
infected (n=3), retreatment (n=66), other reasons (n=7). Then 200 patients
had additional vitamin D, and 219 were in the control group. During the trial,
fourteen patients in the vitamin D group stayed in hospital <2 months, and
12 were drug resistant; while 17 in the control arm stayed in hospital <2
months and 18 were drug resistant. Finally, we analyzed 174 patients in the
vitamin D arm (64 patients with concurrent tuberculosis and diabetes, 110
tuberculosis) and 184 in the control arm (73 patients with concurrent
tuberculosis and diabetes, 111 tuberculosis). The flow of participants is
outlined in Figure 7-1.
Figure 7-1. Flow of participants in vitamin D supplementation trial
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Demographic and clinical characteristics
Demographic and clinical characteristics of the participants were
comparablebetween study groups. The prevalence of diabetes, cavity in
chest radiograph, positive sputum and the severity of TBscore distributed
similarly between the two study groups (Table 7-1).
Table 7-1. Demographic and clinical characteristics of the participants at baseline
Vitamin D (n=174) Control(n=184) P-value
Age, years, mean(SD) 42.0715.44 44.1216.62 0.229
Male, n(%) 137(78.7) 139(75.5) 0.473
SBP 122.2017.12 121.6815.67 0.766
DBP 75.3210.87 76.979.32 0.122
BMI 21.413.14 21.473.19 0.844
<18.5 30(17.2) 34(18.5) 0.571
18.5~23.9 112(64.4) 109(59.2)
≥24.0 32(18.4) 41(22.3)
Marriage status
Married 125(71.8) 137(74.5) 0.576
Unmarried 49(28.2) 47(25.5) 0.234
Smoking history 97(55.7) 91(49.5)
diabetes 64(36.8) 73(39.7) 0.574
Sputum positive 121(71.2) 120(68.2) 0.545
CT-cavity 80(46.0) 81(44.0) 0.710
TB score 3.931.59 3.691.55 0.159
Class 1 35(20.1) 41(22.3) 0.801
Class 2 81(46.6) 87(47.3)
Class 3 58(33.3) 56(30.4)
Mean 25(OH)D3† 6.450.21 7.200.20 0.394
† log10 transformed for t test between the two groups, and 10x/10 for presentation.
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Vitamin D status in the participants
The majority of the subjects (95%) was vitamin D deficient. A similar number
of subjects in the control (63.5%) and vitamin D (68.6%) groups were
severely vitamin D deficient (<10 ng/mL) at baseline. However, vitamin D
supplementation did not result in significant increase in serum 25(OH)D in
the supplementation group compared to the control (p>0.05).
Adverse Events
During the continuous monitoring of adverse events in the following 10 wks
after the start of the trial, the symptoms of adverse effects were reported
most frequently at inclusion, at which time 33% reported any of the
symptoms before receiving the anti-tuberculosis treatment, the number
declined to 25%, 14%, 6% and 5% at 2th, 4th, 6th, 8th wks. Most frequently
reported incident adverse effect was nausea (n=31), other side effects
included stomachache (n=16), dizzy (n=16), diarrhea (n=13), headache
(n=12), mental condition (n=11), vomit (n=9) and joint pain(n=7). No
differences of the adverse effects were observed between the vitamin D
group and controls, except for diarrhea, with a higher incidence in control
group (6.0% vs 1.1%, p=0.015). Also, no cases of hypercalcemia were seen.
Effect of vitamin D supplementation
The TBscore of the intervention and control groups as well as the proportion
in moderate and heavy categories (class 2 and 3) at various time points are
presented in Figure 7-2. An obvious tendency of ameliorated tuberculosis
severity during follow up was observed in both groups, however not
significantly different. As shown in Figure 7-3, the percentage improvement
(change to a lower severity class) in the vitamin D supplementation group
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was borderline significantly higher at weeks 4, 6 and 8 (p=0.083, 0.084 and
0.086, respectively).
Subgroup Analysis by presence of diabetes
Because the co-morbidity of diabetes may have a significant impact on the
clinical treatment, we examined the impact of vitamin D supplementation
among tuberculosis patients with diabetes and tuberculosis patients without
diabetes, separately (n=137, n=221, respectively). Patients with diabetes
were older than those without diabetes (52.211.1 vs 37.516.1, p<0.001),
with higher BMI level and higher prevalence of overweight and obesity
(29.2% vs 14.9%). Also, concurrent diabetes resulted in significantly higher
prevalence of tuberculosis signs and symptoms including positive sputum
(78.1% vs 64.7%), cavity in CT scan (55.5% vs 38.5%) and class 2+3 of
TBscore (88.3% vs 78.2%).
As demonstrated in Figure 7-4 and Figure 7-6, similar results were observed
for both subgroups as in all the subjects shown in Figure 2. We did not find a
significant difference between the two arms in both subgroups. Notably, a
different profile was observed in the improvement rate of TBscore class in
tuberculosis patients with and without diabetes (Figure 7-5 and Figure 7-7).
Obviously higher improvement rates were found in the vitamin D
supplementation group at 4th, 6th and 8th wks in tuberculosis patients with
diabetes (Figure 7-7), while no such effect existed in those without diabetes
(Figure 7-5).
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All TB patients: patients with and without tuberculosis; TB-only patients: tuberculosis patients without
diabetes; TB-DM patients: tuberculosis patients with diabetes
In figure 7-2, 7- 4 and7- 6, the fold line showed the mean TBscore of the patients at various times with
right axis, and the bar chart showed the proportion of severity class II and III with left axis.
Figure 7-2. TBscore and the severity class at
various times in all TB patients
Figure 7-3. Improvement rate of severity class
at various times in all TB patients
Figure 7-4. TBscore and the severity class at
various times in TB-only patients
Figure 7-5. Improvement rate of severity class
at various times in TB-only patients
Figure 7-6. TBscore and the severity class at
various times in TB-DM patients
Figure 7-7. Improvement rate of severity class
at various times in TB-DM patients
vitamin D supplemented control vitamin D supplemented control
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Vitamin D supplementation and improvement of tuberculosis severity
Since difference existed in baseline TBscore between the vitamin D
intervention arm and the controls (Figure 7-6), we further analyzed the
effects of vitamin D by using multivariate logistic regression.
Tables 7-2 show the results of the logistic regression analysis of factors
related to the improvement of TBscore at various time intervals. After
adjustment for possible confounders including age and gender, vitamin D
supplementation still was related to the improvement of TBscore at the 4th,
6th, 8th week in patients with concurrent diabetes (OR 5.48, 95%CI
1.14-26.40). The odds ratios in the multivariable model were almost the
same as the crude one, indicating the effects of vitamin D on the
improvement of TBscore were not influenced by age and gender. No similar
results were observed in patient with tuberculosis only.
Table 7-2. Multivariable logistic regression of the effect of vitamin D supplementation
on the improvement of TBscore at various time intervals
4th week 6th week
Crude OR Adjusted OR§ Crude OR Adjusted OR§
All 1.47(0.95~2.29)^ 1.50(0.96~2.32)^ 1.49(0.95~2.36)^ 1.51(0.95~2.38)^
TB-only 1.19(0.69~2.06) 1.20(0.69~2.07) 1.12(0.64~1.97) 1.10(0.62~1.95)
TB-DM 2.30(1.06~4.98)* 2.29(1.05~5.02)* 2.66(1.19~5.97)* 2.66(1.18~5.99)*
8th week
Crude OR Adjusted OR§
All 1.51(0.94~2.44)^ 1.51(0.94~2.43)^
TB-only 1.03(0.57~1.88) 0.99(0.54~1.82)
TB-DM 2.98(1.31~6.83)* 2.98(1.30~6.84)*
TB-only patients, patients with tuberculosis only; TB-DM patients, patients with
concurrent tuberculosis and diabetes; ^p<0.10* p<0.05; §adjusted by age and
gender.
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The results of positive sputum smear were presented in Figure 8. Significant
decreases were observed with the therapy. In the subgroup analysis, we
found that the time for sputum smear conversion in patients with diabetes
was obviously longer than those without diabetes. However, no significant
difference between vitamin D supplementation and controls was found
when analyzed in all patients or by the presence of diabetes (Figure 7-8).
Figure 7-8. The rate of positive Sputum smear at various time
Left: all the subjects; middle: TB patients without diabetes; right: TB patients with
diabetes
Discussion
Vitamin D supplementation in tuberculosis patients during intensive-phase
treatment did not result in adverse events. The supplementation of vitamin
D showed adjunctive effects on the improvement of tuberculosis severity as
evaluated by TBscore in patients with combined diabetes and tuberculosis at
the 4th, 6th , and 8th week, while no similar effects were found in those
4 80 wks 0 4 8 wks 0 4 8 wks
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without diabetes. Neither did we find an effect of vitamin D
supplementation on sputum smear conversion.
We used an open intervention study design without placebo control in two
separate departments: one was the intervention department and one of the
other departments acted as an external control group. So, a limitation is that
the study was not blind and there was no individual randomization. This
design was adopted after discussions with the co-investigators in the
hospital. This way contamination of treatment between both groups could
be avoided. It was also anticipated that many patients and particularly the
more severe cases would be unwilling to run the chance of getting placebo,
because of the stigmatization and discrimination of tuberculosis patients
that still exist. And the combined diabetes might be associated with worse
situation, since more severe signs and symptom at presentation may result
in higher sensitiveness in the patients. In addition, the ratio of clinician to
patients was approximately 1:7, and the doctors had the responsibility of
outpatient service one day a week, which made it difficult to manage the
patients in case of individual randomization. However, the diagnosed
patients were assigned to each department in turn according to their visiting
order, and a large proportion of the patients would stay in hospital for two
months receiving the intensive-phase chemotherapy. Therefore, from the
perspective of the separate department, patients had a similar degree of
clinical signs and symptoms, sharing similar treatment conditions. The
intervention was given to eligible patients in one department, while patients
from a department that was given standard treatment were observed as a
comparison group. Although the study was carried out in two separate
departments, clinical therapy, physical examination and face-to-face
questionnaire were carried out by using the same procedure, except for the
additional vitamin D intervention.
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To our knowledge, this is the first vitamin D intervention trial in patients
with concurrent tuberculosis and diabetes with sufficient sample size. We
did not find hypercalcemia in the subjects during the process of this trial,
and the potential signs and symptoms related to hypercalcemia were also
not observed. This indicated no significant adverse events due to the
supplementation of vitamin D of 800 IU per day during the intensive-phase
treatment. We used TBscore for the evaluation of tuberculosis clinical signs
and symptoms. The score includes cough, hemoptysis, dyspnea, chest pain,
night sweating, anemia, tachycardia, lung auscultation finding, fever,
BMI<18 and BMI<16. Change in TBscore has been shown to detect clinical
change well; a high TBscore correlates well with mortality and low TBscores
correlate with favourable outcomes, cure, and completed treatment (25).
Since in the subgroup of patients with concurrent tuberculosis and diabetes,
the vitamin D group had a higher average TBscore than the control group,
we considered regression to the mean when setting up the data analysis
strategy. We adjusted for baseline TBscore using the continuous variable.
However, the odds ratio turned to become inflated instead of diminished by
the adjustment. Therefore, we decided to report the odds ratios unadjusted
for baseline TBscore. Further analysis will be necessary to elucidate the
possibility of regression-to-mean in this study. We further adjusted for age
and gender in the model, as the possible confounders. Vitamin D deficiency
is more common among older persons (26) , and in univariate analysis, a
significant correlation with the improvement of TBscore was observed for
gender. The adjusted odds ratios were very similar to the crude ones.
Therefore, we think vitamin D supplementation had an adjunctive effect
from the 4th week onwards during intensive-phase treatment, independent
of age or gender.
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The possible underlying mechanism of vitamin D supplementation may
represent synergistic effects of immunomodulatory(27) and glycemic control (28)
of vitamin D. In line with the immunomodulatory effect is our observation
that serum 25(OH)D was positively related to leptin, while negatively with
TNF-α (chapter 6), indicating the regulation of these immune activity related
cytokines(29). Although the exact pathway of vitamin D on the improvement
of the clinical signs and symptoms in patients with concurrent tuberculosis
and diabetes needs more research, our results provide an important clue of
the role of vitamin D in the adjunctive treatment in patients with combined
tuberculosis and diabetes.
No similar effects of vitamin D were found in tuberculosis patients without
diabetes, which is in agreement with a recent meta-analysis reporting that
the non-skeletal health effects of vitamin D has not been confirmed with
sound evidence in randomized trials till now (30). However, Coussens et al.
reported that adjunctive high-dose vitamin D in tuberculosis treatment
could accelerate sputum smear conversion, and reduce the inflammatory
responses associated with higher risk of mortality(20). The discrepancy may
be due to various factors such as different doses used, different treatment
settings. Another explanation may be that the effect in patients with
tuberculosis only may be smaller. The number of subjects in this subgroup
and the resulting power may have been insufficient to pick up the difference
between the supplementation and comparison group. Therefore, the
question whether vitamin D supplementation benefits tuberculosis only
patients needs further research in an enlarged sample size. A recent study
found that the improvement of sputum clearance by high dose vitamin D
was modified by SNPs in genes encoding the vitamin D receptor (VDR)
and 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) (21). Therefore,
whether vitamin D supplementation has benefits in tuberculosis needs
further research to confirm.
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Diabetes resulted in more severe presentation, high risk of treatment
failure(31) and death(5; 8), and may be associated with increased risk of the
development of multidrug resistant tuberculosis (MDR-TB)(32)(33). Chronic
hyperglycemia is associated with impaired immunity to Mtb in diabetes
patients and may result in reduced effectiveness of anti- tuberculosis
treatment. In recent years, the double burden of tuberculosis and diabetes
in low- and middle-income countries has caused intensive concern of
international agencies such as the WHO, International Union against
Tuberculosis and Lung disease (the Union) and International Diabetes
Federation, to provide strategies upon facing this new challenge. The WHO
recommended optimized glucose control as part of the management of
tuberculosis and diabetes combined patients for improved tuberculosis
outcomes(34). Till now, widely accepted guidelines for the treatment of
tuberculosis patients with concurrent diabetes are not available. Recently, a
group of expert clinicians suggested that for patients with combined
diabetes and tuberculosis, a total of 9 months of therapy is recommended(35).
Although caution should be taken in the interpretation of the results due to
the limitations we have discussed above, our results may open a new
therapeutic perspective. We think vitamin D status of the patients should be
monitored due to the high prevalence of (severe) vitamin D deficiency in the
patients as we previously reported(13). Outdoor activity to ensure enough
sun exposure, higher consumption of fish (especially sea fish), eggs, etc and
vitamin D fortified items such as milk, butter is recommended. Vitamin D
supplements may have a favourable adjunctive effect on clinical treatment
and more confirmative studies are needed in the future concerning the
recommendation of vitamin D supplementation as a routine practice. Also, it
may benefit tuberculosis patients in general.
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In conclusion, for the first time, we identified a favourable adjunctive effect
of vitamin D on the clinical manifestations in tuberculosis patients with
diabetes during the intensive-phase treatment. Our results may open a new
perspective of the treatment of the combined diseases. However, partly due
to methodological limitations of our study, we could not claim effects of
vitamin D with certainty at this stage. The results of our study need to be
confirmed in the future.
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The research described in this thesis aimed to investigate the prevalence of
diabetes in active tuberculosis patients, to compare the risk of having
diabetes between persons with and without tuberculosis, and to elucidate
the role of vitamin D deficiency in the combined occurrence of these
diseases from an epidemiological perspective.
Main findings
The prevalence of diabetes in patients with active tuberculosis in rural areas
of China was 6.3% which was nearly 35% higher than in non-tuberculosis
controls. Adjusted for confounders, tuberculosis patients had a slightly more
than three times higher risk of having diabetes (OR 3.17, 95% CI 1.14-8.84).
Risk factors for diabetes and pre-diabetes among tuberculosis patients were
similar as observed in the general population in China, i.e., older age,
overweight and obesity, higher income level (chapter 2).
Diabetes and pre-diabetes were also associated with a nearly two-fold
higher probability of patient delay of tuberculosis in the community (chapter
3). In addition, we found that compared with tuberculosis only patients,
those with combined diabetes had a higher prevalence of positive sputum
(78.1% vs 64.7%), of pulmonary cavity in CT scan (55.5% vs 38.5%) and of a
more severe class of clinical signs and symptoms including cough,
hemoptysis, dyspnea, chest pain, night sweating, etc. as indicated by severe
General discussion
Chapter 8
- 166 -
TBscore class (88.3% vs 78.2%) at admission (chapter 7). Notably, among
diabetics an increased risk of delayed sputum conversion was observed,
indicating higher risk of transmission of tuberculosis in the community.
A high prevalence of vitamin D deficiency [serum 25(OH)D<20ng/mL] of
nearly 80% was observed in tuberculosis patients in our study. Risk factors
identified for deficiency were severe tuberculosis symptoms at presentation,
low outdoor activity and low fish consumption (chapter 4). Compared with
patients in the highest quartile (≥26.62ng/mL), those in the lowest quartile
of serum 25(OH)D (≤8.57ng/mL) had a 4.73 and 2.50 fold increased risk of
having tuberculosis, and tuberculosis combined with diabetes, respectively,
after adjustment for potential confounders (chapter 5).
Vitamin D status was inversely associated with TNF-α, while positively
associated with leptin, cytokines that are closely related to anti- Mtb
immune activity in the body, indicating a possible mechanism of vitamin D in
the pathogenesis of tuberculosis (chapter 6). The supplementation of
vitamin D showed an adjunctive effect in the clinical improvement at the 8th
week during the intensive-phase treatment in patients with the combined
diseases, after adjustment for confounders, i.e., age and gender (chapter 7).
Underweight was related to hyperglycemia in tuberculosis patients, having a
complex correlation with the risk of having the combined disease in this
study. Furthermore, a synergistic interaction on the risk of having combined
tuberculosis and diabetes was observed between underweight and low
serum 25(OH)D (chapter 2 and chapter 5).
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Internal validity
Study design
We carried out observational studies (chapter 2-6) and an intervention study
(chapter 7) in this thesis. The interpretation of the results of the
cross-sectional studies should be done with caution. Concerning variables
that are not subject to change such as age, gender, race, causal relationships
can more readily be inferred. However, as to other variables such as vitamin
D status, we cannot ascertain the sequence of occurrence and reverse
causality may also explain the results. In addition, despite adjustment for
possible confounders in data analysis, residual confounding cannot be
completely ruled out. In addition, as discussed in chapter 7, a design of an
open intervention with an external control group from the same hospital
was adopted in the vitamin D supplementation trial. These limitations need
to be considered when making causal inference based on the results.
Study Population
Recruitment
The study population in chapters 2, 3 and 5 was recruited from a rural area
in Linyi, located in Shandong province in North China. The patients were
consecutively included from seven tuberculosis clinics, that each had a
defined catchment area comprising approximately 0.9 million inhabitants.
We recruited subjects from county-level tuberculosis clinics where patients
from rural communities are usually diagnosed and treated following the
DOTS principle. Therefore, representativeness for the general population
can be assumed. Cluster random sampling was used to recruit
non-tuberculosis controls from the same communities as the tuberculosis
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cases, stratified for economic status, since people living in economically
developed regions have a higher prevalence of diabetes in China(1). This way,
comparability of tuberculosis patients and non-tuberculosis controls could
be assured.
The subjects in the patient delay study were a subpopulation from the
previous study. We randomly selected 2280 tuberculosis patients from this
study to analyse diagnosis delay and its risk factors (chapter 3). Also, the
subjects in chapter 5 were a subset from the previous large-scale diabetes
screening study. Subjects were randomly selected from the four groups
including tuberculosis-only patients, tuberculosis patients with diabetes,
diabetes-only patients and normal controls. The left-over serum after
determining biochemical parameters (i.e. glucose level, lipid profile) was
used to detect 25(OH)D. Due to an insufficient amount of serum left, finally,
130 tuberculosis, 90 tuberculosis-diabetes, 91 diabetes and 134 normal
controls were included in the analysis for serum vitamin D concentrations
(chapter 5). The demographic and clinical characteristics at baseline of the
included subjects were compared with those excluded, and no significant
difference existed between them. Therefore we are confident that the
exclusion did not give rise to selection bias.
In chapters 4, 6, and 7, we recruited tuberculosis patients from a city level
specialised tuberculosis hospital located in Qingdao, Shandong province of
China. This hospital has a catchment area of about 9 million people, and the
average number of hospitalized patients with tuberculosis was about two
thousand cases per year. In chapter 4, 461 active tuberculosis patients aged
16~86 years were randomly selected including 192 tuberculosis with
diabetes and 269 tuberculosis without diabetes. In chapter 6, a total of
299active tuberculosis patients were randomly recruited also from this
tuberculosis hospital, together with 91 normal controls recruited from a
physical check-up population in a general hospital in the same city. For
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chapter 4 and 6, there is an overlap of 70% between the tuberculosis
patients, which were recruited from the same tuberculosis hospital. In
chapter 7, 358 newly diagnosed pulmonary tuberculosis patients aged 18 y,
staying in the hospital of 8 or more weeks were included from the 461
patients in chapter 4, with 174 cases in VD3 supplementation group and 184
in control group.
Statistical efficiency
Sample size calculation was carried out in the design stage of our study. For
the diabetes prevalence investigation (chapter 2), a sample size of 7000
tuberculosis patients was calculated assuming a diabetes prevalence of 6.7%
among tuberculosis subjects as reported in the literature (2). We considered
a non-response rate of 20%, and assumed an estimated power of 80%. We
calculated the required number of tuberculosis patients and controls using
the formula,
2
2
d
PQz
N

P is the prevalence of diabetes in tuberculosis patients (6.7%), Q=1-P, d is tolerance
error, d=0.1×P and z was taken as 1.96 conform a two-sided significance level α=0.05.
We later adjusted it to 6200 subjects based on the favourable compliance in
a pilot study in two communities in this area. Finally, 6382 active
tuberculosis patients and 6674 non-tuberculosis controls were included in
the analysis, which meets the sample size requirement. Similarly, we
estimated the number of tuberculosis patients needed in the vitamin D
deficiency prevalence study by using a power calculation based on a study
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from Korea (3), a country at similar latitude, reporting 51.5% vitamin D
deficiency in tuberculosis patients. An estimated drop-out rate of 10% was
considered. The number of tuberculosis patients needed to be investigated
was 420 with an estimated power of 80% and the tolerable error of 10%
(chapter 4). Finally, 461 active tuberculosis patients aged 16-86 years were
recruited.
In conclusion, we consider the included study populations as representative
for their source populations, and we are confident that the sample sizes
were sufficient for the purpose of the studies.
Field work model for the multi-centre investigation
As we described in chapter 2, a large-scale epidemiologic study was carried
out to screen diabetes in active tuberculosis patients. This is a multi-centre
investigation in various county-level tuberculosis clinics in Linyi. Therefore, it
was of great importance to set up an efficient field work scheme. The model
of field work is shown as Figure 8-1.
Firstly, the core members of the team examined the possible candidate
clinics with respect to the efficiency of the anti-tuberculosis system, the
number of potentially reachable active tuberculosis patients, the
qualification of the clinic lab, etc. If the conditions were fulfilled, an
agreement was signed. Subsequently, investigation started including
training of co-investigators, screening diabetes in tuberculosis patients, and
administering of the dietary and lifestyle questionnaire, as well as health
promotion in the patients and the lay public. During the implementation of
the field work, the core team members from Qingdao University were on
site nearly 10 days a month, working together with the co-investigators.
Workshops and seminars were held frequently during the project. Any
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problem encountered was discussed promptly, and experience gained was
spread to other centres in time.
Figure 8-1. The field work model for the multi-centre investigation.
A standardised process was practiced in this multi-centre investigation. The
organization of the screening was based on the “county—township—village”
tuberculosis control system. The county level tuberculosis clinics played a core role in
the screening. A collaborative working team was established during this project.
Training
The training was conducted in a stepwise manner in this project (top
level-second level-third level, see in Table 8-1). The trainees included not
only co-investigators (the clinicians from seven county tuberculosis clinics
who would directly take part in the project), but also physicians in local
general hospitals specialized in the treatment of diabetes, and village nurses
working in the first-line health service unit. We expanded the scope of the
trainees mainly due to the poor awareness level of the double burden in this
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rural area which was recognized in the pilot study. In total, nearly 70
tuberculosis workers and 260 clinicians of internal medicine and other
related domains took part in the top-level training; 120 tuberculosis workers
in the counties and 200 in the township health centre attended the
second-level training and about 2000 village nurses were trained
(third-level). The training strategy was designed according to the
“county-township-village” three-level anti-tuberculosis network, which can
cover almost all the local tuberculosis workers. It turned out to be an
effective training method in the rural area, although the training of the
village nurses still faces challenge.
Table 8-1. Training scheme of the project
Level Participants Training model Faculty
Top-level Tuberculosis
workers in charge of
the field work of
each community;
internist, etc.
Concentrated
training
Three from the project
team, one from the
bureau of disease
control, two
pulmonary
tuberculosis experts,
two diabetes experts
Second-level Tuberculosis
workers from the
county tuberculosis
dispensary; county
chest hospital;
township health
center
Concentrated
training
One from the project
team, two trainees
from the top-level
training course
Third-level Village nurses Concentrated
training, panel
discussion, etc.
Three trainees from
the second-level
training course
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The diagnosis of Tuberculosis
The diagnosis of tuberculosis was made within the existing tuberculosis
prevention and control system in China, following the criteria provided by
WHO. Clinical manifestations, sputum smear microscopy and chest
radiography are the central components of the diagnosis (4). Suspected
tuberculosis cases were investigated by sputum smear examination. If
positive, the patient was diagnosed with smear-positive tuberculosis; if
negative, but the chest radiograph was compatible with active tuberculosis,
the patient was diagnosed with smear negative tuberculosis after discussion
between clinical and radiographic specialists. In the local clinical setting of
our study, M. tuberculosis infection was generally not confirmed by sputum
culture. Anyhow, the national tuberculosis epidemiological survey in China
reported that culture confirmation is present in only 26.4% of the active
tuberculosis patients.
Patient delay
A health seeking interval between the onset of tuberculosis symptoms and
the first visit to a county-level tuberculosis dispensary > 28 days was defined
as patient delay in our study (chapter 3). The onset of symptoms relied on
self-report, which may have led to error. However, the diagnostic
procedures in this area were uniform and standard methods were used. The
socio-demographic variables, including income, education level, and type of
health facility consulted by tuberculosis patients, were similar across
participants with and without diabetes, which will have balanced the
possible information error to a large extent and will not have biased the
difference between diabetics and non-diabetics.
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The diagnosis of diabetes
Diagnosis of diabetes and pre-diabetes was according to WHO criteria for
the classification of glucose tolerance based on fasting plasma glucose (FPG)
(5). After an overnight fast, venous blood of each participant was collected.
Glucose oxidase method was used to estimate FPG level. Those with
FPG≥6.1 mmol/L were referred to diabetes clinics for diagnostic
confirmation with a second FPG test. Those with FPG level in the range of
6.1 mmol/L to 6.9 mmol/L were diagnosed as pre-diabetes; those with FPG
level ≥7.0 mmol/L were diagnosed as diabetes. We collected blood from
newly-diagnosed tuberculosis patients and non-tuberculosis controls from
the same community after fasting overnight to determine plasma glucose
concentration. In a considerable number of studies into the double burden
of tuberculosis and diabetes reported in the literature (6; 7; 8), the prevalence
of diabetes was calculated using secondary data from the diabetes
surveillance system or relying on self-report, in which inherent biases cannot
be avoided. Also, in these studies, diabetes prevalence was not investigated
in non-tuberculosis controls from the same source population, which may
have led to impaired comparability.
We chose a suitable moment to detect diabetes in the patients. Tuberculosis,
as a chronic infectious disease, was recognized to induce transient
hyperglycaemia (9). Therefore, over-diagnosis of diabetes might result if
testing would take place prior to initiation of tuberculosis treatment. Since
most of our study subjects were screened for diabetes about 1–2weeks after
the initiation of tuberculosis therapy, this will not have biased our results to
a large extent. Inter-lab comparison of glucose measurement was carried
out frequently to ensure the reliability of the data.
However, diabetes screening as carried out in our study also has its
limitations. Oral glucose tolerance test (OGTT) was not performed in the
participants. The main reason was that most of the participants lived in rural
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villages, usually far away from the tuberculosis clinics located in the county.
This made OGTTs impractical. The prevalence of diabetes in the study
population may consequently have been underestimated. Among Asian
patients with diabetes, isolated hyperglycaemia two hours after glucose
loading is common (10). A national study in China found 46.6% of the cases of
undiagnosed diabetes met the criteria for elevated 2-hour plasma glucose
levels in an oral glucose-tolerance test but not the criteria for elevated
fasting glucose levels (11). We screened diabetes in tuberculosis patients and
controls by using identical procedure, which would lead to the same level of
underestimation and therefore leave the relative odds more or less
unaffected. However, the relatively low sensitivity of the procedures may
have resulted in an unknown bias in the odds ratio estimation.
The measurement of serum 25(OH)D concentrations
Serum 25(OH)D concentrations in this study were measured in Beifang
Institute of Biotechnology (Beijing, China) by using the method of 125I
radioimmunoassay (RIA). The kit from DiaSorin Inc (Stillwater, Minnesota,
USA) was used. For quality control, two reference controls provided with the
kit were utilized (one at low-normal level and one at high-normal level) to
guarantee assay performance. The sensitivity of the assay was 1.5 ng/mL.
The inter-assay variability was 10.5% and the intraassay variability was 8.2%.
To characterise the participants with respect to vitamin D deficiency, the
most widely accepted criteria (12) were used in our study. Serum 25(OH)D of
10ng/mL and 20ng/mL was used as the cut-off value of severe vitamin D
deficiency and vitamin D deficiency respectively. In chapter 5, we used
quartiles of the distribution of serum 25(OH)D to divide the 445 subjects
into four groups, and analysed the risk of tuberculosis-only, tuberculosis
combined with diabetes and diabetes only in the lowest quartile (≤8.57
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ng/mL) compared with the highest quartile (≥26.62 ng/mL). The main reason
for using quartiles here was to ensure sufficient number for each subgroup
to estimate the odds ratios.
Control of Data quality
We took various actions to ensure the reliability of the data in this
epidemiological study. As previously stated, a standardized procedure of
diabetes screening was used in the multi-centre investigation. All
co-investigators were trained before the screening, and core team members
worked in different sites to supervise the implementation of the project.
The diagnosis of tuberculosis and diabetes was carried out by using the
widely accepted criteria, and regular calibration of medical devices for the
determination of blood glucose was carried out. Serum vitamin D levels
were determined by standard method. Information on potential
confounders such as smoking, drinking, physical activity of the subjects was
collected by using a face-to-face questionnaire, and the reliability and
validity of the questionnaire was tested before being used in the field.
Height and weight of the subjects were measured by standard procedure to
calculate BMI.
For data analysis, double data entry was carried out, and then a
computer-based error detection system was used to check the consistency
of the data. In case of inconsistency, the original questionnaire was checked
and the error corrected via a re-entry.
Confounding
Major potential confounders such as BMI, age and income level (13; 14) were
considered in the present study. To eliminate the effects of confounders, we
took account of them in different stages of our study, including design, data
collection and data analysis.
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-Design At the inspection of the probable site, we found that the
economic status differs in different towns in the community. Therefore, we
considered economic status when we selected the non-tuberculosis controls.
We divided economic status into high, middle and low according to report of
local residents’ income level and used stratified cluster random sampling to
recruit the non-tuberculosis controls to ensure similar economic status.
-Data collection Information on the following potential confounders has
been collected by structured face to face interviews: economic status,
environmental situation, food resource, dietary pattern, marital status and
health-related behaviors including cigarette smoking, alcohol drinking,
physical activity of the subject. Height and weight of the subject were
measured to calculate BMI. Since season of the year is also an important
factor that influences vitamin D status in the body, we collected the date of
blood sampling in order to be able to adjust for season in later data analysis.
Nevertheless, we could not collect the individual’s waist-to-hip ratio (15),
which may lead to certain bias in analyzing the risk factors of diabetes in
tuberculosis.
-Data analysis Multivariable analyses were performed to adjust for
possible confounders in data analysis. The variables for inclusion in the
multivariate model were chosen based on plausibility and a p value of <0.1
in univariate analysis. All variables were checked for collinearity in the
multivariable models. In the vitamin D supplementation trial, possible
confounders including age and gender were adjusted.
In conclusion, we are confident that we have adequately adjusted for
potential confounders in our study. We took various methods to guarantee
the quality of the data collected including the confounders. Therefore,
although residual confounding can never be completely ruled out, we think
we minimized it as far as possible in our study.
Chapter 8
- 178 -
External validity
The double burden of diabetes and tuberculosis
The screening of diabetes revealed a nearly three-fold higher risk of having
diabetes among tuberculosis patients compared with controls. Reports of
diabetes prevalence in tuberculosis patients in the literature (16), vary from
1.9% to 45% with high levels reported in South Asia and the Pacific. However,
large diversity exists in screening methods, care centres, and study designs
across studies. To our knowledge, few studies used primary data with
comparison to non-tuberculosis controls in the rural setting, as we did.
Therefore, our data fill an important gap in describing the double burden of
tuberculosis and diabetes. Our finding is in line with another study in
eastern rural area in China that reported a prevalence of 7.7% of diabetes in
1252 tuberculosis patients (17).While other studies in urban areas in China
found higher prevalence, from 11.9%~30.8% (18; 19; 20; 21; 22).
The difference in prevalence of diabetes among tuberculosis patients
between rural and urban areas is in line with the difference in the general
population (23) . This suggests that both populations may share conventional
risk factors such as older age, family history of diabetes as we found in our
study.
A study in a rural area in India reported 27.5% diabetes prevalence in
tuberculosis patients (24). However, the data in this study was drawn from
medical records, coming from a small sample size of 192 tuberculosis
patients. Another study conducted in southern India reported that the
prevalence of diabetes and pre-diabetes in tuberculosis patients was 25.3%
and 24.5%, respectively (25). In the similar setting of the double burden of
tuberculosis and diabetes, like China, India is also witnessing a rapid
increase in the incidence of diabetes in recent years, and a high burden of
tuberculosis that ranks first in the world. From the border area between
General discussion
- 179 -
Texas and Mexico, a study reported that the prevalence of diabetes in
tuberculosis patients was 39% and 36%, respectively (26).
In conclusion, these results together with our findings indicate a significant
double burden of tuberculosis and diabetes which may have important
implications for public health in low-and middle-income countries.
We found the peak age of onset of tuberculosis combined with diabetes to
be ≥50 years, indicating that older age is a risk factor of the combined
disease. This coincides with the incidence of diabetes and indicates that
diabetes may be the primary event in the combined occurrence of both
diseases as widely claimed in the literature (27).
Nearly 80% tuberculosispatients have a health-seeking delay in our study,
which was higher than some previous studies (28). The higher delay in the
present study may be due to different definitions of patient delay and the
different study populations as we stated in chapter 3. We suppose that the
low education level may have contributed partially to the high patient delay,
which was also reported by others (29) (30). Notably, we found that
hyperglycaemia, including diabetes and pre-diabetes, was associated with a
nearly two-fold higher probability of patient delay. This suggests that
diabetes may also facilitate the transmission of tuberculosis. The few
available studies concerning the effect of coexisting diabetes on patient
delay observed similar results. Another study in China reported that
tuberculosis patients with diabetes had a significantly longer median
diagnostic delay than those without diabetes (25 days vs. 6 days), and
diabetes was associated with more serious clinical presentations among
tuberculosis patients (31). Studies in intermediate-to-low tuberculosis
incidence settings reported similar findings (32) (33). A recently reported
retrospective observational study in 133 patients in a low incidence setting
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of Melbourne found that diabetes mellitus was related to prolonged patient
delay (OR 3.02, 95% CI 1.04, 8.78), while the median patient delay [ 28 (0-61)
days] was shorter than the present study (32). However, a study in India
investigated the factors associated with health systems delay and diabetes
was not found to be a significant factor [OR, 95% CI: 1.26 (0.89–1.78)] (34).
At the same time, diagnosis delay is closely related to a more severe clinical
presentation and poorer prognosis in tuberculosis patients. Therefore, the
association between diabetes and patient delay is assumed to aggravate
both the individual and public health burden.
High prevalence of vitamin D deficiency in tuberculosis patients
We reported a high prevalence of vitamin D deficiency (83.1%) and severe
vitamin D deficiency (47.1%) in active tuberculosis patients, and the median
of vitamin D was 8.50 ng/mL. Another investigation in Korea, located at a
similar latitude as our study area, reported that tuberculosis patients had a
low median 25(OH)D concentration of 9.86 ng/mL, which was close to our
findings (3). A study in an equatorial population found that mean serum
25(OH)D in tuberculosis patients was 34.64 ng/mL and the deficiency rate was
41.2% (35). From an ecological epidemiologic viewpoint, latitude is an
important factor of vitamin D status. This is an illustration of the fact that
sun exposure is the main source of natural vitamin D in the body.
Tuberculosis symptoms, outdoor activity and fish consumption were found
to be associated with the prevalence of severe vitamin D deficiency. The
severity of initial tuberculosis signs and symptoms showed a negative
association with serum 25(OH)D and patients with a severe tuberculosis
score class had a nearly 5-fold higher odds of severe vitamin D deficiency
compared with those with a mild class. This provides further evidence for
the perspective that vitamin D deficiency is associated with higher risk of
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tuberculosis. Decreased appetite or diet limitation in certain populations
results in lower food intake including sea fish that may contain some vitamin D.
Being a typical chronic wasting disease, tuberculosis will lead to restricted
outdoor activity, which contributes to the situation. Also, severe weight loss,
decreased appetite and food intake may result in nutrients depletion in
general and vitamin D in particular. Tuberculosis patients obviously have
reduced adipose tissue, which may result in diminished vitamin D reserves (36).
Furthermore, vitamin D requirement increases in tuberculosis, since vitamin
D plays a key role in anti-tuberculosis immunity. It binds to toll-like
receptors on macrophages leading to increased production of 1,25(OH)2D
from 25(OH)D (37), which is a key step in the induction of anti-Mtb peptide in
macrophages. The increased need of vitamin D in tuberculosis patients may
also contribute to lowered serum 25(OH)D concentrations.
However, at this stage we cannot tell whether it is vitamin D deficiency that
induces tuberculosis or vice versa. Further research is needed to find out the
direction of causality in the relationship between vitamin D deficiency and
the incidence of active tuberculosis.
BMI in relation to combined diabetes and tuberculosis
The role of BMI in the setting of co-morbid diabetes and tuberculosis is
complex. Underweight (BMI<18.5 kg/m2) showed an increased risk of
pre-diabetes and a borderline significant increased risk of diabetes among
tuberculosis patients in our study. This finding was in line with a study
carried out in Tanzania (13) that reported an association between severe
underweight (BMI<16 kg/m2) and diabetes among male tuberculosis
patients (OR 2.52, 95% CI 1.34~4.74, p = 0.004). However, the number of
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subjects with both characteristics was relatively small in that study (n=23).
Notably, accumulating evidence has indicated the potential adverse
influence of underweight on cardiometabolic milieu. An U-shaped
relationship was observed between BMI and all-cause mortality (38), and low
BMI was associated with adverse outcomes of coronary heart disease in an
Asian population (39). Moreover, a large-scale cohort study in Japan showed
that underweight may be associated with the risk of type 2 diabetes among
older adults aged 60–79 years (40). Alternatively, reverse causality may also
exist. Poorly controlled glucose in diabetes patients may result in weight loss.
On the other hand overweight and obesity areprotective against tuberculosis (14).
Weight loss due to poorly controlled diabetes and metabolic
de-compensation may take away this protection. Therefore, the interaction
between BMI, diabetes and tuberculosis may work out differently in
different individuals (41).
Moreover, we found a synergistic effect of underweight and low serum
25(OH)D on the risk of having concurrent diabetes and tuberculosis.
Therefore, subjects with both characteristics may have a higher risk. The
correlation between BMI and vitamin D status in tuberculosis patients has
been inconclusive till now. We found that BMI had a borderline positive
association with increased odds of severe vitamin D deficiency (chapter 4),
which is in accordance with existing reports that an inverse correlation
exists between circulating 25(OH)D concentration and BMI in the healthy
population, in overweight/obese subjects and in diabetic patients (42; 43; 44; 45;
46; 47; 48). It was speculated that lower vitamin D status in obesity is due to a
greater pool of distribution (49). However, there is still insufficient evidence
in tuberculosis patients, and the available data diverge. Like our study, Friis
et al. reported that tuberculosis patients with lower BMI had higher serum
25(OH)D (50). However, an investigation in 105 tuberculosis patients found
that vitamin D deficiency is more obvious in those with low BMI (51), and BMI
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is positively associated with serum 25(OH)D (35). The main reason for the
discrepancy may be differences in sample size and inclusion criteria among
those studies. Therefore, the correlation between BMI and vitamin D status
in tuberculosis needs further study in larger populations.
Vitamin D deficiency and the double burden of tuberculosis and diabetes
We found a negative association between serum 25(OH)D and prevalent
tuberculosis with and without diabetes, which is in accordance with other
reports (52). In addition, the supplementation of vitamin D was observed to
have an adjunctive effect on the improvement of clinical manifestations at
8th week in tuberculosis patients with concurrent diabetes, while no similar
result was found in those without diabetes.
Nonetheless, contrary to expected, 25(OH)D concentrations, whether
analysed as a continuous variable or categorized variable (grouped as
quartile levels) were not significantly associated with the prevalence of
diabetes (chapter 5). In recent years, abundant epidemiological studies
indicate the correlation between vitamin D deficiency and higher risk of type
2 diabetes, including some prospective studies (53; 54). However, the
possibility of reverse causality in observational studies was brought up (55),
and the stated correlation has not been verified in randomized controlled
trial till now (56).Similar to our study, a 5-year follow-up study found that low
25(OH)D status was not significantly associated with incident diabetes (57). In
addition, due to the cross-sectional design in chapter 5, we cannot infer
causality. Therefore, more longitudinal investigations are needed in the
future. Furthermore, the odds ratio for prevalent tuberculosis with diabetes
comparing the lowest with the highest quartile [OR (95% CI) = 2.50
(1.04-6.02)] was clearly lower than the same odds ratio for prevalent
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tuberculosis [OR (95% CI) = 4.73 (2.04-10.9)] (chapter 5). Tuberculosis
patients had a significantly lower level of serum 25(OH)D than diabetes
patients (12.2 vs 17.86 ng/mL). This may partially explain the result. In
addition, in a later study (data not shown), we noticed that the prevalence
of severe vitamin D deficiency (serum 25(OH)D <10ng/mL) was higher in
patients with combined tuberculosis and diabetes compared with those
without (28.4% vs 16.0%). Moreover, a higher prevalence of severe vitamin
D deficiency in diabetics than in normal controls (10.0 vs 3.3%) was
observed. Integrating these results, we deduce that there may be a
threshold effect of vitamin D deficiency in the body. Although we cannot
determine the optimal cut-off value at this stage, our data provided an
important clue and further study in a larger population is needed, especially
concerning combined tuberculosis and diabetes.
Interestingly, patients with concurrent tuberculosis and diabetes had
significantly lower serum 25(OH)D which was approximately 60% of that in
diabetes (10.58 vs 17.86 ng/mL) (chapter 4). Since diabetes usually comes
first, and vitamin D deficiency is prevalent in the general population (58; 59; 60),
this result provides evidence for our working hypothesis that vitamin D
deficiency may increase the risk of tuberculosis mediated by diabetes.
Therefore, low serum 25(OH)D levels in diabetes patients, particularly serum
25(OH)D of lower than 10ng/mL may indicate higher risk of tuberculosis in
this population.
We found different results for serum 25(OH)D concentrations (medians) in
chapter 4 versus chapter 5 in patients with tuberculosis and diabetes
combined (10.58 vs 12.90 ng/mL), as well as in patients with tuberculosis
only (7.26 vs 12.20 ng/mL). Although different detection batches may have
some impact, the same detection process and kits from the same
manufacturer were used in this study. The seasons for blood samples
collection were distributed similarly in the two investigations, which may
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have minimized the influence of season. As we have discussed previously,
the study population in chapter 4 was recruited from a city level
tuberculosis hospital, while in chapter 5 from a rural area. We propose two
explanations for the difference. Firstly, most of the patients in rural areas
were farmers, who had more opportunity of sun exposure, the main source
of natural vitamin D in human body. Secondly, the inpatients recruited from
city level tuberculosis hospitals usually had more severe tuberculosis and
consequently less physical activity than the domestically treated patients.
The supplementation of vitamin D3 in patients with combined diseases
showed significant effects on the improvement of TB manifestation at 4th,
6th, 8th week, adjusted for confounders as age, gender. The severity of
clinical manifestation in tuberculosis patients was evaluated by TBscore, a
measure based on tuberculosis related signs and symptoms, including cough,
hemoptysis, dyspnea, chest pain, night sweating, anemia, tachycardia, lung
auscultation finding, fever, BMI<18 and BMI<16. Change in TBscore has
been shown to detect clinical change well; a high TBscore correlates well
with mortality and low TBscores correlate with favourable outcomes, cure,
and completed treatment (61). To our knowledge, this is the first vitamin D
intervention trial in patients with combined tuberculosis and diabetes with
sufficient sample size. The underlying mechanism may be due to the
synergistic effects on the regulation of immune activity (62) and glycaemic
metabolism (63) of vitamin D in the body. Also, more severe baseline TB signs
and symptoms in patients with diabetes may lead to a more obvious effect
of the supplementation. Although the exact pathway of vitamin D related
effects needs more research, our results provide an important clue of the
role of vitamin D in the adjunctive treatment in patients with combined
tuberculosis and diabetes. As reported, diabetes resulted in higher risk of
treatment failure (64) and death (65; 66), which urgently calls for an efficient
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treatment strategy. Therefore, our results may open a new therapeutic
perspective. However, due to the limitations of the intervention trial as we
discussed in chapter 7, we should be cautious to the interpretation of the
effects of vitamin D.
No similar effects of vitamin D were found in patients without diabetes,
which is in agreement with a recent meta-analysis reporting that the
non-skeletal health effects of vitamin D have not been confirmed with
sound evidence in randomized trials till now (56). However, Coussens et al.
reported that adjunctive high-dose vitamin D in tuberculosis treatment
could accelerate sputum smear conversion, and reduce the inflammatory
responses associated with higher risk of mortality (67). The discrepancy may
be due to various factors such as different doses used, different treatment
settings. A recent study found that the improvement of sputum clearance by
high dose vitamin D was modified by SNPs in genes encoding the vitamin D
receptor (VDR) and 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) (68). In
addition, the power of the statistical analysis in patients with TB only may
have been lower than anticipated, which means the sample size in the trial
may have been insufficient to pick up the difference between the
supplementation group and the control. Therefore, whether vitamin D
supplementation has benefits in tuberculosis needs further researches in an
enlarged sample size.
Overall conclusions
The risk of having diabetes in active tuberculosis patients was nearly three
times higher compared to non-tuberculosis controls. In the concurrent cases,
diabetes frequently precedes tuberculosis, and age ≥ 50 years, male gender
in diabetics are associated with increased risk. Severe hypovitaminosis D
was prevalent in tuberculosis patients, the main determinants being severe
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TBscore class in presentation, low outdoor activity and inadequate fish
consumption. Patients with combined diabetes and tuberculosis had a
higher percentage of severe vitamin D deficiency, and in this subpopulation
vitamin D supplementation in the intensive-phase treatment (8 weeks after
anti-tuberculosis therapy) showed an adjunctive effect in the improvement
of tuberculosis clinical manifestations at the 8th week. Regulation of immune
activity related cytokines such as leptin and TNF-α may be one of the
possible mechanisms of vitamin D in the body, together with the synergistic
effects of vitamin D on glycaemic metabolism. Our results indicate an
aggravating role of vitamin D deficiency in the double burden of tuberculosis
and diabetes, and the possible adjunctive effects of vitamin D
supplementation.
Implications and recommendations
The double burden of tuberculosis and diabetes in low- and middle-income
countries such as India, China, Indonesia in recent years have caused
intensive concern of international agencies such as the WHO, the Union
(International Union against Tuberculosis and Lung disease) and
International Diabetes Federation, and urge them to provide strategies for
facing this new challenge. Diabetes has been recognised as a moderate to
strong risk factor for active tuberculosis(69) (70) (71) (72). This has important
public health implications. Besides tripling the risk of active tuberculosis (6),
diabetes was suggested to have an all-around effect on the natural course of
the disease, including a higher risk of the individual becoming infected
(latent infection) (73), a higher lifetime risk of tuberculosis activation, and an
unfavourable clinical course including presentation of more symptoms, more
relapses, treatment failures and deaths (65) (74). In addition, vitamin D
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deficiency may strengthen this association (75). Our study provided further
valuable evidence in a rural setting in China suffering from a typical double
burden. In a community based large-scale investigation, we found a higher
risk of having diabetes and vitamin D deficiency in active tuberculosis
patients, and the combination of tuberculosis with diabetes resulted in
higher proportion of patient delay. Also, we carried out a study in a city level
tuberculosis hospital. In agreement with other reports, more severe
tuberculosis manifestation at presentation was observed in patients with the
combined diseases. The supplementation of vitamin D showed a possible
adjunctive effect on the improvement of clinical signs and symptoms in this
comorbid subgroup. As shown in Figure 8-2, we infer that diabetes may
increase the risk of tuberculosis, resulting in higher possibility of tuberculosis
transmission in the community. In addition, we speculate vitamin D
deficiency may play an aggravating role in this process.
Figure 8-2. The impact of diabetes on tuberculosis epidemic and the role
of vitamin D deficiency
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Therefore, it is urgent to provide strategies to cope with the emerging
challenge of the double burden of tuberculosis and diabetes. The following
actions may have significant public health benefits.
Bidirectional screening for tuberculosis and diabetes
“Bidirectional screening” in the thesis means screening for tuberculosis in
diabetes and the reverse. It was demonstrated that tuberculosis prevalence
in diabetes is high, ranging from 1.7% to 36% (76), and rising with tuberculosis
prevalence in general. As reported before in the present thesis, diabetes will
make an increasingly important contribution to the tuberculosis epidemic.
Experts suggest that tuberculosis control could be further improved by
screening patients with known risk factors, including diabetes (77). Screening
for active tuberculosis in people with diabetes could hasten case detection,
which could lead to earlier therapy and prevention of transmission.
Furthermore, the administration of preventive tuberculosis therapy in
tuberculosis-infected people with diabetes (identified by tuberculin test)
could inhibit progression to tuberculosis. Therefore, to detect active
tuberculosis as well as latent infection in diabetes in an early stage has
significant public health relevance. Screening for tuberculosis in persons
with diabetes still depends on chest X-ray and/or sputum smear now, and it
is infeasible to offer this to all diabetes patients in the population. A
sensitive, reliable and practical strategy is urgently needed. In agreement
with other reported literature, we found that older age of  50 years, male
gender and family history of diabetes are related with increased risk of
tuberculosis. Further, vitamin D status in diabetes patients, together with
underweight, as indicated in our study, may provide a new perspective.
Therefore, we recommend that diabetes patients with the following
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characteristics should be offered tuberculosis screening: poorly controlled
blood glucose (HbA1c >7.0%); low body weight (BMI <18.5), especially
severe emaciation (BMI <16); weight loss of >10% in the recent 2 months;
persistent cough of more than one month; low serum 25(OH)D, especially if
<10ng/mL. This should include chest X-ray and a tuberculin test (78; 79). Male
diabetes patients aged over 50 deserve extra attention.
Conversely, screening for diabetes in patients with tuberculosis could
improve diabetes detection. Also, the rapidly increasing diabetes prevalence
with a high proportion of undetected cases, being about 50% in developing
countries, indicates the importance of screening of possible diabetes in
newly admitted tuberculosis patients. Although this will not help detection
of diabetes in the general population a lot, it may significantly benefit the
clinical treatment of tuberculosis. As we have discussed, patients with
concurrent tuberculosis and diabetes are prone to present atypical
radiographic findings, severe signs and symptoms and higher treatment
failure, relapse and death. When the project started, we found diabetes was
not screened in local county level tuberculosis clinics in the setting of a rural
area in China. Along with the implementation of the project, it has become a
routine check item, and patients with diabetes have been identified at the
beginning of the treatment. This has shown obvious improvement in the
clinical course. We recommend that screening for diabetes should be
routine clinical practice in TB patients.
Increase awareness of the double burden
Various strategies are needed to increase awareness of the double burden,
especially in low- and middle- income countries of a large population.
(1) Increase awareness of health providers: A stepwise training model was
carried out in the present study and proven to be effective. Health providers,
especially those working in primary health care centres should be paid
General discussion
- 191 -
special attention. In China, village nurses play a core role in the practice of
tuberculosis control in rural areas. They are usually the first choice for an
individual with suspicious symptoms seeking for health service, and they are
also responsible for the supervision of compliance of anti-tuberculosis
therapy. However, due to low income level and a remote workplace, as we
experienced in our study, young people with high level education are usually
unwilling to take the job. This resulted in certain problems in village nurses
such as older age, low education level, which may make them incapable to
deal with the new challenge. (2) Increase awareness of the patients: During
the implementation of the project, we introduced various strategies to
increase the awareness in tuberculosis patients including a single sheet of
knowledge paper, pictorial case report, handbook, etc to illustrate the key
principle of the treatment, recommended balanced diet and healthy lifestyle
to the patients. This proved to be useful. Also, in diabetes patients, the
health education about the relationship between the diseases, the early
signs and symptoms indicating tuberculosis should be carried out.
(3) Increase awareness of the lay public: Family members of the patients,
people in the community constitute the lay public. Posters, calendar, video
compact disc, radio, etc. are good media for the health promotion.
The treatment of tuberculosis patients with concurrent diabetes
Diabetes is not only a risk factor for active tuberculosis, but also for poor
tuberculosis treatment outcomes. Also, it may possibly be associated with
increased risk of the development of multidrug-resistant tuberculosis
( MDR-TB) (80) (81), although some studies reported different results (65). As we
have stated in the General Introduction, chronic hyperglycemia is associated
with impaired immunity to Mtb in diabetes patients and may result in
reduced efficacy of anti-tuberculosis treatment. The WHO recommended
optimized glucose control as part of the management of combined patients
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for improved tuberculosis outcomes (82). Till now, widely accepted guidelines
for the treatment of tuberculosis patients with concurrent diabetes have not
been available. Recently, a group of expert clinicians provided treatment
guidelines for drug-susceptible tuberculosis from a perspective of clinical
therapy, with certain special recommendations for patients with combined
diabetes. A total of 9 months of therapy is recommended, mainly based on
the more severe presentation. Also, they suggested to measure drug
concentrations in serum to gain insight into the adequacy of dosing and
need for individual adjustments (83). This is mainly based on the reported
possibly suboptimal plasma levels of anti-mycobacterial antibiotics in
diabetes patients. However, there is discrepancy at this stage (84) (85) and
further study among patients with combined disease is required.
Besides these recommendations, we think vitamin D status should be
monitored in tuberculosis patients given the high prevalence of (severe)
vitamin D deficiency. Outdoor activity in order to ensure enough sun
exposure, higher consumption of fish (especially sea fish), eggs, etc and
vitamin D fortified items such as milk, butter are recommended. Vitamin D
supplements may have a favourable adjunctive effect on clinical treatment
in patients with concurrent diseases, but more confirmative studies are
needed concerning the recommendation of vitamin D supplementation as a
routine practice. The same holds for TB-only patients. Given the high
prevalence of vitamin D deficiency, population supplementation may even
prevent latent infection in areas with a heavy TB burden.
Future study
We observed higher prevalence of diabetes in active tuberculosis patients,
and we found evidence that vitamin D deficiency plays a contributing role in
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the risk of the combined diseases. Although causal relationships cannot with
certainty be deduced from the present studies, we provided important
etiological clues, and more longitudinal studies as well as confirmative trials
concerning the role of vitamin D are needed.
Longitudinal study in patients with combined tuberculosis and diabetes
In recent years, several follow up studies among patients with combined
tuberculosis and diabetes reported about aspects like the reversibility of
diabetes, factors associated with mortality and change of circulating
monocyte populations (51) (55) (57). However, the number of subjects included
was limited, and the follow-up duration was no longer than 6 months after
the initiation of the treatment. Moreover, studies like that have never been
carried out in China. During the implementation of this project, about 600
patients with concurrent tuberculosis and diabetes have been identified.
Future longitudinal studies are needed: (1) to observe the long-term (1~2
years) treatment outcomes, including cure, relapse and death; (2) to collect
information of possible markers of prognosis, including control of blood
glucose, typical tuberculosis signs (cough, night sweating, dyspnea, etc),
nutritional status (body weight, mid-upper arm circumference, etc); (3) to
set up prognostic models to direct early prevention of unfavourable
treatment outcomes in clinical practice.
Cohort study to verity the role of vitamin D deficiency in the double burden
In the present study, we have indicated that vitamin D deficiency may
aggravate the increased risk of tuberculosis mediated by diabetes. However,
due to the cross-sectional design and certain limitations in the vitamin D
intervention study, we cannot draw a causal conclusion at this stage. Further
prospective research comparing tuberculosis risk of diabetic subjects with
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different vitamin D status (severely deficient, deficient and sufficient) is
needed.
Confirmative trial of vitamin D in patients with concurrent tuberculosis and
diabetes
We are the first to report a favourable adjunctive effect of vitamin D3 on the
clinical manifestations in patients with concurrent tuberculosis and diabetes
during intensive-phase treatment. Our results may indicate a new
perspective for treatment. A trial with extra vitamin D in individuals without
active disease may also show the potential for prevention of the combined
diseases.
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Tuberculosis remains a major global health challenge, with an estimated 9
million incident cases worldwide each year, particularly in low-to-middle
income countries. Although China has achieved a 50% reduction in
pulmonary tuberculosis prevalence nationally since the 1990s, it still
accounts for nearly 17% of the world's tuberculosis burden in 2016, with
approximately 0.9 million new cases. At the same time, the prevalence of
diabetes has increased especially rapidly over the last 10 years. The
International Diabetes Foundation Diabetes Atlas estimated that in 2017 the
number of persons with diabetes in China was 114 million, equaling to
nearly a quarter of cases worldwide. Diabetes triples the risk of tuberculosis,
resulting in more symptoms, relapses, treatment failures and deaths.
Currently, 80% of global diabetes mellitus burden is in low-and
middle-income countries. Six of them (India, China, Brazil, Indonesia,
Pakistan and The Russian Federation) also have a high tuberculosis burden.
An aggravation of the tuberculosis epidemic due to diabetes will pose a
serious challenge for a relatively long period of time to come. In accordance,
the WHO has recently identified type 2 diabetes as a neglected risk factor
for the re-emergence of tuberculosis.
In recent years, the non-skeletal function of vitamin D has aroused intense
interest. High prevalence of vitamin D deficiency was documented in many
countries including China, representing a global health problem. Vitamin D
deficiency is associated with increased risk of diabetes as well as the severity
of the disease. At the same time, it is correlated with increased risk of
tuberculosis independently of diabetes.
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Therefore, we hypothesize that the double burden of diabetes and
tuberculosis and its implications to public health in China are influenced by
the high prevalence of vitamin D deficiency. If so, supplementation of
vitamin D may open perspectives for prevention and even therapy. We
carried out this study with the main purpose to investigate the epidemiology
of co-occurrence of tuberculosis and diabetes and their risk factors and to
elucidate the role of vitamin D deficiency in this interrelationship.
We carried out observational studies and an interventional trial in this thesis.
First, a large epidemiological survey was carried out among 6382 newly
diagnosed tuberculosis patients in a rural area in Linyi, Shandong, and
among 6674 non-tuberculosis controls from the same community.
Participants were screened for diabetes. The prevalence of diabetes in
patients with active tuberculosis was 6.3% which was nearly 35% higher
than in non-tuberculosis controls. Adjusted for confounders, tuberculosis
patients had a slightly more than three times higher risk of having diabetes
[OR(95%CI)=3.17(1.14-8.84)]. Risk factors for diabetes among tuberculosis
patients were similar as observed in the general population in China
(chapter 2). Further, 2280 tuberculosis patients were randomly selected
from this study to analyze possible diagnosis delay and its risk factors.
Hyperglycemia was associated with a nearly two-fold higher probability of
patient delay of tuberculosis in the community (chapter 3).
Then, subjects diagnosed with tuberculosis only, concurrent tuberculosis
and diabetes, diabetes only and normal controls were randomly selected for
the analysis of serum vitamin D concentrations and its association with the
risk of the diseases. A more than four-fold [OR(95%CI)=4.73(2.04-10.9)] and
two-fold [OR(95%CI)=2.50(1.04-6.02)] increased risk of having tuberculosis
only, and tuberculosis and diabetes combined was observed in the lowest
quartile of serum 25(OH)D compared with the highest quartile (chapter 5).
Subsequently a city level hospital-based study in Qingdao, Shandong was
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carried out. A total of 461 tuberculosis patients were randomly selected to
assess (severe) vitamin D deficiency and its determinants. A high prevalence
of vitamin D deficiency [serum 25(OH)D<20 ng/ml] of nearly 80% was
observed in tuberculosis patients, and severe baseline symptoms, low
outdoor activity and low fish consumption were identified as the main
determinants (chapter 4).
Then, we randomly selected a population of 299 tuberculosis patients from
the same city level hospital that had 70% overlap with the population of
chapter 4. As normal controls, we selected 91 individuals who underwent
physical check-up from a general hospital in the same city. We investigated
the correlations of vitamin D status with leptin and TNF-α. Besides its satiety
regulatory function as a “hormone”, leptin has also been recognized to have
immune modulating properties in recent years. Vitamin D status was
observed to be inversely associated with TNF-α, while positively associated
with leptin, indicating a possible immune-modulatory mechanism of vitamin
D in the pathogenesis of tuberculosis (chapter 6).
For an intervention trial, we were able to recruit 358 newly diagnosed
pulmonary tuberculosis patients from the 461 patients reported in Chapter
4, aged 18 y, to study the effects of vitamin D3 supplementation (800IU/d)
on tuberculosis clinical signs and symptoms and sputum conversion during
the intensive-phase treatment. Compared those without diabetes, patients
with concurrent diabetes had a higher baseline percentage of positive
sputum (78.1% vs 64.7%), of cavities in CT scan (55.5% vs 38.5%) and had
more severe clinical signs and symptoms. TBscore, a composite index of
eleven signs and symptoms such as cough, hemoptysis, dyspnea, is a tool
aiming to assess changes in the clinical status. The score was categorized
into 3 classes, namely mild, moderate and severe. Improvement was defined
as a change to a lower category. The improvement rates in vitamin D group
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were 26.5% (4th week), 28.5% (6th week) and 31.0% (8th week), significantly
higher than in the control group. Adjusted for confounders, i.e., age, gender,
vitamin D supplementation was still independently associated with clinical
improvement in patients with concurrent tuberculosis and diabetes from
the 4th week during the intensive-phase treatment (chapter 7).
In this epidemiological study, the diagnosis of tuberculosis was made within
the existing prevention and control system of the disease in China, following
the criteria provided by the WHO. Also, diabetes was diagnosed according to
WHO criteria for the classification of glucose tolerance based on fasting
plasma glucose (FPG). Serum 25(OH)D concentrations were measured by
using the method of radioimmunoassay. Major potential confounders such
as BMI, age, smoking, drinking, physical activity, baseline cavity in CT scan
were considered. We took various actions to ensure the reliability of the
data in this study, including a standardized procedure of diabetes screening
used in the multi-center investigation. Although residual confounding can
never be completely ruled out, we think we minimized it as far as possible.
In conclusion, the risk of having diabetes in active tuberculosis patients was
nearly three times higher compared to non-tuberculosis controls. In
concurrent disease, diabetes frequently precedes tuberculosis, and age ≥ 50
years, male gender is associated with increased risk. Severe hypovitaminosis
D was prevalent in tuberculosis patients, with a higher percentage in those
with diabetes. Severe TBscore at admission, low outdoor activity and
inadequate fish consumption were the main determinants. Vitamin D
supplementation showed adjunctive effect in the therapy, i.e., improvement
of tuberculosis clinical manifestations in this subpopulation. Regulation of
immune activity related cytokines such as leptin and TNF-α, as well as
modulation of glucose metabolism may be the possible mechanisms behind
this adjunctive effect. Our result indicates an aggravating role of vitamin D
deficiency in the double burden of tuberculosis and diabetes. The main
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strength of the present study is the community based large-scale
investigation which can assure the representativeness of the sample. In
addition, a trial in patients with combined tuberculosis and diabetes has
seldom been reported before. However, due to the cross-sectional design in
chapter 2-6 and certain limitations in the vitamin D supplementation trial in
chapter 7, we should be cautious in the interpretation of our study and a
certain inference with respect to causality cannot be made at this stage.
Nevertheless, our study provides possible etiological clues for the combined
occurrence of tuberculosis and diabetes and the possible role of vitamin D
deficiency. There is a sufficient body of evidence in the literature, to which
our present study adds, that diabetes increases the risk of active
tuberculosis and influences the clinical course of tuberculosis. This may
facilitate the transmission of tuberculosis in the community. Vitamin D
deficiency may play an aggravating role in this process. Bidirectional
screening for tuberculosis and diabetes, especially early detection of
tuberculosis in diabetes patients, and increasing awareness of the double
burden in various populations including the patients, health providers, and
the lay public may have significant public health benefits. In addition, the
possible adjunctive effects of vitamin D in patients with concurrent
tuberculosis and diabetes may open a new perspective in clinical therapy,
although we cannot recommend the supplementation as a routine practice
at this stage. Also, supplementation may benefit tuberculosis patients in
general. Moreover, extra vitamin D may benefit general population with
especially in a situation of a heavy tuberculosis burden combined with
prevalent vitamin D deficiency. We suggest future studies to address
long-term treatment outcomes of patients with the combined diseases and
to define certain markers to set up a prognostic model. Also, longitudinal
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studies to verify the role of vitamin D deficiency in the double burden, and
confirmative trials of the effect of vitamin D supplementation are needed.
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结核病仍然是重大的公共卫生问题，全球每年估计有 900 万新发病
例，主要在中低收入国家。尽管自 20 世纪 90 年代以来，我国肺结核患
病率已经下降了近 50％，但结核负担仍然严重，2016 年新发病例约 90
万，占世界结核病负担近 17％。与此同时，糖尿病患病率在过去十年间
增长迅速。据国际糖尿病基金会估计，2017 年中国糖尿病患者人数为
1.14 亿，相当于全球近四分之一的病例。糖尿病使结核病风险增加三倍，
且临床症状更加严重、复发、治疗失败和死亡发生率增加。目前，全球
80％的糖尿病负担在低中收入国家，其中六个（印度，中国，巴西，印
度尼西亚，巴基斯坦和俄罗斯）同时有高结核病负担。因此，由糖尿病
导致的结核病流行将在相当长的一段时间对公共卫生构成严峻挑战。据
此，世界卫生组织最近将 2型糖尿病确定为结核病复燃的危险因素。
近年来，维生素 D 的骨骼外功能广受关注。包括中国在内的许多国
家都存在维生素 D 缺乏，已成为一个全球性的健康问题。维生素 D缺乏
与糖尿病风险增加以及严重程度有关，与此同时，它与结核病的风险增
加独立相关。因此，我们设想维生素 D缺乏将加重糖尿病和结核病的双
重负担，补充维生素 D 可能会为预防甚至治疗提供前景。因此，本研究
的主要目的探讨结核病、糖尿病共患的流行病学特征、分析其危险因素，
并阐明维生素 D缺乏对糖尿病并发肺结核的影响。
我们开展了观察性研究和干预实验。首先，在山东临沂农村地区的
6382 名新诊断肺结核患者和来自同一社区的 6674 名未患结核对照人员
中进行了大规模的流行病学调查，对所有参与者进行了糖尿病筛查。结
果发现，活动性结核病患者的糖尿病患病率为 6.3％，比非结核病对照
组高出近 35％。对混杂因素进行调整后，结核病患者患糖尿病的风险增
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加三倍多[OR（95％CI）= 3.17（1.14-8.84）]。结核病患者中患糖尿病
的危险因素与普通人群类似（第 2章）。此外，我们从该研究中随机选
取 2280 名结核病患者，分析了诊断延迟及其危险因素。发现高血糖者结
核病诊断延迟的概率相比血糖正常者高出近两倍（第 3章）。
随机选择单纯肺结核、糖尿病并发肺结核、单纯糖尿病和正常对照者，
分析血清维生素 D 水平与疾病风险的关系。与血清 25（OH）D 最高四分
位 数 者相 比 ， 最低 四 分 位 数者 患 单 纯结 核 [OR （ 95 ％ CI ） =
4.73(2.04-10.9)]、糖尿病并发结核[OR（95％CI）= 2.50（1.04-6.02）]
的风险分别增加约四倍、两倍（第 5 章）。随后我们开展了一项以市级
结核专科医院为基础的研究。随机选择 461 名结核病患者评估维生素 D
缺乏情况及其影响因素。结果发现结核病患者中维生素 D 缺乏率[血清
25（OH）D <20 ng/mL]接近 80％，严重的基线症状、户外活动水平低、
鱼类消费量低是其主要危险因素（第 4章）。我们随机选取了该医院的
299 名结核病患者（选取的患者与第 4章的研究人群有近 70％的重叠），
并选择了 91 名在市级综合医院进行体检的人员作为正常对照。我们研究
了维生素 D水平与瘦素、TNF-α等的关系。除了作为激素调节“饱腹感”，
近年来研究发现瘦素具有免疫调节功能。我们的结果发现血清维生素 D
水平与 TNF-α呈负相关、与瘦素呈正相关，提示维生素 D可能通过相关
的免疫调节机制发挥作用（第 6章）。
我们招募了符合纳入标准的新诊断肺结核患者进行干预试验，观察
维生素 D3 补充（800IU / d）对结核病临床体征和症状、以及痰菌转阴
的影响。与单纯肺结核比较，并发糖尿病患者基线菌阳率更高（78.1％ vs
64.7％）、CT 片所示空洞更多（55.5％ vs 38.5％）、临床体征和症状
更严重。 我们采用 TBscore 来评价临床症状，它是一种综合指数，包括
咳嗽，咯血，呼吸困难等十一种体征和症状，是用于评估结核临床表现
的工具。根据 TBscore 具体分值，将症状分为轻度、中度和重度，症状
改变为较低级别被定义为“改善”。结果发现，维生素 D组干预组的改
善率分别为 26.5％（第 4周），28.5％（第 6周）和 31.0％（第 8周），
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显着高于对照组。调整年龄、性别等混杂因素后，维生素 D 补充仍然与
强化期治疗期间第 4周后患者的临床症状改善独立相关（第 7章）。
本研究患者的诊断采用的是目前公认标准，结核病的诊断是根据我
国现在实行的标准、糖尿病诊断根据 WHO 制定的基于空腹血糖（FPG）的
葡萄糖耐量分类标准进行。血清 25（OH）D 浓度采用放射免疫法测量。
我们考虑了研究中主要的潜在混杂因素，如 BMI，年龄，吸烟，饮酒，
身体活动，基线空洞等。采取了各种措施确保研究中数据的可靠性，包
括多中心调查中糖尿病筛查的标准化程序等。尽管流行病学研究中残余
混杂不可能完全排除，但我们认为本研究已尽可能将其最小化。
总之，与非结核病对照相比，活动性结核病患者患糖尿病的风险几
乎高出三倍。两病并发时，糖尿病常常发生在结核病之前，年龄≥50 岁、
男性与发生风险增加有关。严重的维生素 D缺乏在结核病患者中普遍存
在，合并糖尿病时比例更高，入院时基线症状严重、户外活动量低和鱼
类消费不足是其主要危险因素。维生素 D 补充剂在糖尿病并发结核的治
疗中具有辅助作用，可促进结核病临床表现的改善。调节免疫活性相关
细胞因子如瘦素、TNF-α，以及调节葡萄糖代谢可能是这种辅助效应背
后的机制。我们的结果表明维生素 D 缺乏可加重结核病和糖尿病双重负
担中。本研究的主要优势是基于社区的大规模调查，可以保证样本的代
表性。此外，针对糖尿病并发结核患者的干预研究尚鲜见报道。然而，
由于第2-6章中的横断面设计和第7章中维生素D补充试验的某些不足，
我们在解释研究结果时应该谨慎，尤其是在进行因果关系推断时。
我们的研究为糖尿病并发肺结核、以及维生素 D缺乏的可能作用提
供了病因学线索。已有的文献中提供了两病双重负担的大量研究证据，
本论文增加了新的证据，即糖尿病会增加活动性肺结核的风险并影响结
核病的临床过程，这可能导致人群中结核病传播风险的增加，维生素 D
缺乏可在这个过程中起到加重作用。因此，结核病和糖尿病的双向筛查，
特别是糖尿病患者结核病的早期检测，以及提高患者、医护人员以及社
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区群众等对糖尿病、肺结核双重负担的认识，可对于结核的防控产生显
著促进作用。此外，尽管目前我们尚没有充足证据提出补充维生素 D 作
为常规手段，维生素 D 在糖尿病并发结核中的辅助作用可能为临床治疗
开辟新的视角，此外，维生素 D可能对单纯结核病患者也产生有益影响。
同时，对于存在肺结核、糖尿病负担和维生素 D缺乏普遍存在的情况下，
额外的维生素 D补充可能降低一般人群发生结核的风险。我们建议未来
的研究应观察糖尿病并发结核的长期治疗结果、确定生物标志物以建立
预后预测模型。此外，需要开展更多的纵向研究来验证维生素 D缺乏在
双重负担中的作用，以及补充维生素 D效果的确证试验。
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